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Summary 
Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the 
central nervous system (CNS). Although its etiology is unknown, it is considered an 
autoimmune disease facilitated by genetic and environmental predispositions (Milo 
and Kahana, 2010). Already in the 1990’s, the presence of retrovirus-like particles was 
associated with MS pathology (Perron et al., 1997). The RNA of these particles was 
characterized as the MS-associated endogenous retrovirus (MSRV), which shares good 
homology with the human endogenous retrovirus family W (HERV-W) (Blond et al., 
1999). Both the presence and expression of RNA and proteins of MSRV/HERV-W is 
elevated in MS patients and levels coincide with progression of the disease (Garcia-
Montojo et al., 2013; Mameli et al. al., 2009; Perron et al., 2012). Although MS mostly 
affects the brain, increased expression of MSRV/HERV-W has also been observed in 
the peripherical blood mononuclear cells (PBMC). HERV-W is a family composed of 
more than 600 similar elements integrated throughout the human genome (Pavlicek et 
al., 2002). While similar, detailed sequence analysis allows for discrimination between 
elements (Lander et al., 2001). My studies have focussed on elucidating the exact 
relationship between MSRV and HERV-W on the one hand, and understanding how 
HERV-W overexpression contributes to MS on the other hand.  
I hypothesized that MSRV could be a HERV-W element that is not fixed in the current 
population, and therefore not described in the genome database. My first objective 
was to identify copies of HERV-W not represented in the database. A PCR-based 
method described previously to localize transposable elements (Uren et al., 2009), was 
adapted to HERV-W type sequences. Using the variant method, several HERV-W 
elements present in PBMCs from 4 MS patients have been successfully amplified, 
cloned and localized in the human genome. However, all of the HERV-W sequences 
identified in this way corresponded to copies represented in the database. NGS has 
allowed for identification of HERV-W copies not represented in the database. Their 
implication in MS is presently unknown. 
Thanks to a collaboration with the department of Neurology of Miguel Servet 
University Hospital (Zaragoza, Spain), I have obtained blood samples from MS patients 
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and healthy controls from which I have extracted PBMCs. The number of copies of 
HERV-W in the samples was analysed, and I have detected that it is not enhanced in 
MS patients. HERV-W expression was analysed in PBMCs, and expression was slightly 
elevated in MS patients. Overexpression among patients could be linked to clinically 
active patients. I have analysed which HERV-W elements might be overexpressed or 
overrepresented in the transcriptome of MS patients. Relative expression levels of 
HERV-W that are most abundantly transcribed in PBMCs do not differ between MS 
patients and controls. By contrast, several specific HERV-W elements are exclusively 
transcribed in MS patients, although their relative expression levels are not high 
(between 1-5%). 
Taking other HERVs elements as an example, regulation of HERV-W may be controlled, 
among other mechanisms, by epigenetic mechanisms such as DNA methylation. As the 
methylation status of HERV-W has not been analysed in the context of MS, the 
possibility that the methylation of HERV-W loci would control their expression was 
investigated. Methylation assays for selected HERV-W elements were designed, 
validated and applied to genomic DNA obtained from MS patients. Results show that 
the analysed loci were highly methylated in PBMCs of both MS patients and controls. 
No relation between HERV-W expression and methylation levels could be established. 
Similarly, methylation levels were not altered in MS and did not correlate with the 
pathology. 
Toll-like receptors (TLRs) detect viral proteins or nucleic acids and mediate an antiviral 
response that includes interferon beta (INFb) induction. While dsRNA transcribed from 
HERV loci is capable of triggering a TLR3-mediated immune response in tumour cells 
(Chiappinelli et al., 2015), a similar mechanism in MS has not been studied. The 
possibility that overexpression of HERV-W may induce an inflammatory response 
within the CNS, specifically in oligodendrocytes and neuronal precursor cells (NPCs), 
was investigated. Lentivirus-mediated HERV-W overexpression induced expression of 
INFb in NPCs, possibly through TLR.  
The combined results of my studies suggest that the increase in HERV-W expression 
observed in MS patients does not originate from a single deregulated HERV-W element 
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that may be associated with the pathology. On the contrary, they suggest several 
copies of HERV-W that are expressed at low levels, do so exclusively in patients. My 
results suggest that the deregulation of HERV-W could activate the innate system 
within the CNS and thus contribute to the neuroinflammation present in MS. 
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Resumen 
La esclerosis múltiple (MS, multiple sclerosis) es una enfermedad crónica inflamatoria y 
degenerativa del sistema nervioso central (CNS, central nervous system). Ya en los años 
90 se relacionó la presencia de partículas parecidas a retrovirus con la patología de MS 
(Perron et al., 1997). El ARN (RNA, ribonucleic acid) de dichas partículas se caracterizó 
como el retrovirus endógeno asociado a esclerosis múltiple (MSRV, multiple sclerosis-
associated retrovirus), el cual comparte mucha homología con la familia W de los 
retrovirus endógenos humanos (HERV-W, human endogenous retrovirus family W) 
(Blond et al., 1999). Tanto la presencia como la expresión de RNA y proteínas de 
MSRV/HERV-W se encuentra elevada en pacientes de MS y se asocia al progreso de la 
enfermedad (Garcia-Montojo et al., 2013; Mameli et al., 2009; Perron et al., 2012). 
Aunque la MS afecta sobre todo al cerebro, el aumento de expresión de MSRV/HERV-
W se ha observado también en las células mononucleares de la sangre periférica 
(PBMC, periferal blood mononuclear cells). HERV-W es una familia compuesta por más 
de 600 elementos similares integrados a lo largo del genoma humano (Pavlicek et al., 
2002). Sin embargo, la relación exacta entre MSRV y HERV-W se desconoce a día de 
hoy. 
Para abordar cuál es la relación entre MSRV y HERV-W y, cuál es la contribución de 
HERV-W a la patología, el primer objetivo ha consistido en intentar localizar MSRV o 
copias de HERV-W que no están en la base de datos del genoma en el ADN (DNA, 
desoxyribonucleic acid) genómico de PBMCs de pacientes de MS. Para ello se ha 
modificado un método que nos permitiera amplificar secuencias de HERV-W. El ensayo 
ha permitido localizar en el genoma varios elementos de HERV-W presentes en el 
genoma de pacientes de MS, cuya relación con MS se desconoce a día de hoy. 
Gracias a una colaboración con el Servicio de Neurología del Hospital Universitario 
Miguel Servet (Zaragoza, España), se han obtenido muestras de sangre de pacientes de 
MS y controles sanos de las cuales se han extraído las PBMCs. Posteriormente, se ha 
analizado el número de copias de HERV-W en el genoma humano, y se ha detectado 
que es contante en todos los individuos. También se han analizado los niveles de 
expresión de HERV-W a nivel de RNA en PBMCs. Se ha detectado que la expresión de 
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HERV-W se encuentra ligeramente elevada en los pacientes de MS, y que dicha 
expresión no proviene de una sola copia de HERV-W sino de un grupo de copias de 
HERV-W menos abundantes pero asociadas a los pacientes de MS. 
Como en otros HERV, se supone que la regulación de HERV-W está controlada, entre 
otros mecanismos, por mecanismos epigenéticos como la metilación del ADN. Como el 
estado de metilación de HERV-W no ha sido analizado en el contexto de MS, se planteó 
la posibilidad de que el grado de metilación de HERV-W está relacionado con su 
expresión. Se han diseñado y aplicado ensayos para medir el grado de metilación de 
algunas de las copias de HERV-W previamente identificadas en pacientes de MS. Todos 
los loci analizados han resultado estar altamente metilados tanto en PBMCs de 
pacientes como en controles. Por lo que no parece que los niveles de metilación de 
HERV-W regulen su expresión. 
Los receptores tipo Toll (TLR; Toll-like receptors) detectan productos virales en forma 
de proteína o ácidos nucleicos y median la respuesta antiviral. He iniciado estudios 
para investigar la posibilidad de que la sobre-expresión de HERV-W indujera una 
respuesta inflamatoria dentro del CNS. Debido a la dificultad de generar 
oligodendrocitos, se han utilizado precursores neuronales humanos. Se ha detectado 
que la sobre-expresión de HERV-W desencadena una respuesta inflamatoria mediada 
por interferón β. Estos resultados sugieren que la desregulación de HERV-W podría 
activar el sistema innato residente en el CNS y contribuir así en la neuro-inflamación 
presente en MS. 
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1. Multiple sclerosis 
1.1 Symptoms and epidemiology 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
(CNS), characterized by the demyelination of axons and loss of oligodendrocytes (Brück 
et al., 2002; Lucchinetti et al., 2000; Trapp et al., 1998). Myelin is the protective sheath 
that surrounds the axons of neurons (Figure 1A), acting as an electric insulator and 
allowing the fast propagation of electrical impulses along axons. This myelin is 
produced by oligodendrocytes, a group of specialised cells of the CNS. In addition, 
oligodendrocytes produce growth factors that provide trophic support to neurons, 
such as brain-derived neurotrophic factor (BDNF) or insulin-like growth factor-1 (IGF-1) 
(Du and Dreyfus, 2002). Oligodendrocytes, therefore, support both axon survival and 
function (Simons and Nave, 2016). Although the exact cause of MS remains unknown, 
the immune system is triggered to attack the myelin of the patient, causing the 
disruption of the electrical impulses (Nylander and Hafler, 2012). This interruption of 
communication leads to MS symptoms such as muscle weakness, fatigue, or paralysis 
among others (Figure 1B).  
 
Figure 1. Representation of the structure of a neuron and the main symptoms of multiple sclerosis. A) 
In multiple sclerosis (MS), the myelin sheath that protects the nerve fibres is damaged and the 
transmission of nerve impulses impaired. B) The image summarizes the main symptoms of MS, which 
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range from direct neural pathologies (vision problems, body equilibrium and changes in cognition) to 
bowel and urinary alterations. Image A is taken from Alila Medical Media/Shutterstock.com. Image B is 
taken from Häggström and Häggström, 2014. 
It is estimated that around 2.5 million people suffer from MS worldwide. MS can affect 
people of any age or sex. However, it is most commonly diagnosed in people between 
the ages of 20 and 50 years and is about 2 to 3 times more common in females than 
males (Goodin, 2016). MS, therefore, stands out as the most common neurological 
disorder affecting young adults in developed countries. 
1.2. Diagnosis and clinical course 
MS is difficult to diagnose since there is no single test that can determine that a person 
has MS. Moreover, the absence of a better explanation for the individual’s symptoms 
remains an essential consideration. Diagnosis is a process that weighs evidence 
obtained from a clinical examination, medical history, specific laboratory evidence and 
MRI imaging of the brain and sometimes the spinal cord. It is recommended that MS is 
best diagnosed by a clinician with MS-related expertise based on the evidence 
mentioned above. A set of diagnostic criteria has been defined so that it is applied to 
patients who had suffered a first demyelinating attack, also called clinically isolated 
syndrome (CIS) patients. Such criteria, named as “McDonald Criteria”, was created by 
the International Panel on diagnosis of MS (McDonald et al., 2001). These guidelines 
facilitate the diagnosis of MS and are periodically revised (Latest update: Thompson et 
al., 2018). Briefly, diagnosis of MS requires evidence of the presence of multifocal CNS 
lesions scattered in time and space. Such CNS lesions and their dissemination in time 
and space are usually observed using magnetic resonance imaging (MRI) (“Diagnosing 
MS,” n.d.). On a MRI scan, demyelinated areas show up as white spots or darkened 
areas, depending on the type of scan that is used (Figure 2). Other diagnosis tools are 
usually included to support MS diagnosis. For instance, cerebrospinal fluid (CSF) is 
normally analysed for the presence of CNS-specific oligoclonal bands. Oligoclonal 
bands are antibodies which are detected by separation of CSF proteins. The presence 
of two or more oligoclonal bands in the CSF but absent from the patient’s serum 
indicates a local B-cell response and inflammation of the CNS, providing powerful 
evidence for the diagnosis of MS (Link and Huang, 2006). In particular, immunoglobulin 
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G (IgG) is detectable in CSF of more than 95% of MS patients while undetectable in 
serum (Link and Huang, 2006).  
 
Figure 2. Brain MRI scans. Images are derived from a fluid-attenuated inversion recovery magnetic 
resonance, a kind of MRI scan. The images show MRI scans of the brain of a MS patient (bottom) and a 
healthy control (top). White matter MS lesion are shown as white spots against the healthy white 
matter which looks relatively dark. Images taken from Bakshi et al., 2004. 
Once diagnosed, the Kurtzke Expanded Disability Status Scale (EDSS) is used as a 
measure of physical disability by assigning a severity score (0-10) to the clinical status 
of the patients (Kurtzke, 1983). The EDSS quantifies disability based on mobility 
limitations and independence in self-care of MS patients. 
According to the clinical course, the disease can manifest itself in different ways 
(Figure 3) (Goldenberg, 2012; Lublin, 2005). Relapsing-remitting MS (RRMS) is the most 
common form of the disease (around 85% of MS patients), in which symptoms appear 
for several days to weeks (relapses), followed by periods of remission when symptoms 
improve or disappear. As this stage may last for years, tissue damage accumulates over 
time, changing the pattern of disease from RRMS towards the secondary progressive 
stage of MS (SPMS). In SPMS, MS-related neurologic deficits gradually worsen over 
time, with or without periods of remission. About 15% of patients present primary 
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progressive MS (PPMS), which is characterised by gradually worsening neurologic 
function from the onset, without early relapses or remissions. Progressive relapsing 
MS (PRMS) is a rare form, affecting fewer than 5% of patients. It is defined as gradual 
neurologic worsening from the onset with intermittent relapses along the way with no 
periods of remission. 
 
Figure 3. Types of MS. MS patients are grouped into four categories based on the course of disease. 
RRMS: relapsing-remitting MS; SPMS: secondary progressive MS; PPMS: primary progressive MS; PRMS: 
progressive relapsing MS. Image adapted from Lublin, 2005. 
 
1.3 MS pathogenesis 
The main pathological hallmark of MS is the presence of CNS lesions featuring 
demyelination, oligodendrocytes loss and infiltration of immune cells. Ample evidence 
supports the widely held view that pathogenesis of MS involves an autoimmune attack 
against myelin proteins in the CNS, which subsequently leads to neural degeneration 
(Garg and Smith, 2015; Sospedra and Martin, 2005). An autoimmune attack consists of 
a reaction of the immune system against autoantigens in the own patient’s body. 
Although autoimmunity is a hallmark of a variety of diseases including MS and 
rheumatoid arthritis, its causes are presently unknown. In MS, somehow cells of the 
immune system (T cells, B cells and macrophages among others) are activated, starting 
the autoimmune response (Chaplin, 2010; Medina, 2016). Whether this inflammatory 
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response is directed against myelin or oligodendrocytes is presently debated 
(Stadelmann et al., 2011). Some studies support that demyelination precedes 
oligodendrocyte loss in both MS and its animal model, experimental autoimmune 
encephalomyelitis (EAE) (Romanelli et al., 2016). By contrast, genetically induced loss 
of oligodendrocytes was sufficient to trigger a CD4 T cells-mediated autoimmune 
response against myelin and subsequent demyelination in a mouse model (Traka et al., 
2016).  
 
Figure 4. Antigen presentation and T cells responses. Activation of CD4 and CD8 T cells is mediated by 
the major histocompatibility complex (MHC) present on antigen presenting cells (APC). CD4 and CD8 T 
cells recognise antigenic peptides associated to MHC II or MHC I molecules respectively. As a result of 
these interactions, CD4 T cells mature into helper T cells which will collaborate in raising antibody 
responses and activate CD8 T cells. CD8 T cells, on the contrary, will then differentiate into cytotoxic T 
cells which will destroy infected cells. Image taken from Wikimedia Commons, the free media repository 
(Figure 42 02 04). 
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Immune system mainly protects us against infections. After infection, T cells are 
activated when they recognise antigens associated with molecules of the major 
histocompatibility complex (MHC), present on antigen-presenting cells (APCs). The 
MHC complex is a set of surface proteins that binds antigens, a combination which in 
turn is recognized by T cells. There are two types of MHC complex proteins: class I 
proteins which are expressed by most cell types, and class II proteins whose expression 
is restricted to certain immune cells. In turn, there are two kinds of T cells, CD8 and 
CD4 T cells, characterized by the surface expression of either CD8 or CD4 molecules. 
While CD8 T cells only recognise antigens associated with MHC class I in APCs, CD4 T 
cells exclusively recognise antigens associated with MHC class II in APCs (Figure 4) 
(Chaplin, 2010; Medina, 2016).  Once activated, CD8 and CD4 T cells vary in their 
mechanism of action. Activated CD8 T cells release different cytotoxic factors and 
cytokines, which destroy infected APCs. By contrast, stimulated CD4 T cells produce 
various cytokines which promote activation of MHC class II-containing APCs, such as 
macrophages and B cells. Subsequently, activated macrophages function destroying 
pathogens, and activating B cells to produce antigen-specific antibodies (Figure 4) 
(Chaplin, 2010; Medina, 2016).   
In the context of MS, the most widely accepted hypothesis suggests that the early 
phase of the disease is characterised by the activation of the peripheral immune 
system (Garg and Smith, 2015; Sospedra and Martin, 2005), although mechanisms that 
trigger this initial response remain unclear. In this model, it is assumed that leukocytes 
are activated outside the CNS (Figure 5). Activated leukocytes (specially macrophages, 
T cells and B cells), subsequently, express specific surface adhesion molecules and 
release proinflammatory cytokines that affect the endothelium of the blood-brain 
barrier (BBB) and cause its disruption. BBB is the only barrier separating the CNS from 
the periphery, preserving local homeostasis and an optimal environment for brain 
function. Once the BBB is altered, peripherically activated T cells, B cells and 
macrophages migrate into the brain (Minagar and Alexander, 2003). After entering the 
CNS, the macrophages, T cells, and antibodies secreted by B cells trigger a local 
immune response that ends up causing demyelination and the subsequent 
neuronal/axonal injury (Figure 5).  
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The most widely accepted hypothesis suggests that autoimmunity in MS is CD4 T cells-
mediated, and that autoimmune reactions are directed particularly at myelin proteins 
(Garg and Smith, 2015; Sospedra and Martin, 2005). Within the CNS, activated CD4 T 
cells encounter their specific myelin epitopes, presented by MHC class II of local APCs 
such as dendritic cells, macrophages/microglia, and B cells. Such encounters lead to a 
massive destructive inflammatory response, mediated by the local release of cytokines 
and chemokines, proliferation of T and B cells and reactivation of macrophages and 
microglia. This inflammatory cascade attracts other cells of the immune system and, as 
the ultimate consequence, the myelin-oligodendrocyte complex is attacked resulting in 
damage to the myelin sheath, loss of oligodendrocytes and altered neuronal 
transmission (Figure 5).  
 
Figure 5. Hypothetical immune responses in multiple sclerosis. After peripherical activation of immune 
cells (T cells, B cells and macrophages), such cells mediate blood-brain-barrier (BBB) disruption and 
migrate into the central nervous system (CNS). Activated B cells produce antigen-specific antibodies. 
Activated CD4 T cells recognise specific antigens presented by microglia, and both CD4 T cells and 
activated microglia release cytotoxic cytokines that attack oligodendrocytes. Activated CD8 T cells 
directly attack axons and oligodendrocytes. Image adapted from Hemmer et al., 2002. 
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This view is based on all major characteristics of CD4 T cells in MS. To begin with, 
active myelin-specific T cells and their products have been detected in peripherical 
blood mononuclear cells (PBMCs), cerebrospinal fluid (CSF) and cerebral lesions of MS 
patients (Allegretta et al., 1990; Elong Ngono et al., 2012; Olsson et al., 1992; Wu and 
Alvarez, 2011). Interestingly, activation of autologous myelin-specific T cells is enough 
to CNS inflammation animal models (Genain et al., 1994; MeinL et al., 1997; Stromnes 
and Goverman, 2006). Medication-based studies have revealed that activation of 
myelin-specific T cells in the periphery resulted in damage to the CNS of MS patients 
(Bielekova et al., 2000). Variations in the genes encoding MHC class II molecules 
represent the strongest human genetic risk factor for MS cells (GAMES and 
Transatlantic Multiple Sclerosis Genetics Cooperative, 2003). This provides indirect 
support for the importance of CD4 T cells as MHC class II molecules participate in the 
antigen presentation and CD4 T cells activation. And in addition, peripherically 
activated T cells release the cytokines that contribute to the disruption of the BBB and 
migrate into the CNS more efficiently than other immune cells (Minagar and 
Alexander, 2003). 
Also, although it is widely accepted that myelin-reactive T cells are the main players in 
the immunopathogenesis of MS, the exact triggers that initially stimulate such cells 
have not yet been identified. Nevertheless, several candidates have been studied. T 
cell from MS patients recognise several myelin proteins such as myelin basic protein 
(MBP), proteolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG) and 
myelin-associated oligodendrocytic basic protein (MOBP) among others (Bernard et al., 
1997; Kaushansky et al., 2010; Zhang et al., 1994). However, CNS myelin antigens are 
unlikely to be present in the periphery since they are synthesized by oligodendrocytes 
that only reside in the CNS. The peripheral activation of myelin-reactive T cells may be 
triggered by myelin proteins MBP and PLP that reside in cervical lymph nodes (CLNs) 
(Fabriek et al., 2005). Since CLNs are located in the neck, CLNs-associated myelin 
proteins could trigger a peripherical T cell activation in MS patients. Another 
mechanism suggested is based on molecular mimicry, by which peripherical viral or 
bacterial antigens that have sufficient sequence similarity with autoantigens would be 
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able to cross-activate T cells specific for myelin epitopes (Figure 6) (Stinissen and 
Hellings, 2008; Wucherpfennig and Strominger, 1995).  
 
Figure 6. Hypothetical cross-activation of myelin reactive T cells in the periphery. Activation of myelin 
reactive T cells by molecular mimicry would led to T cells expansion and migration into the central 
nervous system (CNS) in the absence of myelin proteins. Within the CNS, they would become 
reactivated when they encounter their specific myelin epitope presented by local antigen presenting 
cells (APC) such as microglia or macrophages. TCR: T cell receptor. MHC: major histocompatibility 
complex. Image reproduced from Stinissen and Hellings, 2008.  
Beyond the CD4 T cells paradigm, there is also evidence to incriminate CD8 T cells in 
MS pathology (Friese and Fugger, 2009). Several studies have shown that, in fact, CD8 
T cells are the T cell-type more abundantly encountered in CNS lesions, blood and CSF 
of MS patients, beyond CD4 T cells (Babbe et al., 2000; Booss et al., 1983; Jilek et al., 
2007; Traugott et al., 1983). Furthermore, CD8 T cells can induce axonal damage by 
direct injury to MHC class I APCs such as neurons and oligodendrocytes (Batoulis et al., 
2010). In fact, axonal damage within CNS lesions of MS patients, correlates with the 
number of infiltrating CD8 T cells rather than CD4 T cells (Bitsch et al., 2000; Kuhlmann 
et al., 2002), although not necessarily in all cases. 
Sofía Macías Redondo 
20 
 
B cells also play an important role in MS pathology. B cells can act as APCs for T cells, 
and produce myelin-specific antibodies (Sospedra and Martin, 2005). The increased 
presence of specific antibodies in CSF, but not in the serum, of MS patients is one of 
the main diagnostic tools for MS diagnosis (Thompson et al., 2018). B cells and myelin-
specific antibodies have also been detected in lesions of MS patients. Although the 
antigen specificity of antibodies in MS patients is in some cases not well established, 
anti-MOG and anti-MBP antibodies have been found with certainty in human MS 
lesions (Genain et al., 1999; O’Connor et al., 2005; Wucherpfennig et al., 1997).  
1.4. Etiology 
As of today, the etiology of MS has not been precisely defined. Extensive evidence 
supports that MS is a multifactorial disease, which results from complex interactions 
between genetic and environmental factors. Although MS is not considered a 
hereditary disease, studies support a genetic susceptibility for the disease (Milo and 
Kahana, 2010). Around 20% of MS patients have one affected relative and MS 
incidence is increased up to 10 times when both parents are affected (Dyment et al., 
1997; Sawcer et al., 1997). Efforts have been made to discover gene variants 
associated with MS risk. Meta-analysis combining the results of nine whole genome 
screens for MS-associated genomic regions, revealed that the genetic factor with the 
strongest association with MS was the human leukocyte antigen gene complex (HLA) 
class II locus on chromosome 6p21 (GAMES and Transatlantic Multiple Sclerosis 
Genetics Cooperative, 2003). HLA complex is the human version of the MHC. This was 
later fine-mapped to HLA-DRB1 gene, or more specifically to some HLA-DRB1 
haplotypes. Among them, HLA allele DRB1*1501 accounts for near 50% of the total 
genetic basis of MS. Subsequent genome-wide association studies (GWASs) yielded the 
identification of more MS susceptibility loci, and many are related to lymphocyte 
function and/or cytokine pathways (International Multiple Sclerosis Genetics 
Consortium et al., 2011, 2007; International Multiple Sclerosis Genetics Consortium 
(IMSGC) et al., 2013). Altogether, several MHC class I and II alleles, and 110 non-MHC 
variants have been associated with MS risk (Moutsianas et al., 2015). However, no 
single-gene defect or allele that causes MS has been identified so far and GWASs have 
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not yielded reliable genetic predictors of the disease. Therefore, other non-genetic 
causes must contribute to MS risk. 
A large body of data supports a contribution of environmental variables to MS. MS 
frequency increases progressively with geographic latitude and decreasing solar 
radiation (Kurtzke, 2005). A potential explanation for this association is the 
involvement of vitamin D, which is produced in the skin by exposure to ultraviolet 
radiation or supplied in the food. It turns out that both sunlight exposure and vitamin 
D levels have been inversely associated with the risk of MS (Hayes, 2000). Low levels of 
vitamin D in serum has been associated with high risk of developing MS, while vitamin 
D supplementation reduces the risk (Munger et al., 2006, 2004). However, vitamin D 
levels by itself cannot predict MS risk either. Other environmental factors that have 
been reported to modulate MS risk, and approximately correlate with geographical 
distribution, include psychological stress, pollution, dietary fat and smoking (Milo and 
Kahana, 2010). Smoking, in particular, has emerged as one of the most common 
environmental factors associated to MS along with latitude and vitamin D levels. 
Smoking is associated with a higher risk of developing MS, and also correlates  with a 
faster progression of the disease (Hernán et al., 2001).  
Proof for additional environmental factors has been obtained in migration studies.  
Among immigrants that move from an area of higher prevalence of MS to an area of 
lower prevalence, the prevalence trends towards the lower rate (Dean, 1967). Genetic 
susceptibility alone, cannot explain such changes in MS incidence. As alternative 
explanations, the changes have been attributed to sunlight exposure and subsequent 
vitamin D synthesis. However, similar studies, in which the age of migrants was 
considered, revealed that immigrants only acquire the low MS risk when migrating 
before age 15–16, while migration at a later age did not change the risk (Hammond et 
al., 2000). A plausible explanation for these age-related changes in MS risk is the 
apparent MS susceptibility conferred by some viral infections. Among the viral agents 
associated with MS are human endogenous retroviruses (HERVs) (Morandi et al., 
2017b), whose association with MS will be further discussed later (page 47). The risk of 
multiple sclerosis is increased in persons with prior infectious mononucleosis caused 
by Epstein–Barr virus (EBV) (Ahlgren et al., 2009; Nielsen et al., 2007; Ramagopalan et 
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al., 2009). Distribution of EBV is widespread, infecting over 95% of the adult 
population. EBV infection is usually acquired at an early age when the infection is 
mostly asymptomatic. However, EBV infection in adolescence is commonly known as 
mononucleosis and triggers a severe inflammatory immune response. After 
mononucleosis infection is controlled by the immune system, a latent infection 
remains in the form of infected B cells, that do not produce virus. Although the 
mechanism is unknown, it is believed that this mononucleosis-mediated activation of 
immune system increases susceptibility to MS (Ascherio and Munger, 2010). Yet 
another alternative hypothesis is based upon differential exposure to EBV dependent 
on latitude. Children born in developed countries (northern latitudes) would tend to 
experience later exposure to EBV infection than children from undeveloped countries 
(southern latitudes), and therefore, they face a higher MS risk.  
In brief, no single gene or environmental factor has been unambiguously identified as 
the causative agent of MS. It is likely that the combinatorial effects of several genetic 
and environmental factors lead to the onset of the disease.  
1.5. Strategies to study MS disease etiology, pathology and progression 
Epidemiological and genetic studies of patient cohorts have highlighted the influence 
of environmental factors (solar radiation, vitamin D levels, the incidence and timing of 
viral infections, smoking habits) and the genetic background, on MS risk. However, the 
main injury in MS occurs in the CNS, while the peripheral nervous system and other 
organs are not targeted by the disease process. For obvious ethical reasons, in vivo 
observation of CNS lesions is almost impossible, and the histopathology of CNS lesions 
has been mainly studied in post-mortem brain samples of patients. Animal models 
have been useful to better understand etiology and progression of the disease.  
In vivo observation of CNS lesions in MS patients has been mostly limited to the use of 
MRI. MRI scanning allows to diagnose and evaluate MS progression through the 
observation of demyelinating lesion in the brain (Absinta et al., 2016; Harrison et al., 
2015; Louapre et al., 2015). However, in vivo data related to the initiation and 
progression of MS are hard to obtain and changes in brain-specific 
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immunohistopathology, epigenetics and immune processes cannot be followed in 
patients.  
Understanding of the inflammatory response in MS has been greatly shaped by 
findings from animal models. Experimental autoimmune encephalomyelitis (EAE) is the 
most commonly used animal model for disorders characterised by inflammation, 
myelin damage and neurodegeneration, including MS. To create such a model, already 
in the first half of the last century, different susceptible animal species were 
immunised with brain extracts, Freund's adjuvant (CFA) and pertussis toxin (PT) 
(Freund and McDermott, 1942; Kabat et al., 1947; Munoz et al., 1984). This resulted in 
alterations of the immune system and neurological disorders. Among all immunised 
animals generated, mice arose as the best host for an experimental animal model of 
MS due to the availability of genetically engineered animals, which allows for direct 
testing of the involvement of MS-specific proteins in EAE pathology or genetic ablation 
of cell lineages. Susceptible mice, such as SJL/J, C57BL/6 and NOD, were later 
immunised with human recombinant myelin-associated peptides such as MBP and PLP 
(Pettinelli and McFarlin, 1981; Zamvil et al., 1985). Either treatment caused EAE 
pathogenesis. Briefly, immunization triggers the activation of T cells in the periphery. 
These activated T cells produce interferon-gamma (IFN-gamma) and inflammatory 
cytokines, which activate other immune cells such as B cells and 
monocyte/macrophages. All immune cells migrate into the CNS and, along with 
activated resident glial cells, damage the myelin and axons. The release of cytokines 
attracts further inflammatory cells to the CNS, thus perpetuating the inflammatory 
cascade (Constantinescu et al., 2011; Duffy et al., 2014). The symptomatic result is an 
MS-like progressive ascending paralysis starting from the tail. Immunisation usually 
gave rise to an acute phase in which animals may recover (remission phase) or not 
(chronic disease). Models in which animals do recover from the acute phase, or 
develop subsequent relapses and remissions, have been also developed since they 
clearly are more useful to study mechanisms behind relapsing-remitting MS (Al-Izki et 
al., 2012; Baker et al., 1990). In parallel, models in which the neurological deficits 
accumulate to progressive disability (called secondary progressive EAE), better mimic 
the clinical and pathological aspects of SPMS (Hampton et al., 2008). 
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Over the years, EAE models have allowed to study the complex interaction between a 
variety of immunopathological and neuropathological features of MS: inflammation, 
demyelination, axonal loss or damage and gliosis. For instance, the involvement of T 
cell in MS-like pathogenesis has been studied in EAE models, allowing the dissection of 
the pathogenic role of T cell response to MOG in MS-like pathogenesis. (Mendel et al., 
1995; Smith et al., 2005). Staining of EAE brain slices confirmed that CD8-positive T 
cells are targeted against oligodendrocytes and induce oligodendrocyte apoptosis 
(Göbel et al., 2009). EAE models also helped to shed light on the role that cytokines 
play in MS-like pathogenesis, analysing among others, the role of the related 
molecules IL-12 and IL-23 in the susceptibility to autoimmune demyelination (Becher 
et al., 2002; Cua et al., 2003).  
However, although EAE has been a valuable model for studying MS, not all aspects of 
the human pathology are represented in the model (Baker et al., 2011; Vesterinen et 
al., 2010). The main difference between MS and EAE is that animal models require an 
artificial external immunization step, whereas MS patients suffer a spontaneous initial 
trigger. The inducing antigens in EAE are known, whereas triggers for MS remain 
unknown. Several aspects of the disease are not mimicked in EAE models. A major 
drawback of EAE-like models is that responses to therapies often cannot predict 
efficacy in humans (Constantinescu et al., 2011). Another relevant question that EAE 
models cannot address is related to complications restricted to humans, for example 
the implication of human-specific virus in the pathogenesis of MS. A main example is 
again EBV (Ascherio and Munger, 2010; Serafini et al., 2007). These combined 
drawbacks of the mouse model have increased interest in alternatives such as human-
derived in vitro models.  
2. Human stem cells 
There are three characteristics that set stem cells apart from other kinds of cells in the 
body: they are capable of dividing and renewing themselves, they are unspecialized, 
and they can give rise to specialized cell types (Alison et al., 2002; Gardner, 2002). 
Unlike specialized, differentiated cells such as muscle cells, blood cells, or nerve cells, 
which do not normally replicate themselves, stem cells are capable of long-term self-
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renewal. This ability allows them to proliferate without losing their differentiation 
potential and without undergoing senescence (Amit et al., 2000). They can divide 
symmetrically (in which both daughter cells are either stem cells or differentiated 
cells), or asymmetrically (yielding one stem cell and one more differentiated cell). The 
potential to differentiate into other cell types is called developmental potency. Stem 
cells are endowed with varying potency, the more cell types a stem cell can 
differentiate into, the greater its potency (De Los Angeles et al., 2015; Singh et al., 
2016). Thus, stem cells can be either totipotent (they can differentiate into embryonic 
and extraembryonic cell types), pluripotent (descendants of totipotent cells, they can 
differentiate into cells representing any of the three primary germ layers of the early 
mammalian embryo), multipotent (they can only make cells within a given germ layer), 
or unipotent (they can make just cells of a single cell type). 
Depending on their origin, stems cells can be divided into human embryonic stem cells 
(hESCs) and tissue-specific or adult stem cells. Adult stem cells are present in most or 
all human organs and tissues including brain, bone marrow, blood vessels, heart, liver 
and umbilical cord. Compared to embryonic stem cells, they have less lineage potential 
and are generally multi- or unipotent. Their main role is as a source of newly generated 
cells, which are required in the process of regular turn-over in tissues. Therefore, they 
are essential for maintaining and repairing their tissue of residence (Fuchs, 2008; 
Montagnani et al., 2016; van der Flier and Clevers, 2009). hESCs are derived from the 
inner cell mass of the blastocyst-stage embryo, which in human forms three to five 
days after an egg cell is fertilized by a sperm (Reubinoff et al., 2000; Thomson et al., 
1998). Due to the ethical issues of destroying an embryo, hESCs have been mainly 
derived from surplus frozen embryos that remain after a woman or couple has 
completed infertility treatment (Lo and Parham, 2009). The cells are pluripotent and 
provide a renewable resource for studying normal development and disease, and for 
testing drugs and other therapies.  
2.1. Human embryonic stem cells and induced pluripotent stem cells 
The pluripotency of hESCs is driven by several molecular mechanism which regulate 
the expression of genes responsible for the maintenance of pluripotency and 
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repression of differentiation (De Los Angeles et al., 2015). A defined set of 
transcription factors (i.e. OCT4, SOX2, and NANOG) has an essential role in maintaining 
the self-renewal and pluripotency of hESCs, which is regulated by a network of auto-
regulatory and feed-forward loops (Boyer et al., 2005; Singh et al., 2016). In fact, some 
of these pluripotency transcription factors overlap with the ones used to induce 
somatic cells reprogramming to induced iPSCs (Takahashi et al., 2007). Apart from 
transcription factors, pluripotency of hESC is also been linked to the presence of other 
molecular markers such as REX1, NANOG, OCT4 and SOX2 (Chen and Lai, 2015). 
hESCs can be cultured on either a feeder layer (usually proliferation-deficient mouse 
embryonic fibroblasts) or under feeder-free conditions (Kent, 2009; Lee and Lee, 
2011). When cultured on feeder-free conditions, they must be grown on a matrix 
including Matrigel, vitronection, laminin, fibronectin, or collagen IV among others (Xu 
et al., 2001). When culturing hESC, specific growth factors must be added to the 
culture medium to maintain cell pluripotency. For instance, addition of basic fibroblast 
growth factor (FGF2) and noggin suppresses bone morphogenetic proteins (BMPs) 
signalling that would otherwise induce differentiation (Wang et al., 2005, p. 2; Xu et 
al., 2005).  
Over the past 12 years, it has become clear that differentiated, specialized cells can be 
reprogrammed to resemble cells with expanded developmental potency (reviewed in 
Shi et al., 2017). Reprogramming was first achieved by nuclear transfer, and later by 
introduction of transcription factors that induce pluripotency (Takahashi et al., 2007). 
Reprogrammed cells acquire a pluripotent state and are therefore named induced 
pluripotent stem cells (iPSCs). This can be achieved in virtually any somatic mammalian 
cell type, and some of the transcription factors most frequently used are OCT4, SOX2, 
NANOG, and LIN28 (Stadtfeld and Hochedlinger, 2010; Takahashi et al., 2007). Human 
iPSCs possess the same differentiation potential as do hESCs.  
2.2 Applications of hESCs and hiPSCs 
hESCs can differentiate into most if not all cell types of an organism (Figure 7). 
Therefore, controlled in vitro differentiation of hESCs can provide a source of 
differentiated cells and tissues to replace damaged cells for diseases in which native 
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cell types are inactivated or destroyed, such as diabetes and heart disease (Kumar et 
al., 2010; Nadig, 2009). In this context, iPSCs have an important advantage over hESCs. 
In case of transplantation, tissue derived from patient-specific iPSCs would suffer less 
rejection than tissue derived from hESCs. Nevertheless, efficient stem cell-based 
therapy would be restricted to diseases characterised by the loss of a main cell type as 
opposed to more complex diseases such as cancer (Cherry and Daley, 2013). In 
parallel, cell types such as cardiomyocytes and hepatocytes generated from hESCs 
provide ideal populations for predictive toxicology. The use of hESCs, therefore, can 
can reveal toxicity of new drugs not detected using animal models (Bongso and 
Richards, 2004; Keller, 2005). Alternatively, hESCs/ iPSCs-based in vitro models can be 
used to study the pathology of diseases which are difficult to access in human patients 
and/or which are difficult to model in animals (Cherry and Daley, 2013). For instance, 
introduction of targeted mutations into hESCs allowed the generation of hESC-based 
models of monogenic cardiac diseases (Moretti et al., 2013). Manipulation of the 
genome of the hESCs has also provided a model for the Lesh-Nyhan syndrome (Urbach 
et al., 2010). This model was generated introducing a mutated form of the disease 
gene HPRT1, and the resulting lines exhibited some of the attributes of the disease.  
With the arrival of iPSCs, patient- and disease-specific stem cells are now being 
generated. Their availability therefore represents a powerful tool for biomedical 
research and may provide patient-specific in vitro models for tissues that are 
otherwise experimentally not accessible. Human iPSCs from patients with a range of 
human diseases have already been stablished (Park et al., 2008). For instance, 
Parkinson's patient-specific iPSCs have been generated and subsequently 
differentiated into the cell type mostly affected in patients i.e. dopaminergic neurons 
(Soldner et al., 2009). Similarly, iPSCs generated from patients with amyotrophic lateral 
sclerosis can be differentiated into motor neurons (Dimos et al., 2008). The generation 
of iPSCs from a patient enables therefore the production of the cell types affected by 
that patient’s disease. These cells could in turn be used for disease modelling and drug 
discovery.  
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Figure 7. hESC derivation and differentiation. hESC are derived from the inner cell mass of a blastocyst 
and can self-renew indefinitely in vitro, as well as forced to assume more specialized functions cell fates 
associated with specific differentiated cell types. Adapted from Yabut and Bernstein, 2011. 
2.3. In vitro models for multiple sclerosis and others neuroinflammatory disorders 
In vitro culture of CNS cells has enormous advantages. And it turns out, a lot of efforts 
has been invested over the past years to devise and optimise culture systems for all 
the main cell types of the CNS (Gibbons and Dragunow, 2010; Kipp et al., 2012; van der 
Star et al., 2012). In vitro culture of mature neurons, microglia and oligodendrocytes is 
particularly challenging since these cell types do not proliferate easily. Cell lines 
provide unlimited supplies of homogeneous cells, but do not faithfully represent 
alterations observed in pathologies. While the preparation and culture of primary cells 
is much more challenging and provides only limited amounts of cells. 
Both hESCs and iPSCs can be differentiated into neuronal, microglial and 
oligodendrocyte precursors. Different authors claim that subsequent differentiation 
into mature cell types can be achieved using different protocols (Douvaras et al., 2017; 
Gunhanlar et al., 2018; Hu et al., 2009). Mature differentiated cells are characterised 
by the expression of typical markers, and functional assays. (Abud et al., 2017; Hu et 
al., 2009). However, although some of these differentiation protocols seem to be very 
promising, the truth is that they are difficult to carry out, expensive, time-consuming 
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and they are not very efficient nor easy to reproduce (from my personal experience, 
(see Manuscript 4) and personal communications (Anna Duarri Piqué)).  
Interestingly, patient iPSCs-derived CNS cells have been successfully generated and 
used as models of neurological disease such as MS, Alzheimer's disease, Huntington's 
disease and Parkinson's disease (Ghaffari et al., 2018). The successful generation of 
iPSCs from MS patients was demonstrated few years ago (Douvaras et al., 2014; Song 
et al., 2012). MS patient-derived iPSCs have been subsequently differentiated into 
mature astrocytes, oligodendrocytes and neurons which, by definition, contain the 
patient's individual genetic susceptibility to MS. For instance, iPSCs-derived neural 
progenitor cells (NPCs) from MS patients showed inherent defects in myelin injury 
response in vivo when compared to control NPCs (Nicaise et al., 2017).  
2.4. Generation of human oligodendrocytes from human pluripotent stem cells 
Generally, in vitro differentiation is achieved by adding a cocktail of small molecules 
and growth factors to the stem cell culture in order to induce a specific-cell type 
differentiation (Singh et al., 2016). It became clear that, applying factors such as FGF2 
or the epidermal growth factor (EGF) to hESCs, they could directly differentiate in vitro 
into multipotent neural precursor cells (NPCs), which could subsequently be 
differentiated into more specified cell types, including astrocytes, oligodendrocytes, 
and neurons (Reubinoff et al., 2000; Zhang et al., 2001). These NPCs were also able to 
differentiate into astrocytes, oligodendrocytes, and neurons after transplantation into 
newborn mouse brains (Reubinoff et al., 2000; Zhang et al., 2001). In all cases, 
differentiation into the specific cell types were confirmed by the expression of cell 
type-specific markers, such as expression of the neural cell adhesion molecule (NCAM) 
in neurons, glial fibrillary acidic protein (GFAP) in astrocytes, and MBP in 
oligodendrocytes. However, it was not until some years later that a study 
demonstrated that hESCs-derived oligodendrocytes could resemble functional 
oligodendrocytes after transplantation in the shiverer mouse model of dysmyelination 
(Nistor et al., 2005). Oligodendrocytes are mature or functional when they have the 
ability to produce myelin. And it turned out that, while shiverer mice did not contain 
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myelin, MBP immunostaining confirmed myelination by transplanted cells in 
transplanted shiverer mice (Nistor et al., 2005). 
In subsequent years, alternative protocols to generate oligodendrocytes from human 
pluripotent stem cells were developed (Hu et al., 2009; Kang et al., 2007; Kerr et al., 
2010; Nistor et al., 2005). Although quite similar, these mentioned protocols differ in 
the cell line used, culture time, culture method and the growth factors used (reviewed 
in Alsanie et al., 2013). At any rate, the first step of oligodendrocyte differentiation 
consists of differentiating hESC/iPSCs into neural precursors. This can be achieved 
through the generation of embryoid bodies (EBs) in suspension, or in a monolayer of 
cells by addition of supplements (FGF2, N2, B27…). NPCs are subsequently 
differentiated into glial precursors cells (GPCs), which are subsequently converted into 
the different oligodendrocyte stages, consisting of the pre-progenitors, progenitors, 
pre-oligodendrocytes and mature oligodendrocytes (Figure 8). This conversión is 
induced by the addition of specific inducers (mostly growth factors) at each stage. Each 
of these stages can be identified in vivo and in vitro by the expression of specific 
markers. These markers can be either transcription factors that regulate neural and 
oligodendrocyte maturation or growth factors that signal through extracellular 
receptors. Each marker is expressed at specific and defined stages during the 
progressive differentiation of human pluripotent stem cells (hESCs) into myelinating 
oligodendrocytes. Some of the commonly used markers during human 
oligodendrocyte differentiation are: SOX1 and PAX6 in NPCs, OLIG2 in GPCs, NG2 in 
OPCs and O4 and Myelin oligodendrocyte glycoprotein (MOG) in late OPCs and mature 
oligodendrocytes.  
However, these protocols yield low number of mature OPCs. Thus, follow-up studies 
focused on refining the induction protocols, improve cell growth, reduce the number 
steps required, in order to accelerate the process and achieve higher proportions of 
O4+ OPCs and their derived oligodendrocytes (All et al., 2015; Douvaras and Fossati, 
2015; Ehrlich et al., 2017; Stacpoole et al., 2013). Recent studies showed that 
differentiation of hESCs/hiPSCs to oligodendrocytes can be enhanced by 
overexpression of specific transcription factors, which allows for more efficient 
generation of O4+ oligodendrocytes. In fact, the overexpression of transcription 
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factors (such as SOX10, OLIG2, and NKX6.2) in hESCs/iPSCs-derived NPCs resulted in 
the generation of O4+ oligodendrocytes within a month (Ehrlich et al., 2017; García-
León et al., 2018).  
 
Figure 8. Oligodendrocyte differentiation steps. Schematic of the progressive differentiation of human 
pluripotent stem cells to myelinating oligodendrocytes. Protocol begins with human pluripotent stem 
cells which are differentiated into neural progenitor cells (NPCs). Then, the different stages of 
oligodendrocyte development are induced: pre-progenitor, progenitors, pre-oligodendrocyte and 
mature oligodendrocytes. Adapted from Alsanie et al., 2013. 
3. Epigenetics 
Although all cells from a multicellular organism contain the same genetic information, 
they differ in structure and function because there is a strict regulation of gene 
expression within each cell type. For instance, in the context of tissue development, 
some genes are only expressed at a specific developmental timepoint or in a specific 
cell type. Epigenetic processes allow the regulation of gene expression through 
changes in the DNA structure and organization, without altering the DNA sequence 
itself (Dupont et al., 2009; Goldberg et al., 2007). As epigenetics was initially studied in 
the context of cellular differentiation, the term usually refers to heritable 
modifications of DNA and chromatin that are passed on, through mitosis, to 
subsequent cell generations. 
DNA is highly compacted and organized within the nucleus (Figure 9). The DNA helix is 
wrapped around histone proteins giving rise to the DNA-histone complex, which in 
combination with additional DNA binding proteins is known as chromatin. Chromatin 
fibres, in turn, are further compacted into chromosomes (Lodish et al., 2000a). 
Importantly, accessibility of DNA is a major determinant of activity status. While 
transcriptional activation usually coincides with accessible chromatin, lack of 
accessibility of positively acting regulators correlates with transcriptional silencing. 
Therefore, variations in DNA structure or in the structure or activity of associated 
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proteins, either by chemically altering the DNA itself or modifying the proteins 
responsible for unpacking the DNA, can influence gene expression. Among the better 
known mechanisms which are implicated in epigenetic regulation, and able to 
influence DNA accessibility and the activity of DNA polymerase are DNA methylation 
and histone modifications (Qiu, 2006).  
 
Figure 9. Overview of the organization of DNA into chromosomes.  There are two main components of 
the epigenetic processes: DNA methylation and histone modifications. Image taken from Qiu, 2006. 
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3.1. DNA methylation 
In vertebrates, DNA methylation refers to the addition of a methyl group (-CH3) 
covalently to a cytosine residue. In the vast majority of methylated cytosines, this 
modification occurs in at CpG dinucleotides (A Jones, 2012) (Figure 10). The 
distribution of CpGs across the genome is not random; genomic regions enriched in 
CpGs, called CpG islands, are usually found at gene promoter sequences. Indeed, CpG 
islands characterize the promoter regions of more than half of all genes in the human 
genome (Antequera and Bird, 1993). Although most of the CpG islands are methylated 
(Bird, 2002), CpG islands in promoters of important genes are principally 
unmethylated, suggesting the influence of DNA methylation in gene regulation by 
regulating both chromatin structure and accessibility to regulatory factors.  
 
Figure 10. DNA methylation process. DNMTs catalyse the addition of a methyl group to the 5 position of 
a cytosine in a CpG dinucleotide. 
Methylation of DNA is an essential epigenetic control mechanism in mammals. 
Historically, DNA methylation has been associated with gene repression. DNA 
methylation of specific promoters often blocks the binding of activating transcription 
factors. Alternatively, methylated CpGs are recognized by proteins that alter the 
chromatin structure, turning it more compacted and less accessible to the 
transcription machinery (Lande-Diner and Cedar, 2005). However, the actual 
transcriptional effect of DNA methylation at promoter regions is related to the local 
CpG-density. In general, methylation only has a significant transcriptional effect at 
high-CpG density promoters, which are usually hypomethylated, and low CpG-density 
promoters, which are usually methylated. In contrast, intermediate CpG-density 
promoters can be either methylated or unmethylated and remain transcriptionally 
active regardless of their methylation state (Hackett and Surani, 2012; Messerschmidt 
et al., 2014). Besides the role of DNA methylation in transcriptional control at 
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promoters, DNA methylation also control specific regions. DNA methylation is essential 
for important processes in mammalian development such as X-chromosome 
inactivation, transcriptional silencing of endogenous transposable elements, genomic 
imprinting, long-term gene silencing and regulation of chromatin structure (Bird, 1997; 
Hore et al., 2007; Lande-Diner et al., 2007).  
DNA methylation is catalysed by DNA methyltransferases (DNMTs), particularly 
DNMT1, DNMT3A and DNMT3B. These enzymes are responsible for regulating normal 
DNA methylation and, although the mechanism is similar for different DNMTs, they 
have different responsibilities in various developmental stages within organisms (A 
Jones, 2012). DNMT1 oversees the maintenance of correct DNA methylation, 
methylating hemimethylated DNA. On the other hand, DNMT3A and DNMT3B 
generate new DNA methylation marks (de novo DNA methylation). They both are 
essential for DNA methylation patterns in early development, and their activity 
contributes to the repression of genes that are no longer required after cell 
differentiation (A Jones, 2012). 
DNA-methylation can be cell type-specific and patterns are often transmitted through 
cell division. However, DNA methylation is not a static mark and apart from 
methylating enzymes, demethylating processes are operative. DNA demethylation can 
occur through passive or active mechanisms (Chen and Riggs, 2011). DNA 
demethylation can be achieved passively in the absence of methylation of the newly 
synthesized DNA strand after replication. One passive mechanism, for instance, is the 
inhibition of DNMT1 by the action of DNMT inhibitors (DNMTi). Active DNA 
demethylation, on the other hand, is a replication-independent process, mediated by 
multiple demethylating enzymes. Enzymatic mechanisms result in the direct removal 
of the 5-methyl group, the 5-methylcytosine base or the 5-methylcytosine nucleotide. 
Removal of methylated bases is followed by insertion of an unmethylated one using 
base excision repair machinery (BER), while removal of the entire nucleotide is 
followed by insertion of a new one by nucleotide excision repair (NER) or mismatch 
repair (MMR). Both DNMT and DNMTi are essential for maintaining the balance of the 
DNA methylation level throughout the genome. The gene- or locus-specific alterations 
that occur by either de novo methylation or directed demethylation influence the 
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acquiescence of cellular identity during differentiation, and its subsequent 
maintenance across cell divisions.  
3.2. DNA methylation in MS and other diseases 
Defects and alterations in epigenetic marks have also been associated with a variety of 
human diseases, such as cancer, neurological disorders and autoimmune diseases 
(Baylin and A Jones, 2011; Portela and Esteller, 2010). Epigenetic alterations may 
predispose to subsequent pathological insult or represent the secondary result of 
disease processes. When it comes to cancer, although research has been focused for 
many years on genetic mutations, genome-wide methylation studies have revealed the 
possible association between aberrant DNA methylation and cancer. Overall genomic 
hypomethylation has been historically reported in several cancers, promoting 
chromosomal instability and oncogenes upregulation (Ehrlich, 2009; Sharma et al., 
2010). Additionally, hypermethylation has been observed to contributes to 
oncogenesis by silencing tumour suppressor genes (Ehrlich, 2009; Sharma et al., 2010).  
Epigenetic modifications have also been related to neurological diseases such as 
schizophrenia, Alzheimer’s Disease and multiple sclerosis among others. For instance, 
genomic DNA of monozygotic twins discordant for schizophrenia has been analysed, 
showing differences in DNA methylation patterns of specific genes (Tsujita et al., 
1998). This finding suggested that DNA methylation patterns could be associated with 
disease-specific gene expression changes in the glutamic acid decarboxylase (GAD67) 
and reelin (RELN) genes. And it turned out that, compared to normal neurons, the 
decrease of GAD67 and RELN expression in neurons of patients with schizophrenia was 
directly correlated with the DNMT1-mediated hypermethylation on CpG sites within 
these genes’ promoters (Noh et al., 2005). In AD disease, initial genome-wide analysis 
of DNA methylation levels in post-mortem brain tissues or in lymphocytes did not 
show differences between patients with AD and controls. However, DNA methylation 
patterns in specific AD-associated genes differed when comparing patients with 
controls (Wang et al., 2008). Specific examples are the differential methylation in the 
CRTC1 gene in the hippocampus of AD patients and methylation-dependent 
(hydroxymethylcytosine) TREM2 upregulation (Celarain et al., 2016; Mendioroz et al., 
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2016) The exact contribution of such differences to AD risk or pathology is presently 
unknown.  
Similar to cancer and AD, searches have been conducted to identify epigenetic 
alterations relevant for the etiology or progress of MS. In a search of MS-biomarkers, 
genomic DNA of CD4+ lymphocytes from monozygotic twins discordant for MS was 
analysed in order to test if any discordance could be attributed to methylation changes 
in MS susceptibility genes . However, no evidence was found for genetic, epigenetic or 
transcriptome differences that explained disease discordance. These results contrasted 
with similar analysis performed for other neurological diseases as mentioned above . 
In another contemporary study, the methylation patterns of 56 genes, previously 
shown to be differentially methylated in ovarian cancer tissue (Melnikov et al., 2009), 
were compared using a microarray-based technique in plasma from MS patients and 
controls (Liggett et al., 2010). 15 out of 56 genes showed significant differences in 
methylation patterns between MS patients and controls. Additional studies have been 
conducted on post-mortem brain tissue. Such studies have revealed epigenomic 
changes in pathology-free areas of MS–affected brains(Huynh et al., 2014). Specifically, 
genes affecting oligodendrocyte susceptibility to damage are affected. As an example, 
the BCL2L2 and NDRG1 genes were hypermethylated and expressed at lower levels in 
pathology-free brain tissues from MS patients than in controls. As the products of 
these genes are involved in oligodendrocyte survival, these results suggest that 
oligodendrocytes in MS patients might be short lived in MS. Additionally, these results 
suggested that pathology-free areas in a MS brain might harbour epigenomic changes 
that might modulate the ability to respond to the pathological process. Other studies 
have been conducted in peripheral cells of MS patients. The promoter of the protein 
tyrosine phosphatase SHP1, a negative regulator of pro-inflammatory signalling and 
autoimmune disease, is inappropriately hypermethylated in peripheral blood 
leukocytes of MS subjects (Kumagai et al., 2012). As a result, SHP1 expression levels 
and activity are reduced, which is associated with increased leukocyte-mediated 
inflammation in MS (Kumagai et al., 2012). A genome-wide DNA methylation analysis 
of CD4+ T cells from MS patients and controls revealed evidence for association of DNA 
methylation at the HLA-DRB1 locus with risk for MS (Graves et al., 2014). The selected 
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examples above, along with many others, highlight the presence of DNA methylation 
alterations in multiple sclerosis (Miyazaki and Niino, 2015).  
4. Transposable elements 
Mammalian genomes have been usually thought to be stable and unchanging. 
However, it has become increasingly clear that the genome is not static but dynamic, 
and that its DNA content is subject to rearrangements, insertions and deletions (Prak 
and Kazazian, 2000; Smit, 1999). In fact, only half of the human genome is “unique”, 
while around 42% of the human genome consists of repetitive DNA, mostly in the form 
of transposable elements (TEs) (Lander et al., 2001). TEs are mobile DNA sequences 
that are dispersed throughout the genome. Barbara McClintock's discovery of these 
"jumping genes" earned her a Nobel Prize in 1983 (McClintock, 1950). These 
sequences can change its position within the genome, sometimes creating or reversing 
mutations, or resulting in duplication of DNA sequences (Prak and Kazazian, 2000; 
Smit, 1999). TEs therefore have the potential to drive genome evolution by causing 
rearrangement of genomes (Ayarpadikannan and Kim, 2014). TEs are increasingly 
recognized as a potent source of regulatory sequences in eukaryotic genomes (Chuong 
et al., 2017). Expression of a gene might be disrupted by insertion of a TE by providing 
novel or stronger promoter sequences. Alternatively, enhancer functions carried 
within a TE might activate the expression of more distant genes upon transposition 
(Girard and Freeling, 1999). 
Transposable elements can be divided into two broad classes: DNA transposons and 
retrotransposons, according to their mechanism of action (Figure 11) (Kazazian, 2004; 
Prak and Kazazian, 2000). DNA transposons encode the protein transposase, which 
they require for excision and insertion, cutting and pasting themselves into new 
genomic locations. In contrast, the transposition of retrotransposons occurs by a 
replicative mechanism. DNA is first transcribed into RNA, which is subsequently 
reverse transcribed to DNA by a retro-element-encoded reverse transcriptase. This 
copied DNA is then inserted back into the genome at a new position while the original 
retrotransposon is maintained in situ. Retrotransposon are divided into two classes 
based on whether they contain a long terminal repeats (LTRs) at both ends (LTR 
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retrotransposons) or lack LTRs (non-LTR retrotransposons). The main function of such 
LTRs is to mediate the integration of the retroviral DNA via an LTR-specific integrase. In 
addition, they function as transcriptional promoters for both retroviral proteins and 
surrounding genes after genomic insertion. Non-LTR retrotransposons, in turn, consist 
of two sub-types: long interspersed elements (LINEs) and short interspersed elements 
(SINEs). The main different in their mechanism of action is that while LINEs encode for 
a reverse transcriptase and are transcribed by RNA polymerase II, SINEs do not encode 
reverse transcriptase and are transcribed by RNA polymerase III. 
 
Figure 11. Classification of transposable elements. LTR: long terminal repeats; LINEs: long interspersed 
elements; SINEs: short interspersed elements.   
4.1. Viruses: retroviruses 
A virus is the smallest type of infectious particles. A virus cannot reproduce by itself, 
but once it infects a susceptible cell (a host), however, it can direct the cellular 
machinery to produce more viral particles. The entire infectious virus particle, called a 
virion, consists of the nucleic acid (RNA or DNA) enclosed in a protein coat (Lodish et 
al., 2000b). Animal viruses are classified in 6 groups based on the composition of their 
genomes (DNA or RNA) and pathway of mRNA formation (Figure 12). 
Class VI corresponds to retroviruses. A retroviral particle contains two copies of single-
stranded positive-sense molecules of RNA within an internal protein core named 
capsid (Figure 13). Within this compartment, there are also several viral proteins such 
as a reserve transcriptase, capsid proteins, an integrase, and a protease. The inner core 
is composed of capsid protein, is surrounded by an outer layer composed of matrix 
protein(s), which is in turn surrounded by the envelope glycoprotein. 
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Figure 12. Classification of animal viruses. Viruses are divided into 6 classes (I-VI) depending on the 
composition of their genomes and pathway of mRNA formation. Genome can consist of a single- or 
double-stranded nucleic acid of DNA (shown in blue) or RNA (showed in red). The viral mRNA (plus 
strand) can, in turn, can derived from a minus strand of DNA or RNA. Image taken from Lodish et al., 
2000b. 
 
 
Figure 13. Retrovirus virion and provirus structure. The viral particle contains two copies of positive-
stranded RNA within an internal core named capsid. Also located within the capsid are several viral 
enzymes such as integrase, protease and reverse transcriptase enzymes. The inner core is surrounded 
by an outer matrix protein core, which is in turn encompassed by a glycoprotein envelope. The viral 
genome, termed provirus once integrated into the host genome, consists of an internal region 
containing GAG, POL, and ENV genes, flanked by LTR. Picture adapted from O’Keefe,2018.  
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Figure 14. Retroviral life cycle. After a retrovirus enters a host cell by fusion (step 1), reverse 
transcriptase converts the retroviral RNA genome into double-stranded DNA (step 2). This viral DNA 
then migrates to the nucleus and becomes integrated into the host genome (step 3). Viral genes are 
transcribed and translated (step 4). New virus particles assemble, exit the cell, and can infect another 
cell (step 5). Image taken from Lodish et al., 2000b. 
Retroviral infection is initiated when viral glycoproteins embedded in the lipid 
envelope recognize receptors displayed on the host cell plasma membrane and 
mediate viral attachment (Figure 14). Subsequent membrane fusion between the viral 
and host cell membrane follows and allows viral entry. Once inside the host cell 
cytoplasm, the virus is uncoated and replicates through the process of reverse 
transcription. First, the virus encodes for reverse transcriptase enzyme, which 
catalyzes the conversion of its RNA genome into DNA. This new retroviral double-
stranded DNA is then integrated into the host cell genome in a process catalyzed by 
the virus-encoded integrase. Once integrated, the retroviral genome is named named 
provirus. The provirus consists of an internal region containing GAG, POL, and ENV 
genes, flanked by LTRs (Figure 13). GAG encodes for the matrix and capsid proteins, 
POL encodes for proteins such as reverse transcriptase, protease and integrase 
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enzymes, and ENV encodes for the envelope proteins including surface envelope 
glycoproteins and transmembrane glycoprotein. Within the proviral 5’-LTR there is a 
promoter, which is recognized by the cellular RNA polymerase, and enhancer regions, 
which are important in the initiation of transcription. As any part of its genome, the 
host cell starts transcribing the viral genes, producing viral RNAs and translating these 
into the proteins required to assemble new copies of the virus. Progeny virions are 
subsequently released by budding from the host-cell membrane. Most retroviruses do 
not kill their host cells. Infected cells can, therefore, replicate and produce daughter 
cells with integrated proviral DNA and new progeny virions.  
4.2. Human endogenous retrovirus  
Human endogenous retroviruses (HERVs) are the result of ancestral retroviral 
infections that entered the human germline. The resulting permanent retroviral 
integrations termed as provirus are transmitted to the offspring in a Mendelian fashion 
(Figure 15). HERVs are part of the LTR retrotransposon group. In fact, the typical 
structure of a proviral HERV contains an internal region containing GAG, POL, and ENV 
genes, flanked by two LTRs (Figure 16). The structure and nature of the HERVs 
indicates that following the initial integration, HERV elements have been subjected to 
amplification and transposition events, leading to a widespread distribution of 
complete or partial retroviral sequences throughout the human genome. As a result, 
nowadays HERVs comprise approximately 8% of our genome (Cho et al., 2008; Löwer 
et al., 1996). However, since their conversion to Mendelian genetic elements, HERVs 
have also accumulated mutations and have been subjected to recombination events. 
Therefore, most (if not all) HERVs are unable to replicate due to deletions and 
mutations acquired during evolution. 
Apart from HERVs with the typical provirus structure, the human genome is littered 
with HERV-related sequences: pseudoelements, solo LTR and truncated elements 
(Figure 16). Pseudoelements are the result of LINE-mediated transpositions of the 
HERVs mRNA. They are characterised by the presence of a poly(A) tail and the partial 
truncation at the 5’ end (Pavlicek et al., 2002). The presence of solo LTRs is the result 
of homologous recombination events occurring between the two LTRs of an element, 
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which results in the excision of the internal open reading frame (ORF) (Pavlicek et al., 
2002). Truncated elements refer to HERVs with a truncated internal sequence or 
truncated LTRs. Since the U3 region of the LTR typically contains the binding motifs 
necessary for transcriptional initiation, only proviral elements were initially considered 
transcriptionally active. However, all kinds of HERV sequences have been found to be 
transcribed in human cells and tissues (Li et al., 2011), suggesting that transcription 
may be driven by control elements outside the HERV sequence. HERV elements are 
divided in around 30 multicopy families, each derived from an independent infection 
by an exogenous virus (Belshaw et al., 2005). Each family, in turn, is composed of 
closely related but distinguishable elements dispersed in the human genome.  
 
 
Figure 15. The endogenization process of retroviruses. Transmission of retroviruses can occur through 
two pathways: horizontal and vertical transmission. In horizontal transmission, retroviruses are 
transmitted among individuals of the same generation. However, when an exogenous retrovirus infects 
a germ line cell, the integrated viral DNA become part of the host’s genome and is transmitted vertically 
to the offspring like a human endogenous retrovirus. Imagen taken from Dewannieux and Heidmann, 
2013. 
INTRODUCTION 
 
43 
 
 
Figure 16. Schematic structure of HERV elements. HERV elements can show a complete proviral 
structure (an internal open reading frame flanked by two long terminal repeats (LTRs), or other 
incomplete structures such as pseudoelement, truncated element or solo LTR. A complete LTR is 
segmented into two unique regions (U3 and U5), and a repeated (R) region in between them. LTR 
contains a promoter in the U3 region, and a polyadenylation sequence in U5. Imagen taken from Li et 
al., 2011. 
Most HERVs are highly defective, unable to replicate and unable to produce infectious 
exogenous viruses due to deletions and mutations acquired during evolution. In fact, 
until recently, many scientists considered HERV a type of “junk” DNA since they 
apparently served no function but rather were remnants of past infections. However, 
while most repetitive DNA and HERV sequences may be devoid of biological relevance, 
particular HERVs have been observed to play biological roles. Although very few of the 
identified HERV loci contain proviruses with preserved open reading frames (ORFs) for 
the three major structural proteins GAG, POL, and ENV, some HERVs have retained 
ORFs putatively encoding functional proteins (Bénit et al., 2001; Villesen et al., 2004). 
HERVs have been principally reported to be implicated in stem cell identity and 
embryonic development (Grow et al., 2015; Schoorlemmer et al., 2014). The best 
illustration of the biological role of HERVs is the contribution of Syncytin to placental 
physiology. It turns out that a HERV copy of the family W located on chromosome 7q 
encodes for a competent HERV-W envelope protein named SYNCITIN-1, which is 
expressed in placenta and involved in placental development (Blond et al., 2000; Mi et 
al., 2000). However, although a small number of HERV-encoded proteins can be found 
under normal physiological conditions, expression of HERVs is usually silenced in adult 
tissues under normal physiological conditions (Dewannieux and Heidmann, 2013).  
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4.3. Regulation and dysregulation of retrovirus 
Several steps in the viral life cycle are blocked by a variety of silencing mechanisms to 
inhibit replication of retro-elements including HERV. Anti-retroviral defence 
mechanisms have been described that interfere with receptor binding and uncoating, 
trafficking of retroviral particles or components and viral DNA replication (Goff, 2004a, 
2004b; Wolf and Goff, 2008). For instance, APOBEC (apolipoprotein B mRNA-editing 
enzyme, catalytic polypeptide-like) proteins is a family of cytidine deaminases which 
deaminates cytosines to uracils during viral reverse transcription, contributing to 
hypermutation of viral synthesised DNA (Harris and Liddament, 2004). Retroviral 
particles and ribonucleotides are also detected by the innate immune system (Barbalat 
et al., 2011; Pertel et al., 2011). Silencing mechanisms are active and inhibit 
transcription and/or expression, and include DNA methylation, RNA interference 
(RNAi), repressive histone modifications, and ATP-dependent chromatin remodelling 
(Maksakova et al., 2008). HERVs expression is mainly repressed by epigenetic 
mechanism as histone modifications and DNA methylation (Maksakova et al., 2008). In 
fact, HERVs are heavily methylated in normal tissues(Hurst and Magiorkinis, 2017; 
Rowe and Trono, 2011). And for those HERV elements that are not fully methylated, as 
exemplified by the family of HERV-K(HML-2) elements, 5’LTR methylation levels 
inversely correlated with transcriptional activity of these elements (Lavie et al., 2005). 
Altogether, the combined activity of restriction mechanisms and especially DNA 
methylation restricts HERV expression to almost undetectable levels in physiological 
circumstances. 
HERVs have been suspected to be associated with several diseases such as cancer and 
neurodegenerative diseases (Colmegna and Garry, 2006; Dolei, 2006; Kurth and 
Bannert, 2010). However, it is not very well-known which mechanism induce 
upregulation of HERV transcripts and proteins in patients. Although HERVs are usually 
silenced by epigenetic mechanisms, silent HERVs can be activated by environmental 
triggers. In fact, it has long been known that CpG DNA demethylation can reverse the 
silencing of HERV (Stoye, 2012). Epigenetic changes observed in pathological 
conditions could explain HERV activation, and their direct or indirect contribution to 
diseases. For instance, genomic hypomethylation of HERV elements has been observed 
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in ovarian tissue of patients with ovarian clear cell carcinoma, and in T cells from 
systemic lupus erythematosus patients (Iramaneerat et al., 2011; Nakkuntod et al., 
2013). HERVs are induced in some tissues and at different development stages, which 
means that they are capable of responding to different external and internal signals 
(Figure 17).  
 
Figure 17. Schematic view of the different inducing factor that may act on HERVs. Several inducing 
factor may induce HERV mRNA synthesis, protein expression and even the formation of retroviral 
particles. Image adapted from Balada et al., 2009. 
Environmental factors and different molecules have been suggested to induce HERV 
expression (Balada et al., 2009). Environmental stimuli such as radiation, chemicals or 
infectious agents have been reported to modulate HERV expression. For instance, UVB 
irradiation of human epidermal keratinocytes and infection of the neuroepithelial cell 
line SK-N-MC with Toxoplasma gondii resulted in an increased transcriptional activity 
of HERV elements (Frank et al., 2006; Hohenadl et al., 1999). Similarly, infection of the 
SK-N-MC cell line with of herpes simplex virus 1 (HSV-1) or influenza viruses led to 
increased levels of transcripts from HERV-W elements (Nellåker et al., 2006). And HIV-
1 infected cell lines presented an up-regulated HERV expression compared to the 
corresponding uninfected cells (Vincendeau et al., 2015). All the above-mentioned 
findings   
4.4. Association of human endogenous retrovirus with diseases  
Although expression of HERVs is usually silenced in adult tissues under normal 
physiological conditions, contributions of HERV to pathologic processes have been 
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described, especially with respect to autoimmune diseases and cancer (Young et al., 
2013). There are several possible mechanisms that could explain the pathogenicity of 
HERVs. The most obvious pathogenic mechanism that can be considered for a HERV is 
the production of infectious virions. In theory, replication-competent retroviruses 
could arise from a series of recombination events between two or more replication-
defective HERVs, which would restore their respective defects. Although in vitro 
alignment of several defective members of the family HERV-K resulted in a replication-
competent recombinant retrovirus (Lee and Bieniasz, 2007), the frequency of this in 
vivo event was very low and no infectious HERV has been yet identified. We therefore 
assume, that the association of HERV with disease does not depend on retroviral 
infection, although particles may be present.  
Even if not transcribed or translated, HERV integrations may impact genome regulation 
and stability (Jern and Coffin, 2008; Young et al., 2013). Depending on their position 
and transcriptional orientation in relation to a host gene, HERV LTRs can act as 
transcriptional promoters or repressors of neighbouring genes. They could also disrupt 
genes at their integration site or alter ORFs to generate truncated proteins. HERVs 
could also promote genomic rearrangements and genome instability by providing 
regions of homology for DNA recombination. Non-allelic homologous recombination 
may cause deletions and duplications, resulting in genomic disorders and diseases 
(Campbell et al., 2014). For instance, apparent homologous recombination between 
HERV15 elements results in deletion of azoospermia factor a (AZFa) within the human 
chromosome Y, and leads to male infertility (Sun et al., 2000).  
As HERVs exist in the genome of all individuals, how HERVs may cause disease in some 
individuals and not in others is not obvious. A plausible explanation for this could lie in 
the existence of genetic polymorphisms in HERVs. For instance, a specific allelic variant 
or single nucleotide polymorphism (SNP) could be related to disease, an example of 
which is the suggested association of HERV-K18 polymorphisms with type 1 diabetes 
(Marguerat et al., 2004), and the association of HERV-W polymorphism in chromosome 
X is associated with MS risk (García-Montojo et al., 2014). On the other hand, 
insertional polymorphisms may also exist and be related to specific diseases. HERV-
K113 and HERV-K115 are insertional polymorphic proviruses present in the genomes of 
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29 and 16% of individuals respectively and, HERV-K113 prevalence has been associated 
with MS and Sjögren’s syndrome (Moyes et al., 2007).  
HERVs may cause disease by inducing or altering immune responses. Although most 
HERVs are replication-defective, many still retain the potential to generate transcripts 
and express retroviral proteins. Upregulated HERV transcripts or proteins synthesis 
would therefore be detected as foreign by the immune system and trigger an immune 
response (Fierabracci, 2009). In fact, elevated expression of several HERV transcripts 
and proteins has been reported to be associated with disease. In response to viral 
infection, antiviral innate immunity is activated, mediated by intracellular toll-like 
receptors (TLRs) that recognize viral DNA, RNA or protein as pathogen-associated 
molecular patterns (PAMP). TLR activation in turn triggers signalling pathways that 
induce transcriptional activation of genes encoding proinflammatory cytokines and 
type I interferons (IFN-α/β). This response could subsequently trigger anti-viral innate 
immune responses and modulate adaptive immunity (Xagorari and Chlichlia, 2008). For 
example, HERV-encoded ENV protein has been reported to interact with TLR4 in 
human monocyte, resulting in the production of proinflammatory cytokines (Rolland et 
al., 2006). And dsRNA overexpressed from HERV loci has been shown to trigger a TLR3 
mediated-immune response in cancer cells (Chiappinelli et al., 2015).  
4.5. Association of human endogenous retrovirus family W with multiple sclerosis 
An association between HERVs and multiple sclerosis (MS) was suggested when in the 
late 1980’s extracellular retroviral-like particles with reverse transcriptase (RT) activity 
were discovered and isolated from MS patient-derived cell cultures (Perron et al., 
1991, 1989). Molecular characterization of the RNA encapsidated in these particles, 
allowed for the identification of a novel retrovirus named multiple sclerosis-associated 
retrovirus (MSRV) (Perron et al., 1997). MSRV presented a strong homology with the 
family W of human endogenous retroviruses (Blond et al., 1999; Komurian-Pradel et 
al., 1999; Perron et al., 2000). Both MSRV and HERV-W have the structure typical of 
retrovirus (Figure 16). 
 The HERV-W family is a multicopy family consisting of approximately 650 closely 
related but distinguishable elements dispersed throughout the human genome. The 
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HERV-W family is composed by complete and truncated HERV-W elements (Figure 16). 
Whether MSRV represents an exogenous member of the HERV-W family or whether it 
originates from modified endogenous HERV-W copies is presently unknown 
(Komurian-Pradel et al., 1999; Laufer et al., 2009; Perron et al., 2000). Continuing 
uncertainty about the origin of MSRV and its relation to HERV-W led to the MS-
associated virus being relabelled as MSRV/HERV-W in several studies. 
The linkage between the presence or expression of MSRV/HERV-W and MS has been 
repeatedly underlined (Hon et al., 2013; Morandi et al., 2017b, 2017a). On one hand, 
the number of MSRV virions detected in serum, blood and cerebrospinal fluid (CSF) 
have been reported to be higher in MS patients (Dolei et al., 2002; Garson et al., 1998). 
On the other hand, in a large study of over a 200 samples, MSRV-like DNA copy 
number was also increased in peripherical blood mononuclear cells (PBMCs) of MS 
patients (Garcia-Montojo et al., 2013). In other studies, MSRV/HERV-W mRNA was 
detected at higher levels in plasma, CSF, PBMCs and autopsied brain from MS patients 
(Mameli et al., 2007; Perron et al., 2012). MSRVENV and SYNCYTIN-1 transcripts are 
closely related and difficult to distinguish from each other. In fact, they have 94% 
identity and only differ by an insertion of 12 nucleotides in the MSRV ENV RNA that is 
lacking in SYNCYTIN-1, in a region corresponding to the trans-membrane domain of 
MSRV ENV protein. The lack of discriminating tools has generated confusing reports in 
the literature for years, during which SYNCYTIN-1 was thought to be involved in MS 
pathology as well. Confusion was exacerbated by the fact that antiSYNCYTIN 
antibodies cross-react with all HERV-W-encoded ENV protein. As a result, the ENV 
protein detected in autopsied normal and MS human brain tissue (Antony et al., 2006, 
2004) was described as SYNCYTIN. However, in 2009, the 12 bp insert that 
distinguishes MSRV ENV and SYNCYTIN-1 transcripts was selected for the development 
of a discriminatory real-time PCR assay (Mameli et al., 2009). Both transcripts were 
expressed in autopsied human brain and PBMCs, but only MSRV ENV sequences were 
found more frequently in MS patients compared to controls (Mameli et al., 2009). 
Based on these results, the hypothesis that associated SYNCYTIN-1 and MS was finally 
rejected. 
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Many searches aimed at the identification of transcribed HERV-W loci in MS patients 
have been performed, but few clear results have been achieved accomplished. Seven 
HERV-W loci are reportedly transcribed in human PBMCs of MS patients and controls 
(Laufer et al., 2009). However, transcriptional activity of individual identified HERV-W 
elements did not significantly differ between patients and controls. A similar analysis 
was performed in autopsied brain tissue (Schmitt et al., 2013). Likewise, among more 
than 100 transcribed HERV-W loci identified, none of them was found to be 
upregulated in brains of MS patients. To date, neither MSRV as a unique HERV, nor 
novel copies of HERV-W whose is associated with MS have been identified. Therefore, 
the origin of MSRV and its location within the human genome still remain unknown. 
At the protein level, HERV-W ENV and GAG proteins have been detected in normal and 
MS autopsied human brain tissue, but reports varied. Some studies reported HERV-W 
proteins in brain tissue from MS patients but also in controls (Perron et al., 2005), 
while others only detected HERV-W proteins in MS brain and serum (Mameli et al., 
2007; Perron et al., 2012). As no antibody specific for a unique HERV-W had been 
identified, the choice of antibody along with the technique applied and the patient 
cohort may influence in the results. HERV-W ENV proteins have also been reported to 
be expressed in higher quantities on the surface of B cells and monocytes in patients 
with active MS (Brudek et al., 2009). 
Once overexpressed, the is no doubt regarding the pathogenic potential of 
MSRV/HERV-W proteins. In vitro infection of human peripheral blood lymphocytes 
from healthy donors with MSRV particles induced a T-lymphocyte-mediated immune 
response (Perron et al., 2001). On the other hand, MSRV-type envelope protein has 
the potential to trigger a TLR4-mediated immune response in human monocytes, with 
the consecutive cytokine production (Rolland et al., 2006). Consistent with the latter 
finding, immunohistochemical analysis of brain and spinal cord from both control and 
multiple sclerosis patients, revealed enhanced expression of TLR3 and TLR4 in inflamed 
CNS tissues (Bsibsi et al., 2002). More recently, stimulation of human cultured primary 
oligodendrocyte precursor cells (OPCs) with MSRV-related ENV protein provoked a 
TLR4-mediated induction of proinflammatory cytokines and an enhanced nitric oxide 
(NO) production (Kremer et al., 2013).  Altogether, these results indicate the ability of 
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MSRV/HERV-W proteins may have to trigger a TLR-mediate immune response and 
contribute to diseases. 
Following the repeated association of MSRV ENV protein with MS, a selective 
humanized antibody targeting MSRV ENV protein was developed and named GNbAC1 
(Curtin et al., 2014, 2012). GNbAC1 was obtained after immunizing mice with 
recombinant MSRV ENV protein, expressed from a cloned RT-PCR amplicon, which was 
obtained using purified extracellular MSRV virions. GNbAC1 selectively binds with high 
affinity to the SU domain of the MSRV ENV protein and neutralizes its TLR4 binding. 
GNbAC1, therefore, could be used as a treatment for MS and is currently being tested 
in clinical trials with promising results (Curtin et al., 2016; Derfuss et al., 2015; 
Zimmermann et al., 2015). Altogether, it remains entirely possible that dysregulation 
of the immune system triggered by MSRV-type transcripts and proteins contributes to 
MS pathogenesis.  
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Since the first description and characterization of multiple sclerosis-associated 
retrovirus (MSRV) (Perron et al., 1997), the connection between MSRV and multiple 
sclerosis (MS) has been addressed in a variety of studies. Despite the strong homology 
between MSRV and the family W of human endogenous retroviruses (HERV-W), the 
exact relationship between MSRV and HERV-W remains unknown (Blond et al., 1999). 
Both the presence and expression of MSRV/HERV-W RNA and proteins is elevated in 
peripherical blood mononuclear cells (PBMCs) and cerebral lesions of MS patients 
(Garcia-Montojo et al., 2013; Mameli et al., 2009; Perron et al., 2012). However, 
neither the location of MSRV within the human genome, nor MS-associated HERV-W 
elements have been identified so far (Laufer et al., 2009; Perron et al., 2000; Schmitt et 
al., 2013). Regulation of retroviruses involves several mechanisms including epigenetic 
regulation. Nevertheless, while HERV hypomethylation is associated with a range of 
diseases such cancer (Gimenez et al., 2010; Iramaneerat et al., 2011), HERV-W 
methylation status in the context of MS has not yet been evaluated. Therefore, the 
possibility that hypomethylation-induced overexpression of HERV-W may serve as a 
diagnostic marker, or even contributes to disease, remains viable. In response to viral 
infection, toll-like receptors (TLRs) play an important role in the activation of antiviral 
innate immunity pathways. As retroviral and HERV-derived RNAs have the potential to 
trigger a TLR3-mediated immune response in cancer cells (Chiappinelli et al., 2015), I 
was interested in the possibility that TLR recognition of upregulated HERV-W RNA 
expression and subsequent immune responses (including interferon-beta production) 
play a role in MS. 
 
Objectives: 
1. Identify the location of MSRV and/or MS-associated HERV-W elements within the 
human genome. 
2. Confirm the increased expression of MSRV/HERV-W in MS patients. 
3. Identify which among the 600 described HERV-W elements are overexpressed in 
PBMCs of MS patients. 
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4. To determine whether DNA methylation may be involved in the regulation of HERV-
W expression. 
5. To evaluate the TLR-mediated activation of the immune system by HERV-W 
overexpression in oligodendrocytes or cell types relevant for MS. 
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Manuscript I. Development of a splinkerette-PCR method for the 
genome-wide amplification of multiple sclerosis-associated HERV-W 
copies in humans. 
 
Abstract 
While the presence and expression of Human Endogenous Retroviruses family or type 
W (HERV-W) has been repeatedly associated with Multiple Sclerosis (MS), disease-
specific copies have not been identified in the human genome. To date, no systematic 
searches for disease-specific proviruses of HERV-W have been reported. Therefore, the 
possibility that unfixed copies or rare polymorphic loci contribute to the disease has 
not been directly addressed. Here we describe a variant of so-called splinkerette 
amplification of proviral sequences, in which DNA fragments containing genomic 
sequences flanking the termini of HERV-W proviral sequences are selectively amplified 
by PCR. Subsequent sequencing of the products obtained allows genomic positioning. 
A total of 7 alternative primer sets were successfully applied in an attempt to identify 
potential unfixed HERV-W proviruses specific to MS patients. We surveyed the HERV-
W proviral content of 4 unrelated humans, including several that had been previously 
shown to carry a high genomic load of HERV-W-like elements. In an initial analysis of 
about 100 cloned products, we failed to identify unfixed HERV-W proviruses specific to 
MS patients. The assay also revealed the presence of a non-disease related 
polymorphism in HERV-W Xq21 loci. Splinkerete-PCR products obtained from 2 MS 
patients were analysed by next-generation sequencing (NGS). The NGS data obtained 
were analysed using the software RetroSeq, which can accurately discover non-
reference transposable element insertions. While several non-reference insertions 
were identified in this analysis, their relation to MS has not been established yet. The 
method we describe, in combination with NGS, allows for systematic searches for 
uncharacterized HERV-W proviral sequences and thereby provides a direct means to 
assess inter-individual genetic variation associated with HERV-W proviruses and their 
potential relation to MS.  
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Introduction 
Human endogenous retroviruses (HERVs) are the result of ancestral retroviral 
infections that entered the human germ line, leading to a permanent retroviral 
integration transmitted to the offspring in a Mendelian fashion. After initial 
integration, HERVs continued to generate self-copies and as a result they comprise 
approximately 8% of our genome (Cho et al., 2008; Löwer et al., 1996). Typical 
structure of a HERV contains an internal region containing GAG, POL, and ENV genes, 
flanked by two long terminal repeats (LTR). Although most HERVs are highly defective 
and unable to replicate due to deletions and mutations acquired during evolution, 
some HERVs have retained open reading frames (ORFs) putatively encoding functional 
proteins (Bénit et al., 2001; Villesen et al., 2004). As an example, a HERV-W copy 
located on chromosome 7q is been reported to encode for a competent HERV-W 
envelope protein named SYNCYTIN-1, which is expressed in placenta and involved in 
placental development (Blond et al., 2000; Mi et al., 2000). HERVs have been stated as 
well to be associated to several diseases such as cancer and neurodegenerative 
diseases (Colmegna and Garry, 2006; Dolei, 2006; Kurth and Bannert, 2010).  
In the late 1980’s an association between HERVs and multiple sclerosis (MS) was 
suggested, as extracellular retroviral-like particles with reverse transcriptase (RT) 
activity were discovered and isolated from MS patient-derived cell cultures (Perron et 
al., 1989, 1991). Follow-up studies using PCR-based approaches yielded the molecular 
characterization of the RNA encapsidated in these particles, and a novel retrovirus 
named multiple sclerosis-associated retrovirus (MSRV) was reported (Perron et al., 
1997). However, no replication-competent MSRV provirus encoding such particles 
could be identified (Perron et al., 2000). MSRV presents a strong sequence homology 
with the HERV-W family, although the exact relationship has not been clarified yet 
(Blond et al., 1999; Komurian-Pradel et al., 1999; Perron et al., 2000). The HERV-W 
family is a multicopy family consisting of approximately 650 closely related but 
distinguishable elements dispersed in the human genome. Whether MSRV represents 
an exogenous member of the HERV-W family or whether it originates from modified 
endogenous HERV-W copies remains unknown (Komurian-Pradel et al., 1999; Laufer et 
al., 2009; Perron et al., 2000).  
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The linkage between the presence or expression of MSRV/ HERV-W and MS has been 
repeatedly underlined (Hon et al., 2013; Morandi et al., 2017a, 2017b). Not only the 
number of MSRV virions detected in serum, blood and cerebrospinal fluid (CSF) have 
been reported to be higher in MS patients over controls (Dolei et al., 2002; Garson et 
al., 1998), but also MSRV/ HERV-W expression has been established to be higher in 
plasma, CSF, peripheral blood mononuclear cells (PBMCs) and autopsied brain from 
MS patients versus controls (Mameli et al., 2007; Perron et al., 2012). In addition, 
MSRV/ HERV-W proteins express in human brain and can trigger an immune response 
(Perron et al., 2001, 2005; Rolland et al., 2006), thus suggesting their potential 
pathogenicity. Nevertheless, the mechanism of HERV action in MS has not been 
conclusively demonstrated to date (Antony et al., 2011; Grandi and Tramontano, 
2017). 
The genomic distribution of HERV-W and the number of copies has been described 
(Grandi et al., 2016). Moreover, searches for transcribed HERV-W loci have clarified to 
which extent HERV-W loci described in the human genome database are active in MS 
patients (Laufer et al., 2009; Schmitt et al., 2013). Most HERVs copies are present in 
the human population and described in the human reference genome sequence 
because they integrated a long time ago (fixed copies). However, if some HERVs have 
continued replicating in the human population, it is possible that some copies have 
integrated in some individuals’ genome but are absent from the reference genome, 
since they have not had time to drift to fixation (unfixed copies) (Marchi et al., 2014). 
This hypothesis is reinforced by the fact that novel retroviral insertions of HERV-K 
elements have been reported (Kahyo et al., 2013; Wildschutte et al., 2016). In addition, 
other studies have supported that retroelements preserve their mobile properties in 
spite of their evolutionary age (Kremer et al., 2013), as well as revealing that some 
HERVs actually occur polymorphically in the human genome (Moyes et al., 2007; 
Turner et al., 2001). Therefore, there is a possibility that MS might be associated only 
with specific unfixed HERV-W/MSRV loci. This issue has not been amply addressed, as 
few searches for additional genomic copies of HERV in MS patients have been reported 
(Nissen et al., 2012). In order to address this issue, further searches for the genomic 
location of MSRV or novel HERV-W copies are required. To the best of our knowledge, 
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we present the first systematic approach to discover potential MS-associated copies of 
HERV-W. We have successfully adapted a previously reported splinkerette-PCR 
method (Uren et al., 2009), initially designed for the isolation of retroviral insertion 
sites, to identify HERV-W-like sequences. This new method was validated and easily 
allowed for the identification of referenced HERV-W copies present in gDNA samples 
from MS patients. To increase the scope of the search, we carried out a next-
generation sequencing (NGS) analysis that enlarged the number of HERV-W copies 
identified in gDNA samples from MS patients.  With the aim of identifying unfixed 
HERV-W loci, we analysed the NGS data using the software RetroSeq, which can 
accurately discover non-reference transposable element (TE) insertions (Keane et al., 
2013; Marchi et al., 2013). Several non-reference HERV-W copies could be identified 
using this approach. Further research is required to clarify the importance of these 
unfixed HERV-W copies to MS. 
Materials and methods 
PBMCs isolation and gDNA extraction  
Blood samples were collected from MS patients and healthy controls from the 
Neurology Department of Miguel Servet University Hospital (Zaragoza, Spain). Clinical 
samples were obtained with "Informed Consent", in the context of the study 
"Reactivation of Human Endogenous Retrovirus in Multiple Sclerosis as a diagnostic 
tool: Epigenetic control and inducing factors”. This study has been approved by the 
local Ethics committee (CEICA, PI14/0021) in 2014. Whole fresh blood was drawn into 
vacutainer tubes (Becton Dickinson Vacutainer) containing EDTA. Within the day, 
peripheral blood mononuclear cells (PBMC) were isolated using Histopaque-1077 
(Sigma) as previously described (Böyum, 1968) (Figure s1). Cells were incubated with 
Genomic Lysis Buffer (10 mM Tris-Cl pH8, 25 mM EDTA, 0.5% SDS, 100 mM NaCl) and 1 
U/ml Proteinase Q (QIAGEN) at 65 °C overnight. Genomic DNA was subsequently 
extracted using phenol-chloroform, precipitated using sodium acetate-ethanol 
precipitation, re-suspended in 100 µl of TE buffer (10 mM Tris-Cl pH 8, 1 mM EDTA pH 
8) and quantified using Nanodrop (Thermo Scientific). Two additional gDNA samples 
from MS patients, obtained from the Multiple Sclerosis Unit of San Carlos Clinic 
Hospital (Madrid, Spain), were generous provided by Roberto Alvarez Lafuente. They 
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had been included in a previous study (Garcia-Montojo et al., 2013), and represent 
samples with high HERV-W copy numbers (Roberto Alvarez Lafuente, personal 
communication). 
Library construction and amplification 
A splinkerette-PCR method previously described (Uren et al., 2009) was adapted for 
HERV-W sequences and carried out as follows. Genomic DNA (2 µg) was digested with 
40 U of a restriction enzyme (Table s1) in a 30-µl reaction containing 1 mM DTT. 
Digestion was incubated overnight at 37 °C, followed by a heat inactivation of the 
enzyme at 75 °C for 10 minutes. The digestion product was cleaned up using phenol-
chloroform and precipitated with sodium acetate-ethanol according to standard 
protocols. The final product was re-suspended in 20 µl of TE buffer and 300 ng of 
digested DNA was ligated to the splinkerette adaptors (Table s2). The splinkerette 
adapter mix was prepared containing according to the instructions given (Uren et al., 
2009). The ligation reaction was carried out in a 40-µl volume using 25 pmol 
splinkerette adaptor mix, 10 U of T4 DNA Ligase and 1X T4 DNA Ligase Buffer. Ligation 
was incubated at 4 °C overnight, followed by heat inactivation of the T4 DNA Ligase at 
75 °C for 10 minutes. The 40-µl ligation was then digested at 37 °C overnight with 10U 
of a second restriction enzyme (Table s1), in the presence of 1 mM DTT. Following 
digestion, the T4 DNA ligase was heat inactivated at 75 °C for 10 minutes and the 
digested product was cleaned up using the Geneclean Turbo kit (MP Biomedicals), re-
suspended in 20 µl of TE buffer and stored at -20 °C until used. For the following 
nested-PCR, primers required have been listed (Table s1) and cycling conditions were 
as described (Uren et al., 2009). Primary PCR amplification was carried out in a 50-µl 
volume using 5 µl of purified splinkerette adaptor ligated DNA, 0.1 µg splink1 primer, 
0.1 µg LTR1 primer, 250 µM dNTPs, 1.5 mM MgCl2, 1.25 U Platinum® Taq DNA 
Polymerase and 1x PCR Buffer. For the nested PCR, we used 1 µl of the first PCR 
product as template and it was performed in a 50-µl volume containing 0.1 µg splink2 
primer, 0.1 µg LTR2 primer, 250 µM dNTPs, 2 U Taq DNA Polymerase from Thermus 
aquaticus (Sigma-Aldrich) and 1x PCR reaction buffer containing MgCl2 (Sigma-Aldrich). 
The presence of amplified products was confirmed on a 2% agarose gel (Figure s2A). 
All enzymes were obtained from Thermo Scientific™ unless otherwise indicated. 
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Splinkerette-PCR product sequencing 
Splinkerette-PCR product was purified using the GeneClean Turbo Kit (MP 
Biomedicals), eluted in 20 µl of TE buffer and cloned into the pGEM®-T Easy Vector 
System I (Promega) according to manufacturer's instructions. The vector was 
transformed into E. coli XL1 cells and cultured in Luria–Bertani (LB)-agar plates 
supplemented with 50 µg/mL ampicillin at 37 °C. Colonies were screened for the 
presence of insert by colony PCR and further analysed by plasmid miniprep and 
sequencing. DNA sequencing analyses were performed by Secugen S.L (Madrid, Spain) 
and the genomic locations of HERV-W insertions were mapped to the human genome 
(GRCh38) using the blastn option of BLAST 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch) (Altschul et al., 
1990) (Figure s2B). Species-specific filters for retroviral elements were not activated 
(or de-activated). To avoid mismapping as a result of the high degree of homology 
among HERV-W elements, a similarity of > 97% between the database sequence 
and the total length of a particular sequence was used as criterium to assign the 
sequences to a particular locus. 
Polymorphism analysis  
For the PCR we used as template 100 ng of gDNA, previously fragmented by sonication 
for 5 minutes at high power with cycles of 30 seconds ON, and 30 seconds OFF. PCR 
primers were designed using Integrated DNA Technologies (IDT) PrimerQuest tool 
(https://eu.idtdna.com/PrimerQuest/Home/Index) (Forward primer: 5’-
CACCATCTTGGGAGCTCTG-3’, reverse primer: 5’-
[Btn]CTAAACATCAACCTGAGAACTAAGC-3’). The PCR reaction was carried out in a 50-µl 
volume using 200 µM dNTPs, forward and reverse primers (400 nM each), 1 mM 
MgCl2, 0.5 U Taq DNA Polymerase from Thermus aquaticus (Sigma-Aldrich) and 1x PCR 
reaction buffer containing MgCl2 (Sigma-Aldrich). gDNA was boiled for 3 minutes and 
cycling conditions were as follows: 94 °C for 2 minutes and then 35 cycles of 94 °C for 1 
minute, 60 °C for 1minute and 72 °C for 1 minute, with a final extension of 72 °C for 10 
minutes. The presence of amplified product was confirmed on a 2% agarose gel. PCR 
product was sequenced using PSQ 96MA System (Pyrosequencing) according to 
manufacturer’s instructions. The resulting data was analysed and quantified with the 
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PSQ 96MA 2.1 software (Biotage) applying the default settings. The forward PCR 
primer was used as sequencing primer, and the nucleotide dispensation order for the 
assay was as follows 5’- CTGCAGCAGTACTGCGCT-3’. Several negative controls were 
included in the sequence to assess the absence of undesired PCR products. 
Next-generation sequencing analysis  
NGS and subsequent analysis including RetroSeq was carried out by the Sequencing 
and Functional Genomics Service (Servicio Científico Técnico de Secuenciación y 
Genómica Funcional) of the Aragon Health Sciences Institute (IACS, Zaragoza). 
Methods for sequencing were recommended or approved for IonTorrent technology 
by the relevant manufacturers. PCR products were end repaired and purified with 
Agencourt AMPure XP paramagnetic beads (Beckman Coulter) and amplicons were 
quantified using the Qubit 3 fluorometer (Qubit BR dsDNA assay, Thermofisher). 
Adapters and barcodes (Ion Xpress Barcode Adapters, Thermofisher) were added by 
ligation, followed by product purification with AMPure XP beads. Libraries were 
prepared separately for each simple using the Kapa Lib Prep Kit for Ion Torrent 
(Roche). Libraries were quantified by qPCR (Ion Library TaqMan™ Quantitation Kit, 
Thermofisher) and equimolar amounts of sample were pooled before template 
preparation. Emulsion PCR, template enrichment and chip loading were carried out 
manually using the Ion 520&530 Kit-OT2 (Thermofisher) and samples were sequenced 
on the Ion Torrent S5XL platform using a Ion 530 chip. 
The Fastq files produced by the sequencer (barcodes removed) were further trimmed 
to remove PCR primer sequences and sequence reads were mapped to the human 
reference genome (version hg19) using the Torrent MApping Program (TMAP v5.2.22). 
Mapping criteria were evaluated based on the error rate, and adjusted accordingly. 
Strict criteria were applied to maximize mapping differences between different copies 
(soft clipping off, mismatch penalty 100, open gap penalty 100, gap extension penalty 
10, minimum alignment length 135, "unique best hit and stage1 map4"). For each 
sample, the number of reads corresponding to individual known HERVW copies was 
extracted, as well as the cumulative error rate. 
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Discovery of HERV-W elements not represented in the reference genome 
Fastq files produced by IonTorrent sequencing (Figure 3A) were trimmed to remove 
PCR primer sequences. Reads were converted "in silico" to first double stranded DNA 
sequences, and subsequently into 50 bp long paired-end reads. The resulting read 
pairs were mapped to the human reference genome (version hg19) using BWA 
(version 0.7.16a-r1181). The resulting bed file was loaded into RetroSeq (Keane et al., 
2013), a software that specifically designed screen NGS data to discover proviral 
insertions not present in the reference genome. HERV-W sequences present in this 
version of the genome database were downloaded from RepBase (Bao et al., 2015). 
RetroSeq analysis can be separated into 3 steps: reads pairs that map to different 
genomic locations are first identified, compared to locations of known HERVW 
elements (one of the paired reads is required to overlap), and scored based on the 
number of overlapping reads and the mapping scores. The result is a list of 
breakpoints, which indicates the positions in the reference genome where a not-listed 
HERVW insertion is present in the sample analysed.  
Results 
Strategy for identification of HERV-W-like sequences in human genome based on a 
variation of a splinkerette-PCR method 
Although MSRV has been repeatedly associated with MS, systematic searches for its 
genomic location have not been reported. To develop assays allowing such systematic 
analysis, a previously reported splinkerette-PCR method to isolate retroviral insertion 
sites (Uren et al., 2009) has been effectively adapted (Figure 1A). This highly efficient 
technique is a variant of ligation-mediated PCR, using a splinkerette ‘hairpin loop’ to 
avoid artefacts caused by ‘end-repair priming’ and improve specificity by requiring 
synthesis from a primer that anneals within the proviral sequences. Briefly, genomic 
DNA is first digested with a high-frequency-cleavage restriction enzyme, linked to 
compatible splinkerette adaptors and selectively digested with a low-frequency-
cleavage restriction enzyme to remove one of the splinkerette adaptors. The final 
product is amplified in two rounds of PCR, and the resulting fragments are cloned and 
sequenced. Therefore, this technique allows the amplification, sequencing and location 
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of the genome sequence that lies outside of a known retroviral sequence. Due to the 
strong homology shared between MSRV and HERV-W, we adapted this method to 
selectively amplify HERV-W-like sequences with the aim of identifying MSRV-like 
sequences or HERV-W copies not described in the human genome database. Since 
MSRV is not describe in any human genome database to date, we consequently 
gathered the human genome sequences that did match 100% with a set of external 
primers that specifically amplify MSRV-type ENV (Mameli et al., 2009), and we used the 
consensus sequence of these MSRV/HERV-W sequences as a template to adapt the 
method. Furthermore, as HERV-W elements contain different elements (complete 
provirus, pseudoelement, truncated copies and solo LTR) (Costas, 2002; Li et al., 2011), 
different splinkerette-PCR assays were designed by selecting the appropriate restriction 
enzymes and primers in order to cover these different structures (Figure 1B). Design A 
aims to amplify the area downstream of the U5 region of the 3’ LTR of a complete 
HERV-W element. Design B intends to amplify the area downstream of the U3 region of 
the 3’ LTR of a HERV-W pseudoelement. Design C focuses on amplifying the area 
upstream of the U3 region of the 5’ LTR of a complete HERV-W element. Design D 
amplifies from the ENV gene region towards 3’ LTR. This last assay is quite relevant 
because it takes advantage of a set of primers used to detect higher MSRV-like 
sequences expression in PBMCs of MS patients over controls (Mameli et al., 2009), 
pretending this way to enclose the pool of sequences where to look for MSRV-like 
sequences. Assay designs A to D were carried out using genomic DNA from PBMCs of 
two MS patients. Among a total of 73 clones that were sequenced after cloning, 70 
corresponded to sequences closely related to HERV-W (>97% identity between the 
cloned sequence and the database sequence was used as criterium) (Table 1A). The 3 
remaining clones corresponded to PCR artefact (data not shown). Out of these 70 
clones, 41 did not contain suficient sequence outside of the HERV-W-part to allow for 
the identification of their genomic position. In contrast, the 29 remaining clones could 
be unequivocally localized and corresponded to copies represented in the UCSC 
Genome database.  
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Figure 1. Overview of the splinkerette-PCR protocol used to determine the location of HERV-W/ MSRV 
copies. A) Steps performed to generate splinkerette-PCR products for sequencing. B) Different 
splinkerette-PCR designs carried out in order to cover most of the HERV-W copies described by Mameli 
G et al., 2009. The red arrows indicate the location of the primer in the 1st round of PCR. It is not drawn 
to scale. 
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Table 1. Numbers represented above are derived from the sequencing of splinkerette-PCR products. 
Designs A-G are explained in Figure 1B. Clones were generated by cloning splinkerette-PCR products. 
Located: non-LTR sequence that allows localization in human genome (>97% homology with GRCh38). 
Copy expected: located in copies expected based on primer design. Other copies: located with >97% 
homology to HERV-W copies in the reference genome different from the copies expected. New location: 
LTR location not present in the reference genome (GRCh38).  
In a separate study, we cloned and sequenced MSRV/HERV-W-ENV-specific PCR 
products, generated after reverse transcription of RNA of MS patients to identify loci 
transcribed in PBMCs (Manuscript II). 21 transcribed HERV-W loci were found within 
more than 100 sequenced clones, of which HERV-W copies on chromosome 19q13.2 or 
5p12 were among the most abundantly transcribed. However, if unfixed MSRV/ HERV-
W copies existed, this high level of transcription could mask the expression of non-
reference HERV-W copies with high similarity to HERV-W 19q13.2 or 5p12, if such 
copies existed. To discriminate weather the high level of transcription really originated 
from the HERV-W 19q13.2 or 5p12 copies as opposed to unfixed copies with high 
similarity, we developed more splinkerette assays. These novels designs (E-G) aimed to 
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specifically amplify HERV-W loci 19q13.2 and 5p12 or close relatives (Figure 1B). Once 
validated, assays were carried out using genomic DNA from PBMCs of one MS patients, 
allowing us to efficiently locate both HERV-W copies and others HERV-W loci. 
However, all clones analysed could be unequivocally localized, indicating they are not 
unfixed HERV-W copies (Table 1B). 
Additionally, we applied the splinkerette-PCR design F in two gDNA samples presenting 
a high copy number of HERV-W elements (Garcia-Montojo et al., 2013) (M&M). All 22 
sequenced clones corresponded to HERV-W-like sequences, and 17 out of 22 clones 
could be unequivocally localized. Except for one particular clone (see below), the 
sequence of all of them corresponded to known HERV-W copies represented in the 
UCSC Genome database (Table 1C).  
Validation of a HERV-W polymorphism 
When the sequence of one clone was mapped to the human genome (GRCh38) using 
BLAST, the best match found shared only a 93% identity and corresponded to the 
location X: 147021204 to 147021360 (Figure 2A). Although the search aimed to 
undoubtedly locate the clone sequence, there were mismatches between the 
retroviral sequence of the clone and its best match in the database. This lack of 
homology meant that the clone sequence was not described in the database and it 
could be an unfixed HERV copy. To study if the polymorphism was linked to multiple 
sclerosis, a SNP genotyping analysis was performed by pyrosequencing. First, a set of 
primers was designed to specifically amplify both the cloned sequence and its best 
genomic match. PCR amplification was carried out using these primers and using the 
gDNA sample in which the polymorphism had been found as a template. The PCR-
amplified product was analysed by pyrosequencing (Figure 2B). It turned out that 
98.5% of the PCR product corresponded to the sequence described in the database, 
while just a 1.5% of the PCR product matched the sequence of the clone. The low 
percentage of polymorphism detected in the sample indicate that it is not a frequent 
allele in PBMCs. Given this confirmation, it could not be confirmed if the clone 
sequence corresponded to a newly discovered unfixed copy or a PCR-generated 
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artefact. However, these data ratified the usefulness of the adapted method allowing 
the identification of possible loci of interest. 
 
 
Figure 2. Analysis of a suspected genetic polymorphism. A) Alignment of the sequenced polymorphic 
clone that carries the (Query) with its best match in the human genome database (Sbjct). Location: 
Homo sapiens chromosome X, GRCh38.p7 Primary Assembly 147021204 to 147021360, identities: 
146/157(93%), gaps: 1/157(0%), strand: Plus/Plus. LTR sequence is marked in blue, the sequence that 
lies outside the retroviral element is marked in green. The sequencing primer used in the 
pyrosequencing is highlighted in yellow. Partial representation of its chromatogram is represented 
above and the rectangle indicates the region analysed by pyrosequencing. B) Pyrogram resulting from 
the SNP analysis. Vertical axis: signal intensity; horizontal axis: order of residues analysed. The signal 
intensity is proportional to the number of incorporated nucleotides, and the DNA sequence can be read 
based on the appearance of a peak and the height of the signal in the pyrogram.  Position of SNPs is 
highlighted in yellow. The quality of the result at each position is estimated by the software and 
represented through a colour-based score: blue (“passed”), yellow (“to check”) and red (“failed”). 
Next-generation sequencing analysis 
To extend the genomic search for HERV-W loci not represented in the genome 
database, splinkerette-PCR products were analysed with NGS technology. Splinkerette-
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PCR design A was applied to DNA samples from 2 MS patients with verified high HERV-
W copy numbers (Roberto Alvarez Lafuente, personal communication), splinkerette-
PCR products were generated, and subjected to IonTorrent based NGS (Figure 4A). 
NGS data was examined using the software RetroSeq (Keane et al., 2013), which 
detects non-reference TE insertions from paired-ends NGS data. In the context of 
splinkerette-PCR products, the paired reads of the DNA sequence correspond to the 
sequence of a HERV-W element and its bordering genomic sequence, respectively 
(Figure 3). Briefly, RetroSeq software selects pairs with homology to HERV-W and 
compares the location of mapped paired-end reads in the human reference genome. If 
the different reads of a pair are mapped close to each other, the DNA sequence is 
described in the human reference genome and corresponds to a copy present in the 
reference genome. While if the couple of reads are not mapped in nearby positions, 
they are a “discordant read pair” and it could be a variant HERV-W integration site. 
Additional filters incorporated in the software require a minimum number of reads to 
overlap in the same location. RetroSeq software did identify non-reference HERV-W 
insertions within our NGS data (Figure 4B). The relationship between these insertions 
and MS is unknown at present, and their presence should be compared between MS 
patients and a control cohort. 
 
Figure 3. Schematical representation of RetroSeq analysis. A typical splinkerete-PCR product is 
composed of a partial HERV-W element and its bordering genomic sequence. DNA fragments generated 
by splinkerette-PCR were sequenced and data obtained was converted to short paired-end reads 
(indicated as Read 1 and Read 2 in the figure). The obtained pairs were mapped to the human reference 
genome (version hg19). RetroSeq software analysis determines whether the two alignments are 
adjoining or not and detects whether the sequence corresponds to the human reference genome 
or represents a variant HERV-W integration site. 
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Figure 4. A) The table shows the Fastq files produced by IonTorrent sequencing for samples 1 and 2 
(total reads), the average read lengths for each sample (bp, base pair), along with the number of total 
mapped reads. B) The table indicates the non-reference HERV-W insertions that RetroSeq software 
identified within the NGS data (total reads). The genomic location within the human genome (version 
hg19) is indicated for each HERV-W insertion and underlined for those non-reference HERV-W insertions 
that overlaps (within hundred base pairs) between the two samples.  
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Discussion 
Since MSRV particles were detected in MS patient-derived cell cultures, the enlarged 
presence of MSRV/ HERV-W elements has been repeatedly observed in MS patients. 
However, limited searches with the aim of identifying the genomic location of MSRV or 
MS-associated HERV-W copies have been conducted. The distribution and genetic 
composition of several HERV-W elements in the human reference genome has been 
approached (Grandi et al., 2016). And other studies have yielded the identification of 
the HERV-W element which are transcribed in MS patients (Laufer et al., 2009; Schmitt 
et al., 2013). However, to date, neither replication-competent MSRV provirus encoding 
such particles nor MS-specific HERV-W locus has been identified within the human 
genome. 
To the best of our knowledge, our study represents the first method to discover 
potential MS-associated copies of MSRV/HERV-W. Adapted from a previously reported 
splinkerette-PCR method (Uren et al., 2009), this new assay was used successfully to 
amplify MSRV/HERV-W-like sequences (Table 1). A variety of different HERV-W copies 
present in gDNA samples from MS patients were detected, showing that the method is 
not restricted to single element. Sequence reads were mapped to unique HERVW 
copies with more than 97% sequence identity. Copies identified using this mapped, all 
represented known HERVW copies. Around 100 PCR products were analysed, of which 
97% corresponded to HERV-W elements. We observed that among the 7 alternative 
splinkerette-PCR designs that were applied, design F (Figure 1B) was the most 
successful in generating traceable PCR products (Table 1). Such design allowed not 
only to locate 94% of amplified HERV-W sequences (Table 1) but also revealed a 
possible non-disease related polymorphism. Nevertheless, all designs applied only 
identified reference HERV-W elements, failing to identify MSRV or novel HERV-W 
elements (Figure 2).  
MSRV has been defined by several overlapping cDNA sequences derived from MSRV 
particle-associated RNA isolated from MS patients. However, to date, no complete 
infectious MSRV sequence has been found within the human genome. Likewise, the 
origin and nature of MSRV remains unknown. Although at first MSRV was proposed to 
be an exogenous replication-competent member of the HERV-W family (Perron et al., 
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1997), posterior studies are increasingly remarking or suggest that MSRV-like cDNA 
sequences could be derived from recombination events between HERV-W elements 
(Laufer et al., 2009). In this study, we intended to locate MSRV sequences using a set 
of primers published and used to detect higher MSRV-like sequences expression in 
PBMCs of MS patients over controls (Mameli et al., 2009). Nevertheless, our method 
(Figure 1, design D) only yielded HERV-W elements present in the reference genome. 
Therefore, we failed so far to amplify novel HERVW sequences that may represent 
MSRV, or sequences identical to MSRV-sequences published (Blond et al., 1999; Perron 
et al., 1997). We therefore did not find evidence supporting the existence of a unique 
HERV-W related copy that could represent MSRV. 
On the other hand, we have hypothesized that unfixed HERV-W loci and/or unmapped 
polymorphisms could play a relevant role in MS disease. To date, several 
retrotransposition events have been associated with human disease (Hancks and 
Kazazian, 2012, 2016; O’Donnell and Burns, 2010). Most of the causative agents 
corresponded to the known TEs active subfamilies such as Alu and LINE-1. Within HERV 
subfamily, in theory, novel retroviral insertions have only been reported for elements 
of the HERV-K family (Belshaw et al., 2005, 2005; Kahyo et al., 2013; Wildschutte et al., 
2016), but cannot be totally rejected that does not occur for HERV-W family members. 
In relation to polymorphisms, on the contrary, there are already some described 
polymorphisms associated with MS susceptibility, such as one near HERV-W locus in 
chromosome Xq22.3 and another one near HERV-Fc1 locus (an HERV-H family 
member) on chromosome X (García-Montojo et al., 2014; Hansen et al., 2011). 
However, all except one of the sequences amplified by the technique were described 
in the human reference genome. The sequence missing in the databases resulted to be 
a low frequently allele (Figure 2) and, therefore, it seems unlikely that is MS-related.  
In recent years different informatics tools have been developed to identify novel 
transposable elements (TEs) insertions in the human genome (Rishishwar et al., 2017). 
Such methods could help in identifying disease-causing insertions, and better 
interpreting the consequences that genetic variation may have on human phenotype. 
All these informatics tools work using NGS sequence data as input. Here we took 
advance of one of such informatic tools, named RetroSeq (Keane et al., 2013), which 
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can accurately discover non-reference TEs insertions. Splinkerette-PCR was carried out 
on DNA obtained from 2 MS patients, NGS was applied to the resulting PCR products, 
and data was analysed using the RetroSeq software. Several non-reference insertions 
were identified in this analysis (Figure 3B), but their relation to MS has not been 
established yet. In conclusion, the method we describe here along with NGS, allows for 
systematic searches for uncharacterized HERV-W proviral sequences. However, further 
research is required to clear up the origin and nature of MSRV and identify possible 
MS-associated unfixed HERV-W copies.   
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Supplementary materials 
 
 
Figure s1. Isolation of mononuclear cells from human peripheral blood by density gradient 
centrifugation. Differential migration of blood cells during centrifugation results in the formation of 
layers containing different cell types. From top to bottom: plasma and other constituents, a layer of 
mononuclear cells (PBMC), Ficoll, and erythrocytes and granulocytes which should be present in pellet 
form.  
 
Design 1
st 
enzyme 2
nd 
enzyme LTR primer sequence (5’-3’) 
A MseI BlpI LTR1:TCCTGCATGGCTAAGTGCCCAG 
LTR2:TCTTCCGTGACCCATGGCTTCT 
Degenerate primers: 
LTR1:TCCTGCAYGGCTAAGTGCCYRGG 
LTR2:TYTTCCRTGACCCAYGGCTTCT 
B TaqI or 
Sau3AI 
(AvrII+ NheI) + BlpI LTR1:GAATYCCTAAGCCTAGCTGGGAA 
LTR2:GGGCTTGYAACTYAGCTCAC 
C TaqI  AhaIII or (AhaIII + 
NheI) 
LTR1:TCACCTTCCCAGCTAGGCTTAG 
LTR2:AGGAAATCCAGCTAGTCCTGTCTCT 
D TaqI or 
Sau3AI 
EarI LTR1:CTTCCAGAATTGAAGCTGTAAAGC 
LTR2:TTCTTCAAATGGARCCYCAGAKG 
E Sau3AI NaeI LTR1:CCGGCAACGACTACCCTCTT 
LTR2:CCTTTGTATGGGAGCTCTGT 
F MseI BlpI+ SpeI LTR1:ATAACACTCACCGCATGGCCCAA 
LTR2:GTCAGAGAACGTGAGGCTTG 
G Sau3AI AhaIII+ ScaI LTR1:TCACCTTCCCAGCTAGGCTTAG 
LTR2:AGGAAATCCAGCTAGTCCTGTCTCT 
Table s1. List of all splinkerette designs. The table shows the first enzyme (1st enzyme) and the second 
enzyme (2nd enzyme) used in the library construction of each splinkerette design. The table also 
includes a list of primer sequences used for the first (LTR1) and second (LTR2) round of PCR in each 
design. Y= C or T. 
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Primer name Primer sequence (5’-3’) 
Long strand adapter  CGAAGAGTAACCGTTGCTAGGAGAGACCGTGGCTGAATGAGACTGGTGTCGACACTAGTGG 
Short strand adapter 
MSEI  
TACCACTAGTGTCGACACCAGTCTCTAATTTTTTTTTTCAAAAAAA 
Short strand adapter  
TAQI 
CGCCACTAGTGTCGACACCAGTCTCTAATTTTTTTTTTCAAAAAAA 
Short strand adapter 
SAU3AI 
GATCCCACTAGTGTCGACACCAGTCTCTAATTTTTTTTTTCAAAAAAA 
Splink1 CGAAGAGTAACCGTTGCTAGGAGAGACC 
Splink2 GTGGCTGAATGAGACTGGTGTCGAC 
Table s2. List of additional primers used in the library construction and amplification. 
 
 
 
Figure s2. Example of a gel electrophoresis related to splinkerette-PCR products that have been cloned 
and an alignment between a sequence clone (Query) with its best match in the human genome 
database (Sbjct). A) Colony PCR amplicons indicate plasmids containing insert. Note the difference in 
size of the amplicons representing the different sequences amplified by the splinkerette-PCR design. 
Bp= base pairs. B) Location: Homo sapiens chromosome 11, GRCh38.p7 Primary Assembly 56874107 to 
56874305, identities: 196/199(98%), gaps: 0/199(0%), strand: Plus/Plus. LTR sequence is marked in blue 
and the sequence that lies outside the retroviral element is marked in green.  
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Manuscript II. HERV-W expression in multiple sclerosis 
 
Abstract 
The upregulated presence and expression of multiple sclerosis (MS)-associated 
retrovirus (MSRV) and its relative human endogenous retroviruses family W (HERV-W) 
has been repeatedly detected in autopsied brain tissues and peripheral blood 
mononuclear cells (PBMCs) of MS patients. However, little is known about which 
HERV-W elements are overexpressed in MS patients and none MS-associated HERV-W 
loci have been identified so far. We therefore intended to assess HERV-W ENV 
expression in PBMCs of MS patients and search for MS-associated HERV-W loci. 
We analysed HERV-W ENV transcription levels by real-time quantitative PCR (qPCR) in 
PBMCs of MS patients and controls. An initial assay revealed that while MS patients did 
not show differences in HERV-W ENV expression over controls, CIS patients presented 
a 1.37-fold increase in HERV-W ENV expression compared to controls (p=0.006). We 
analysed HERV-W ENV-specific PCR products generated after reverse transcription of 
RNA of 6 CIS patients and 6 controls to identify loci transcribed in PBMCs. After 
cloning, sequencing identified 21 transcribed HERV-W ENV loci within 141 sequenced 
clones. Moreover, one locus on chromosome 5p12 showed relative transcript levels 4-
time higher in MS patients over controls (p=0.016). In addition, a next-generation 
sequencing (NSG) analysis yielded the identification and genomic location of HERV-W 
ENV loci transcribed in PBMCS of 4 CIS patients and 4 controls. While the most 
abundantly transcribed HERV-W ENV loci did not differ between patients and controls, 
several MS patient-associated HERV-W ENV loci, including the HERV-W 5p12 element, 
were identified. To extend these finding to larger study cohorts, HERV-W ENV 
expression was analysed in a larger collection (n=116). Results showed that HERV-W 
ENV expression was just slightly induced in MS patients, which presented a 1.2-fold 
increase in HERV-W ENV expression compared to controls. A second cohort of PBMCs 
samples from MS patients confirmed the overexpression of HERV-W ENV in MS 
patients, especially in those being clinically active, which presented a 2-fold increase in 
HERV-W ENV expression compared to controls (p=0). We therefore identified specific 
copies that may contribute to HERV-W overexpression in PBMCs MS patients  
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Introduction 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
(CNS), characterized by demyelination of axons of nerve cells and loss of 
oligodendrocytes (Compston and Coles, 2002, 2008). When neural damage occurs, the 
communication among different parts of the nervous system is blocked and MS 
symptoms appear, including muscle weakness, weak reflexes, impaired body 
movement, and miss-coordination among others. There are several types of MS which 
are mainly defined by how often a person experiences symptoms (Lublin et al., 1996). 
Relapsing-remitting MS (RRMS), the most common type of MS, is characterized by 
clearly defined attacks (relapses) of new or increasing neurologic symptoms. These 
attacks are followed by periods of partial or complete recovery (remissions). Initial 
RRMS usually leads to a secondary progressive MS (SPMS), in which there is a 
progressive worsening of neurologic function over time. Primary progressive MS 
(PPMS) is characterized by worsening neurologic function from the onset of symptoms, 
without early relapses or remissions. Later, new disease courses were determined, 
such as clinically isolated syndrome (CIS) (Miller et al., 2005). CIS refers to a first 
neurological episode, caused by inflammation or demyelination in the CNS, which may 
be either the onset of MS, or represent an isolated episode not related to MS. 
Human endogenous retroviruses (HERVs) are the result of ancestral retroviral 
infections that entered the human germ line, leading to a permanent retroviral 
integration transmitted to the offspring in a Mendelian fashion. After initial 
integration, HERVs continued to generate self-copies and as a result they now 
comprise approximately 8% of our genome (Cho et al., 2008; Löwer et al., 1996).  
The association between human endogenous retroviruses (HERVs) and MS was first 
studied in the late 1980’s, when free virus-like particles were purified from cells and 
plasma of MS patients (Perron et al., 1989, 1991). Molecular characterisation of the 
viral RNA within these particles revealed partial retroviral-like sequences, upon which 
the retrovirus was named MS-associated or MSRV (Perron et al., 1997). MSRV turned 
out to be closely related to human endogenous retroviruses family W (HERV-W), a 
multicopy family consisting of approximately 650 closely related but distinguishable 
elements dispersed in the human genome (Pavlícek et al., 2002). However, the exact 
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relationship between MSRV and HERV-W has not been clarified yet (Blond et al., 1999; 
Komurian-Pradel et al., 1999; Perron et al., 2000) and therefore, the term MSRV/HERV-
W is often used. The linkage between expression of MSRV/HERV-W and MS has been 
repeatedly underlined since MSRV discovery. Not only was DNA load of MSRV/ HERV-
W found to be increased in peripherical blood mononuclear cells (PBMC) from MS 
patients (Garcia-Montojo et al., 2013; Perron et al., 2012), but also MSRV/HERV-W 
expression was found to be increased in cerebrospinal fluid (CSF), PBMCs and post-
mortem brain tissue of MS patients (Dolei et al., 2002; Mameli et al., 2007; Serra et al., 
2001). In line with these findings, the levels or amounts of MSRV/HERV-W ENV protein 
detected in post-mortem brain tissue or serum of MS patients were higher compared 
to controls (Mameli et al., 2007; Perron et al., 2012). Although most HERVs are highly 
defective and unable to replicate due to the acquisition of deletions and mutations 
during evolution, within the HERV-W family there is a copy located on chromosome 7q 
that encodes for a competent HERV-W envelope protein named SYNCYTIN-1, which is 
expressed in placenta and involved in placental development (Blond et al., 2000; Mi et 
al., 2000). Nevertheless, a discriminatory PCR study showed that RNA encoding MSRV-
type envelope protein but not SYNCYTIN-1 is expressed at increased levels in PBMCs of 
MS patients (Mameli et al., 2009).   
Further pursuing this HERV-W association with MS, several studies have tried to 
identify which HERV-W ENV loci are transcribed and the relative transcript levels of 
those loci in PBMC and brain of MS patients and controls (Laufer et al., 2009; Schmitt 
et al., 2013). However, transcriptional activity of individual HERV-W ENV elements did 
not significantly differ between patients with MS and controls in these studies. 
In the present study, we hypothesise that specific copies of HERV-W are overexpressed 
in MS, and therefore represent MSRV. We tried to identify MS-associated HERV-W loci. 
We collected PBMCs samples from MS patients and healthy controls and both HERV-W 
ENV DNA load and RNA levels were assessed. HERV-W ENV-specific cDNA derived-PCR 
products were sequenced to identify transcribed HERV-W ENV loci in PBMCs of MS 
patients and controls. To the best of our knowledge, we present the first evidence that 
HERV-W ENV expression might be limited to clinically active stages of the disease. We 
also identify candidates for MS-associated HERV-W loci. 
Sofía Macías Redondo 
84 
 
Materials and methods 
PBMCs isolation and gDNA extraction  
PBMCs isolation and gDNA extraction was performed as described before (M&M, 
Manuscript I). 
HERV-W ENV copy number quantification: qPCR 
For the PCR we used as template 100 ng of gDNA, previously fragmented by sonication 
for 5 minutes at high power with cycles of 30 seconds ON, and 30 seconds OFF, using a 
bioruptor sonicator (Diagenode). Real-Time PCR was performed under standard 
thermal cycling conditions on a ViiA™ 7 Real-Time PCR System (Applied Biosystems) 
using the Premix Ex TaqTM (Probe qPCR) Master Mix (RR390A, Takara) according to 
manufacturer’s protocol. The assay was carried out in a total volume of 20 μl using 1x 
TaqMan® Copy Number Reference Assay RNase P (4403326, Life Technologies), a 
specific pair of primers and probe (used at 200 nM) for MSRV ENV (Mameli et al., 
2009), and 1 μl of sonicated genomic DNA as template. Amplification efficiency of all 
Taqman assays between 90% and 110% was assessed in standard curves (Appendix I). 
All reactions were carried out in triplicate and only measurements with a standard 
deviation < 0.2 were considered. Copy number quantification, normalized to the 
house-keeping control RNAseP, was calculated using the 2-ΔΔCt method (Livak and 
Schmittgen, 2001). 
RNA isolation and cDNA synthesis  
PBMCs were homogenized with TRIzol® reagent (Invitrogen). Total RNA was 
subsequently isolated from the resulting homogenate using an in-house method 
(Pérez-Palacios et al., 2016). Isolated RNA was quantified using a Nanodrop 
spectrophotometer (Thermo Sci., Nanodrop 2000) and kept at -80ºC until further use. 
cDNA was synthesized from 500 ng of RNA with either random hexamer primer or 
oligo(dT) using the ThermoScriptTM RT-PCR System (11146-024, Invitrogen) according 
to manufacturer’s protocol.  
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HERV-W ENV expression analysis: qPCR 
cDNA was analyzed by Real-Time PCR on a ViiA™ 7 Real-Time PCR System (Applied 
Biosystems), under standard thermal cycling conditions (ViiA™ 7 System). HERV-W ENV 
expression analysis was performed using a specific pair of primers and probe for MSRV 
ENV (Mameli et al., 2009)  in a TaqMan qPCR, using the Premix Ex TaqTM (Probe qPCR) 
Master Mix (RR390A, Takara) according to manufacturer’s protocol. HERV-W locus-
specific expression analyses were performed in a SYBR Green qPCR, using the SYBR 
Green Master Mix (SYBR Premix Ex Taq II (Tli RNase H Plus), RR820A, Takara) according 
to manufacturer’s protocol. In all cases, hGAPDH expression analysis was performed in 
a SYBR Green qPCR. Sequences of all primers used are described in Table s1. 
Amplification efficiency of all set of primers between 90% and 110% was assessed in 
standard curves (Appendix I) and, sequences of all primers used (used at 200 nM) are 
listed in Table s1. All reactions were carried out in triplicate and only measurements 
with a standard deviation < 0.2 were considered. Target gene expression levels were 
recalculated as 2-ΔΔCt with respect to the median Ct value of the samples in the 
control group, using hGAPDH as a reference gene (Livak and Schmittgen, 2001). 
Identification and localization of transcribed HERV-W loci 
cDNA from PBMCs obtained from MS patients and healthy controls, and primed with 
either oligo dT or random primer, was amplified employing the specific MSRV ENV pair 
of primers described by Mameli et al., 2009 (Table s1). PCR amplification was carried 
out in a 50-µl volume using 2 µl of cDNA, the pair of primers previously mentioned 
(used at 400 nM), 200 µM dNTPs and 0.5 U Taq DNA Polymerase (D1806, Sigma-
Aldrich) along with its corresponding 1X PCR reaction buffer containing 1.5 mM MgCl2. 
PCR cycling conditions were as follows: initial activation at 98 ºC for 2 min, followed by 
35 cycles of 95 ºC for 30 seconds, 60 ºC for 30 seconds and 72 ºC for 30 seconds. The 
final extension step was at 72 ºC for 10 minutes. The PCR product was purified using 
the Diffinity RapidTip®2 (D2947, Sigma) and precipitated with sodium acetate-ethanol 
according to standard protocols. The final product was re-suspended in 3 µl of TE 
buffer and cloned into the pGEM®-T Easy Vector System I (A1360, Promega) according 
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to manufacturer's instructions. The vector was transformed into E. coli XL1 cells and 
cultured in Luria–Bertani (LB)-agar plates supplemented with 50 µg/mL ampicillin at 37 
ºC. Colonies were screened for the presence of insert by colony PCR and further 
analysed by plasmid miniprep and sequencing. DNA sequencing analyses were 
performed by Secugen S.L (Madrid, Spain) and chromosomal location of cloned HERV-
W/MSRV cDNA sequences was mapped to the human genome (GRCh38) using the 
blastn option of BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch) 
(Altschul et al., 1990). Species-specific filters for retroviral elements were not activated 
(or de-activated). More than 97% identity between the cloned sequence and the 
database sequence was used as criterium to map the sequenced fragments. 
Next Generation Sequencing analysis 
Next Generation Sequencing analysis was performed as described before (M&M, 
Manuscript I). 
Statistical analysis 
SPSS software was used for all analyses (IBM Corp. Released 2013. IBM SPSS Statistics 
for Windows, Version 15.0). Normality was assessed with Shapiro-Wilk test (when n< 
50) or Kolmogorov-smith test (when n> 50). For the assessment of the statistical 
significance of differences, a specific test was performed depending on normality and 
number of groups of samples compared. Normally-distributed data: t-student test (2 
groups) or ANOVA test (>2 groups). Non-normally distributed data: U de Mann-
Whitney test (2 groups) or Kruskal-Wallis test (>2 groups). The graphs were generated 
using SPPS software as well. Within a box plot, the bottom line of the box represents 
the first quartile (Q1) of the data, the middle of the box (shown as a line) represents 
the median (or second quartile Q2), and the top line of the box represents the third 
quartile (Q3). The interquartile range (IR) is a measure of dispersion and it is defined as 
Q3-Q1. The vertical lines extend from the ends of the box to the minimum and 
maximum values of the data. Outliers are indicated as individual points and defined as 
being more than 1.5*IR outside the box. 
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Results 
DNA copy number of HERV-W ENV in PBMCs 
Aiming at analysing HERV-W ENV DNA load in genomic DNA of PBMC from MS 
patients, HERV-W ENV copy number was analysed by a specific quantitative PCR 
(qPCR). 79 MS patients and 37 healthy controls were included in the analysis (Table 1). 
Although CIS not necessarily indicates the onset of MS, in the absence of additional 
clinical data, throughout this manuscript they are considered patients. HERV-W ENV 
DNA load (copies/haploid genome) was measured by a duplex real-time PCR with 
specific primers and probe for MSRV ENV-like sequences (Mameli et al., 2009), and for 
the endogenous reference gene RNAseP. RNAseP, a known single-copy gene, was 
included to normalize the results. MSRV ENV-like DNA load was mostly the same in MS 
patients (17.16 ± 2.66) and controls (17.48 ± 3.44) (U. de Mann Whitney; p= 0.46) 
(Figure 1A). The stratification of MS patients by clinical status (CIS, PPMS, RRMS, 
SPMS), showed that there was not difference either in the HERV-W ENV DNA load 
among clinically defined groups (Krustal-Wallis; p= 0.82) (Figure 1B). Therefore, in our 
cohort HERV-W ENV DNA load in PBMCs was not associated with MS. 
COHORT 1 
 
MS patients (n=79) Controls (n=37) 
Disease form 
CIS 
PPMS 
RRMS 
SPMS 
 
n=6 
n=10 
n=36 
n=27 
 
Table 1. Clinical data of cohort 1. For this study, a cohort of 116 participants, including patients with 
multiple sclerosis (MS) and controls, were recruited. MS patients presented different diasease forms: 
relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS) and 
CIS (clinically isolated syndrome).  
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Figure 1. DNA copy number of human endogenous retrovirus-W quantification in PBMCs. HERV-W 
ENV DNA load represents HERV-W ENV copies per haploid genome in PBMC samples from MS patients 
and controls, normalized to the RNAse P reference gene. Analysis was performed comparing A) MS 
patients versus controls and B) different clinical status in MS and controls. Tables show numerical values 
taken from the graph.  
Human endogenous retrovirus-W ENV expression in PBMCs 
Previous studies had indicated a substantial increase in HERV-W ENV expression in a 
small cohort of patients (Mameli et al., 2009), and a small but statistically significant 
increase in a much larger cohort (García-Montojo et al., 2014). As we were interested 
in identifying specific copies of HERV-W overexpressed in MS patients, we first 
confirmed overexpression within a small test cohort of MS patients (n= 7) and healthy 
controls (n= 5). HERV-W ENV expression was measured in PBMCs by quantitative PCR 
(qPCR), using the same set of primers and specific probe for MSRV ENV-like sequences 
used in the above-mentioned publications. To compare different assays to determine 
expression levels, cDNA primed with either random primer and oligo dT was obtained  
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and analysed (Figure 2). While oligo dT-primed cDNA analysis showed that HERV-W 
ENV expression was decreased in MS patients (71.52% ± 59.75) compared to controls 
(100% ± 40.53) (t-student; p= 0.247), the study of random-primed cDNA showed an 
increase of HERV-W ENV expression in MS patients (137.3% ± 119.39) compared to 
controls (100% ± 29.8) (U. de Mann Whitney; p= 0.685) (Figure 2). Therefore, the 
choice of primer used to initiate reverse transcription was found to alter or influence 
HERV-W ENV detection in PBMCs. Since HERV-W ENV overexpression in patients was 
uniquely detected in random primer-primed cDNA samples, we decided on the use of 
random primer for all future reverse transcriptions. Interestingly, we observed that 
among the 7 MS samples analysed, those with higher levels of HERV-W ENV expression 
corresponded to the clinical status CIS (data not shown). We therefore decided to 
include all CIS samples available in the analysis. 
 
Figure 2. Human endogenous retrovirus-W ENV expression in PBMCs. HERV-W ENV expression was 
measured by quantitative PCR (qPCR), using a specific set of primers for MSRV ENV (Mameli et al., 
2009). Analysis was performed using cDNA, primed with either oligo dT or random primer, from 7 MS 
patients and 5 controls. Results were normalized using GAPDH as a reference gene, calculated using the 
2-ΔΔCt method, and represented as a percentage of the fold expression compared to the median 
expression level in controls. Tables show numerical values taken from the graph.  
The optimized qPCR assay described above was repeated to discriminate whether 
HERV-W ENV overexpression was biased by the clinical status of MS patients. For 
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comparison, the overall sample size was slightly increased to MS patients (n= 11) and 
healthy controls (n= 9). Of those 11 MS patients, 6 samples corresponded to CIS 
patients (not properly classified as MS patients yet) and 5 to MS patients (RRMS and 
SPMS). Results were calculated and represented in the same way as above. In this 
cohort, HERV-W ENV expression was significantly increased in MS patients (142.48% ± 
64.92) compared to controls (100% ± 28.51) (t-student; p= 0.045) (Figure 3A). 
Interestingly, the stratification by clinical status of patients (CIS patients, other MS 
patients) showed that although HERV-W ENV overexpression was detected in both MS 
and CIS patients, it was higher in CIS patients (142.97% ± 32.66) (t-student; p= 0.006) 
than in MS patients (123.06% ± 89.01) (t-student; p= 0.449), compared to controls 
(100% ± 28.51) (Figure 3B). Therefore, while a trend towards HERV-W ENV 
overexpression was detected in MS patients, overexpression was more prominent in 
CIS patients.  
 
Figure 3. Human endogenous retrovirus-W ENV expression in CIS patients. Analysis was performed 
using cDNA primed with random primer from 11 MS patients and 9 controls. Results were represented 
comparing A) control group versus MS patients group and, B) control group versus MS patients group 
divided into CIS patients (n= 6) and the rest of MS patients (n=5). Results were normalized using GAPDH 
as a reference gene, calculated using the 2-ΔΔCt method, and represented as a percentage of the fold 
expression compared to the median expression level in controls. Tables show numerical values taken 
from the graph.  
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Identification of transcribed HERV-W ENV loci in PBMCs 
Aiming at finding MS-associated HERV-W ENV loci, we intended to identify which HERV-W 
ENV copies were more abundantly expressed in PBMC from MS patients relative to controls. 
Oligo dT-primed cDNA was obtained from PBMCs of 6 MS patients and 6 controls, and 
amplified using the specific PCR for MSRV ENV described by Mameli et al., 2009. After 
molecular cloning, individual clones were sequenced, the sequences were mapped to the 
human genome and relative cloning frequencies were calculated (the number of cDNA clones 
mapping to an individual HERV-W ENV element relative to the total number of cDNA clones 
analysed). A total of 76 and 65 cDNA clones, generated from MS patients and controls, 
respectively, mapped to 21 different HERV-W ENV elements. Among those, clones originating 
from HERV-W ENV copies located on chromosomes 5p12, 19q13.2 and Xq22.3 were most 
frequently encountered (Figure 4A). The relative cloning frequency of individual HERV-W ENV 
copies did not significantly differ between MS patients and controls, except for one HERV-W 
element. It turned out that the HERV-W copy located on chromosome 5p11 (HERV-W ENV 
5p12) was 4 times more frequently cloned in samples from MS patients (51.11% ±21.47) 
compared to controls (12.69% ± 23.18) (U. de Mann Whitney; p= 0.016) (Figure 4B). 
 
Figure 4. Analysis of transcribed HERV-W ENV loci in PBMCs. A specific PCR (Mameli G et al., 2009) was 
applied to a subset of the samples analysed previously (Figure 2). After molecular cloning, individual 
clones were sequenced, and their location was determined by comparing the resulting sequences the 
human genome. A) The chromosomal location of HERV-W ENV clones is indicated in the first column. 
Numbers in the second and third columns represent the percentage of clones mapping to the loci 
indicated in 6 MS patients and 6 control, respectively. B) The relative frequency of clones derived from 
the 5p12 locus is indicated. Tables show numerical values taken from the graph.  
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Therefore, results suggested that HERV-W ENV 5p12 overexpression might be 
associated with MS. 
A similar search using random primer-primed cDNA yielded data suggesting that HERV-
W ENV 19q13.2 overexpression was potentially MS-associated (data not shown). To 
verify the possible association between both HERV-W ENV 5p12 and 19q13.2 elements 
and MS prevalence, we performed locus-specific expression analyses. HERV-W ENV 
5p12 and 19q13.2-specific qPCR assays were designed (Figure 5A). Primer pairs were 
designed so that they do not match the sequences most similar to elements HERV-W 
ENV 5p12 and 19q13.2. Melting curve analyses of these qPCR assays showed a single 
peak, verifying the presence of a single PCR product and the specificity of the qPCR 
assays (data not shown). Expression levels were assessed in PBMCs from 7 MS patients 
and 5 controls. MS patients showed less HERV-W ENV 5p12 expression levels (62.91% 
± 44.2) than controls did (100% ± 124.04) (U. de Mann Whitney; p= 0.062) (Figure 5B). 
HERV-W ENV 19q13.2 expression levels were also found to be lower in MS patients 
(85.38% ± 40.01) than in controls (100% ± 12.45) (U. de Mann Whitney; p= 0.063) 
(Figure 5C). Therefore, although initial analyses pointed out HERV-W copies 5p12 and 
19q13.2 as potential MS-associated elements, we were unable to verify those data in 
copy-specific expression analyses. 
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Figure 5. qPCR specific expression analysis for HERV-W ENV 5p12 and 19q13.2 in PBMCs. A) 
Schematical representation of the copy-specific expression assays designed. Arrows represent the pair 
of primers used in the qPCR to specifically amplify the elements HERV-W 5p12 and 19q13.2 within the 
ENV region. LTR: long terminal repeats. B) Copy-specific expression analysis of HERV-W 5p12 in oligo dT-
primed cDNA. C) Copy-specific expression analysis of HERV-W 19q13.2 in random primer-primed cDNA. 
B, C) Samples, 7 MS patients and 5 controls, were taken randomly from the samples analyzed previously 
(Figure 2). Results were normalized using GAPDH as a reference gene, calculated using the 2-ΔΔCt method, 
and represented as a percentage of the fold expression compared to the median expression level in 
controls. Table shows numerical values taken from the graph.  
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Next-generation sequencing analysis of transcribed HERV-W ENV loci in PBMCs 
We next performed a NGS analysis to identify new candidate MS-associated HERV-W 
copies. NGS analysis was performed on amplification products obtained using the 
specific PCR described by Mameli et al., 2009 and random-primed cDNA from PBMCs 
of CIS patients (n=5) and control (n=5) as templates. Reads (around 60,000 per sample) 
were assigned to a HERV-W ENV locus (the sequences were mapped to the human 
genome according to criteria described in M&M) and relative frequencies were 
calculated (the number of reads mapping to an individual HERV-W ENV element 
relative to the total number of reads). The resulting NGS data showed that sequences 
obtained from CIS patients mapped to a significant higher number of different HERV-W 
ENV loci (31 ± 13), compared to those obtained from controls (16 ± 5.5) (t-student; p= 
0.018) (Figure 6A). Reads mapped with high frequency to a limited number of loci, 
especially to HERV-W ENV copies located on chromosomes 19q13.2, Xq22.3, 8q21.13, 
15q21.3, 12q23.3 and 4q21.22 (Figure 6B). We found no significant differences 
between CIS patients and controls in the relative frequency of reads mapping to these 
loci (Figure 6B). However, reads mapped with intermediate frequency to another 
subset of loci, located on chromosome 3q11.2, 5p12 and 9q22.31. Reads mapping to 
these loci were mainly identified in CIS patients. The relative frequency of reads 
mapping to these showed an increase of 17.5, 6.8 and 11 times respectively in CIS 
patients compared to controls (Figure 6C).  It stands to reason, that the relative 
frequency after mapping is the equivalent of relative overexpression. As most reads 
obtained from both CIS patients and controls mapped to a limited set of apparently 
highly transcribed copies, our data indicate that the observed HERV-W ENV 
overexpression in CIS patients (Figure 3B) did not originate from a single HERV-W ENV 
copy. Such overexpression appears to be derived from less abundantly transcribed but 
CIS-related HERV-W ENV loci. 
To verify the overexpression of CIS-related HERV-W copies in CIS patients, specific 
qPCR assays were designed and applied. A copy-specific qPCR assay to selectively 
amplify HERV-W 9q22.31 was designed. Due to the high identity shared among HERV-
W elements, one primer was designed to match outside of the HERV-W-part in order 
to increase PCR specificity (Figure 7A). This assay, along with the already optimised  
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Figure 6. NGS analysis of transcribed HERV-W ENV copies in PBMCs. A specific MSRV ENV PCR 
described by Mameli G et al., 2009 was applied to samples taken randomly from the samples analyzed 
previously (Figure 3) and sequenced by NGS. Relative frequency (%) of individual HERV-W ENV copies 
was calculated as the number of reads from individual HERV-W ENV loci relative to the total number of 
reads analysed). A) HERV-W ENV copies were identified in PBMC of 5 CIS patients and 5 controls. 
Numerical values taken from the graph are indicated. B) Representation of chromosomal location and 
relative frequency (%) for the most abundant HERV-W copies in CIS patients and controls. C) Relative 
Sofía Macías Redondo 
96 
 
frequency (%) in CIS patients or controls, of reads mapped to the individual HERV-W ENV copies 
indicated. Tables show numerical values taken from the graph. 
To verify the overexpression of CIS-related HERV-W copies in CIS patients, specific 
qPCR assays were designed and applied. A copy-specific qPCR assay to selectively 
amplify HERV-W 9q22.31 was designed. Due to the high identity shared among HERV-
W elements, one primer was designed to match outside of the HERV-W-part in order 
to increase PCR specificity (Figure 7A). This assay, along with the already optimised  
 
Figure 7. qPCR specific expression analysis for HERV-W 5p12 and 9q22.31 in PBMCs. Schematical 
representation of the new copy-specific expression assay designed is illustrated (A). Arrows represent 
the pair of primers used in the qPCR to specifically amplify the element HERV-W 9q22.31. LTR: long 
terminal repeat. Random primer-primed cDNA from 6 CIS patients and 6 controls was analyzed with the 
copy-specific expression analysis for HERV-W ENV 5p12 (B) and HERV-W 9q22.31 (C). Samples were 
taken randomly from the samples analyzed previously (Figure 6). Results were normalized using GAPDH 
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as a reference gene, calculated using the 2-ΔΔCt method, and represented as a percentage of the fold 
expression compared to the median expression level in controls. Table shows numerical values taken 
from the graph.  
copy-specific qPCR assay for HERV-W ENV 5p12 (Figure 5A), were applied in PBMCs 
from 6 CIS patients and 6 controls. HERV-W ENV 5p12 relative expression was higher in 
CIS patients (133.94% ± 44.72) compared to controls (100% ± 35.74) (t-student; p= 
0.117) (Figure 7B). Likewise, HERV-W 9q22.31 relative expression levels were increased 
in CIS patients (374.51% ± 663.3) compared to controls (100% ± 146.12) (t-student; p= 
0.139) (Figure 7C). This time, both copy-specific qPCR analyses detected and quantified 
HERV-W overexpression in CIS patients. Although not statistically significant, 
expression levels for both HERV-W loci were increased in CIS patients. Data, therefore, 
are evidence that CIS patients present elevated expression of certain specific MS-
related HERV-W copies such as HERV-W loci 5p12 and 9q22.31. 
Is HERV-W overexpression associated with active disease? 
Initial results pointed out that HERV-W ENV overexpression was specifically found in 
CIS patients. Due to the close association between CIS patients and the presence of 
clinical activity, we intended to distinguish whether such retroviral overexpression 
could be linked to active disease rather than being exclusively CIS-associated. We 
gathered a new collection of PBMCs samples, taken from MS patients either 
presenting (n=12) or not presenting (n=12) clinical activity (Table 2). Within the group 
of MS patients, some were under treatment (n=7) and others were not undergoing 
treatment (n=5). HERV-W ENV expression was analysed using the same expression 
assay mentioned above, and results were compared to the median expression of the 
control group defined within the initial cohort (Figure 3). Both, MS patients with and 
without clinical activity showed a significant increase of HERV-W ENV expression 
compared to controls (t-student; p= 0 and p= 0.019 respectively) (Figure 8A). And 
although not statistically significant, HERV-W ENV expression was indeed slightly 
higher in active MS patients (208.75% ± 199.5) than in non-active MS patients 
(185.95% ± 77.03), compared to controls (100% ± 28.51) (t-student; p= 0.158) (Figure 
8A). On the other hand, HERV-W ENV expression was not significantly influenced in 
active MS patients receiving treatment compared to those without treatment (U de 
Mann-Whitney; p= 0.685) (Figure 8B). In this new cohort, HERV-W ENV expression was 
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therefore not only associated with MS, but specially associated with the presence of 
clinical activity. These results strengthen the plausible linkage between HERV-W ENV 
expression and MS and indicate a possible correlation between such overexpression 
and active stages of the disease.  
COHORT 2 
 
MS patients (n=24) 
With clinical activity  
Treated 
Non-treated 
n=7 
n= 5 
Without clinical activity n=12 
Table 2. Clinical and treatment data of cohort 2. A new cohort of 24 MS patients were recruited either 
presenting or not presenting clinical activity. Within the group of MS patients with clinical activity, some 
were under treatment and others were not undergoing treatment. 
 
Figure 8. Human endogenous retrovirus-W ENV expression. A) Analysis was performed using cDNA 
primed with random primer from 24 MS patients, of which 12 were non-active MS patients and 12 were 
active MS patients. Control group was the same used in figure 3. Results were normalized using GAPDH 
as a reference gene, calculated using the 2-ΔΔCt method, and represented as a percentage of the fold 
expression compared to the median expression level in controls. B) Results were also stratified 
according to whether MS active patients were undergoing treatment (w/) or not (w/o). Table below 
shows numerical values taken from the graph.  
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Human endogenous retrovirus-W ENV expression in PBMCs of the larger cohort 
After confirming HERV-W ENV overexpression in two different small cohorts (Figures 
3A and 8A), we analysed HERV-W ENV expression in the larger collection of samples 
from which the initial small group of samples was taken (Figure 3). The collection was 
composed of samples of MS patients with different clinical status (CIS, PPMS, RRMS 
and SPMS) (n=79) and controls (n=34). HERV-W ENV expression was analysed using 
random-primed cDNA and the specific PCR assay described by Mameli et al., 2009. 
Results were calculated and normalized as already described. HERV-W ENV expression 
turned out to be quite similar in MS patients (120% ± 101) and control (100% ± 117.75) 
treatment (U de Mann-Whitney; p= 0.272) (Figure 9). Although these results did not  
 
Figure 9. Human endogenous retrovirus-W ENV expression in PBMCs. qPCR analysis was performed 
using cDNA primed with random primer from 79 MS patients and 34 controls. Results were normalized 
using GAPDH as a reference gene, calculated using the 2-ΔΔCt method, and represented as a percentage 
of the fold expression compared to the median expression level in controls. Tables below show 
numerical values taken from the graph.  
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completely correlate with the previous ones (Figure 3), they did show the general 
tendency for HERV-W ENV expression to be increased in MS patients (120% versus 
100% in controls). Since our findings indicated that MS-associated HERV-W elements 
are not very highly expressed (Figure 6C), it is not surprising the difference in HERV-W 
ENV expression between patients and control is not very big. 
Discussion 
All assays discussed here were done on PBMC unless indicated otherwise. An 
discriminatory real-time PCR assay was developed to selectively amplify MSRV (Mameli 
et al., 2009). As HERV-W ENV sequences are related to MSRV, independent of the 
exact relationship between HERV-W and MSRV, I have used the term HERV-W to refer 
to these sequences. And all assays discussed here were done on PBMC unless 
indicated otherwise. Using this assay, higher HERV-W copy numbers have been 
detected in MS patients (Garcia-Montojo et al., 2013; Mameli et al., 2009; Perron et 
al., 2012). However, here we did not find differences in the DNA load of HERV-W 
elements when applying this same assay in a cohort of 116 samples (Figure 1A). We 
suggest that the difference between individuals, populations and cohorts may reside in 
genetic variability. In fact, copy number may vary due to the presence of unfixed 
HERV-W copies derived from novel LINE-1-mediated retrotransposition events in 
modern populations (Costas, 2002; Grandi and Tramontano, 2017; Pavlícek et al., 
2002). Therefore, the copy number of HERV-W elements may differ between cohorts. 
As opposed to published studies (Perron et al., 2012), we did not observe any 
differences in the DNA copy number of HERV-W elements when MS samples were 
stratified  according to their clinical status (Figure 1B). Gender-specific differences in 
DNA copy number of HERV-W elements have also been reported (Garcia-Montojo et 
al., 2013). Although we would like to analyse our data likewise, this data is unavailable 
as of yet for our cohort. 
The assay described by Mameli et al. that discriminates between MSRV and SYNCYTIN-
1, has been used to detect upregulated HERV-W ENV expression in MS (Mameli et al., 
2009; Perron et al., 2012). We re-evaluated this assay, comparing cDNA priming 
procedures and securing calibration curves for low expression samples (Appendix I). 
After these verifications, we present a robust and reproducible assay to measure 
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expression of MS-associated copies of HERV-W (Figure 2). We found in a small cohort 
(n=12) that non-active MS patients did show increased levels of HERV-W ENV 
expression (185.95% versus 100% in controls; p= 0.019) (Figure 8A). By contrast, 
analysis of a different, larger cohort showed a weak tendency for HERV-W ENV 
expression to be increased in MS patients (120% versus 100% in controls; p= 0.272) 
(Figure 9). This supports the hypothesis that HERV-W ENV overexpression somehow 
contributes to MS. The high variability in the larger cohort suggests that stratification 
based on clinical activity or disease pattern, may yield better information. 
Unfortunately, we do not have access to the information on the clinical activity of MS 
patients recorded at the time of sample taking, precluding analysis. To better evaluate 
this, cohorts should be enlarged, and data stratified according to clinical history, 
clinical status and type of treatment. 
Expression analyses using the optimized assay described by Mameli et al. (Mameli et 
al., 2009) in a first cohort of MS patients demonstrated upregulated HERV-W ENV 
expression in CIS patients (p= 0.006) (Figure 3B). Several considerations suggest that 
this overexpression may be associated with active disease in general, and not to the 
clinical status CIS itself. Of course, CIS patients are defined as active patients showing a 
first disease outbreak. When copy-specific expression assays were designed to detect 
HERV-W 5p12, increased expression was evident in CIS patients (Figure 7B), as 
opposed to a mixed group of patients (Figure 5B). To further investigate the hypothesis 
that correlation exists between the presence of clinical activity in MS patients and 
higher HERV-W ENV expression levels, a new set of samples was collected. Samples 
were separated in groups according the presence or absence of clinical activity. Both 
subgroups showed upregulated HERV-W ENV expression (Figure 8A). Stratification by 
clinical activity revealed that active MS patients displayed a slightly higher HERV-W 
ENV expression levels compared to non-active MS patients (208.75% versus 185.85%; 
p= 0.158). Pending confirmation, this finding may suggest that, independent of the MS 
subtype, HERV-W ENV expression is linked to the presence of clinical activity.  
Previous studies failed to identify MS-specific loci or expression (Laufer et al., 2009; 
Schmitt et al., 2013). We succeeded in identifying which overexpressed HERV-W 
sequences are detected by the MSRV-specific qPCR assay of Mameli et al. Although 
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initial analysis suggested HERV-W loci 5p12 and 19q13.2 as possible MS-associated loci 
(Figure 4), copy-specific qPCR assays developed for these loci failed to detect increased 
expression levels in MS patients. To increase the scope of the search, cDNA sequences 
were sequenced by NGS. Posterior analysis revealed that most reads map to a selected 
set of 6 HERV-W loci with a similar relative frequency in MS patients and controls 
(Figure 6B). However, the relative frequency of reads mapping to HERV-W loci 5p12, 
3q11.2 and 9q22.31 was much higher in CIS patients (p< 0.05) (Figure 6C). Moreover, 
copy-specific qPCR assays for HERV-W loci 5p12 and 9q22.3 confirmed increased 
expression in CIS patients (Figure 7). As most reads obtained from both CIS patients 
and controls mapped to a limited set of apparently highly transcribed copies, our data 
indicate that the observed HERV-W ENV overexpression in CIS patients (Figure 3B) did 
not originate from a single HERV-W ENV copy. Such overexpression appears to be 
derived from less abundantly transcribed but CIS-related HERV-W ENV loci. In the light 
of these finding, the hypothesis that a given HERV-W element could uniquely provoke 
MS seems highly unlikely since the most abundant HERV-W elements are apparently 
the same in all individuals. However, MS appears associated with the upregulation of 
specific HERV-W loci. This finding now awaits confirmation in a larger cohort.  
Finally, it deserves to be mentioned that since the specific assay used throughout our 
studies (Mameli et al., 2009) only amplifies a limited number of MSRV-like HERV-W 
elements, our study may miss other HERV-W elements. Moreover, transcripts of other 
HERV families (such as HERV-K and HERV-H) have been occasionally associated with 
MS (Morandi et al., 2017). Overexpression of MSRV/HERV-W has been associated with 
MS in a variety of studies (Dolei et al., 2002; Mameli et al., 2007, 2009; Perron et al., 
2012). We studied an additional cohort and found a weak overexpression (Figure 9), 
which did not reach statistical significance. It should be noted, that other study also 
reported a lack of overexpression in MS brain (Schmitt et al., 2013). Our detailed 
studies aimed at which HERV-W may be overexpressed in CIS patients, have yielded 
two separate findings (Figure 6). First of all, after sequencing of cDNA prepared from 
overexpressed HERV-W, reads from CIS patients mapped to almost double the number 
of different HERV-W loci compared to reads obtained from controls (p=0.018) (Figure 
6A). We conclude that more HERV-W loci are expressed in CIS patients than in control 
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subjects. This finding may be more relevant than overexpression per se. Similar 
findings have been reported previously (Schmitt et al., 2013), who analysed MS brain. 
In addition, we show that the HERV-W copies relatively overexpressed in CIS patients 
do not produce high levels of transcripts and only represent 1-3% of total transcripts 
(Figure 6C). The combined findings on low levels of overexpression, activation of more 
loci, and activation of low-expressing HERV-W elements in MS suggest that their 
potential contribution to the pathology may not reside simply in high expression levels. 
CIS-associated copies may produce proteins that are especially active in TLR4 
activation (Rolland et al., 2006). Alternatively, HERV-W products in the form of RNA 
may activate the native immune system through TLR3  (Hurst and Magiorkinis, 2015; 
Stetson, 2012). It remains perfectly possible, that additional HERV-W copies or the CIS-
associated HERV-W copies (Figure 6), produce or overproduce LTR3-activating agents 
functioning as Pathogen Associated Molecular Pattern. We therefore highlight the 
potential contribution to MS of TLR3 activation through RNAs that originate from 
HERV-W, and stress the importance of searching for such substances in MS patients.  
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Supplementary materials 
 
Target Sequence (5’-3’) 1 mM MgCl
2
 addition 
MSRV ENV  
(Mameli et al., 2009) 
For: CTTCCAGAATTGAAGCTGTAAAGC 
Rev: GGGTTGTGCAGTTGAGATTTCC 
TaqMan® probe:  
FAM-5’-TTCTTCAAATGGAGCCCCAGATGCAG-3’-TAMRA 
No 
hGAPDH For: ATCAGCAATGCCTCCTGCAC 
Rev: TGGCATGGACTGTGGTCATG 
No 
HERV-W 19q13.2 For: GCAGGATTTCCTAGGCCGATT 
Rev: CTTACCTGATGGGTCGGGTG 
Yes 
HERV-W 5p12 For: CCTGCTAGACTATGCTCTGATG 
Rev: CTGCTCTAACTGCTTCCTACTG 
Yes 
HERV-W 9q22.31 For: GCTTGCAACTTAGCCCACAC 
Rev: AAACAAAACCTTACCATCTTAACCA 
Yes 
Table s1. List of set of primers used for the qPCR expression analysis. The first column shows the 
target, the second column indicates the oligo sequence (For= forward; Rev= reverse) and, the third 
column points out whether the PCR reaction needs an extra addition of 1 mM MgCl2 or not. 
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Manuscript III. HERV-W methylation in multiple sclerosis 
 
Abstract 
The presence and expression of human endogenous retroviruses family W (HERV-W) 
has been repeatedly associated with multiple sclerosis (MS). However, little is known 
of the regulation of HERV-W expression and the pathological significance of 
overexpression. A number of studies have reported that DNA hypomethylation 
correlates with HERV activation in a range of diseases. Nevertheless, the possible role 
of DNA hypomethylation in the induction of HERV-W expression in MS has not yet 
been directly addressed. HERV-W ENV copy-specific methylation assays were designed 
for HERV-W ENV loci 19q13.2, 15q21.3 and Xq22.3. Assays span 100 bp amplicons and 
allow assessment of methylation level of individual CpG sites by pyrosequencing.  After 
validation, they were applied to analyse methylation levels in genomic DNA from 
peripherical blood mononuclear cells (PBMCs) of 5 MS patients and 6 controls. 
Methylation patterns in the loci analysed did not differ between MS patients and 
controls. In all cases, DNA sequences were highly methylated, and no MS-specific 
changes were observed. Therefore, 5-aza-2-deoxycytidine (5-azadC) was used as a 
demethylating agent in an attempt to force HERV-W demethylation and address the 
relation to expression levels. Neither in oligodendrocyte precursor cells (OPCs), nor in 
lymphocytes 5-azadC treatment was effective and demethylation could not be 
demonstrated. Human embryonic stem cells (hESCs) were more susceptible to 5-
azadC, and treatment caused demethylation of POU5F1, LEFTY1 and SERPINA3 genes, 
However, DNA methylation of the HERV-W elements was not altered. It seems that 
DNA methylation levels of HERV-W elements are ordinarily high in PBMCs and do not 
correlate with MS. Efforts to artificially force HERV-W demethylation using 5-azadC, 
demonstrated that the high methylation levels at HERV-W elements maybe unusually 
stable and resistant to demethylation. 
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Introduction 
Human endogenous retroviruses (HERVs) are permanent retroviral integration which 
comprise approximately 8% of our genome (Cho et al., 2008; Löwer et al., 1996). 
HERVs can be divided into multicopy families, consisting of closely related but 
distinguishable elements dispersed in the human genome. Typical structure of a HERV 
provirus contains an internal coding region containing GAG, POL, and ENV genes, 
flanked by two long terminal repeats (LTR). HERVs are present within full length or 
incomplete sequences and, most of them have lost their protein-coding capacity by an 
accumulation of mutations (Kim, 2012). However, an increasing number of studies 
have reported HERV expression in several tissues and cells (Balestrieri et al., 2015; 
Seifarth et al., 2005).  
HERVs have been found to be active in human cells in a tissue-specific manner, with a 
considerable expression in skin, thyroid gland, placenta, and tissues of reproductive 
organs (Seifarth et al., 2005). Control of HERVs expression depends on regulation at 
the level of the LTRs, which contain multiple binding sites for transcription factors and 
act as promoters (Kovalskaya et al., 2006). It widely assumed that transcriptional 
activity of HERVs is regulated by epigenetic mechanisms, mainly by DNA methylation 
(Hurst and Magiorkinis, 2017). In fact, tissue-specific epigenetic modifications in the 
LTR promoter region have been reported to be associated with HERVs expression. For 
instance, promoter of HERV elements expressed in placenta tissue, have been 
reported to be unmethylated in placenta but heavily methylated in other cell types, 
where these HERV elements do not express (Matoušková et al., 2006; Reiss et al., 
2007).  
Upregulated HERV expression has repeatedly been associated to a range of diseases 
such as cancer and neurodegenerative diseases (Colmegna and Garry, 2006; Dolei, 
2006; Kurth and Bannert, 2010). And such aberrant HERVs expression has also been 
linked to altered DNA methylation. DNA hypomethylation has been observed to 
correlate with HERVs activation in cancer cells and in CD4+ T cells from lupus patients 
(Goering et al., 2011; Wu et al., 2015). In particular, demethylation of HERV-K LTR has 
been reported to induce HERV-K expression in cancer cells (Stengel et al., 2010). 
However, although HERV family W (HERV-W) presence and expression has consistently 
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been associated to multiple sclerosis (MS) (Dolei et al., 2002; Garson et al., 1998; 
Mameli et al., 2007; Perron et al., 2012), HERV-W methylation status in the context of 
MS has not yet been addressed. In a previous study (Manuscript II), we identified 
HERV-W loci that were overexpressed in peripherical blood mononuclear cells (PBMCs) 
of MS patients. We now intended to address the relationship between genomic 
methylation of HERV-W loci and induced expression. Based on that initial study, copy-
specific methylation assays for specific HERV-W loci were designed, developed, 
validated and applied to PBMC samples taken from MS patients and controls. As no 
MS-related changes in DNA methylation were observed, we resorted to an alternative 
strategy to analyse whether HERV-W hypomethylation correlates with HERV-W 
activation. Strategies to study epigenetics include the use of drugs which inhibit DNA 
methyltransferases (DNMTs), resulting in demethylation and reactivation of silenced 
genes (Chistiakov et al., 2017; Palii et al., 2008; Ramos et al., 2015). Different cell types 
were treated with the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine (5-
azadC), and the effect on HERV-W methylation status was assessed. 
Materials and methods 
PBMCs isolation and gDNA extraction  
PBMCs isolation and gDNA extraction was performed as described before (M&M, 
Manuscript I). 
Sodium bisulfite modification 
Genomic DNA samples (500 ng) were bisulfite modified using the EZ DNA 
Methylation™ Kit (D5001, Zymo Research) following the manufacturer’s instructions. 
The converted DNA was eluted in 20 µl of TE Buffer and stored at -20 °C until used. 
PCR amplification and methylation assays 
Bisulfite-converted genomic DNA was amplified by PCR or nested PCR depending on 
the locus analyzed. For the first round of amplification, PCR reaction was carried out in 
a 50-µl volume using 4 µl of bisulfite-converted DNA (previously boilt at 100 °C for 3 
minutes), 200 µM dNTPs, forward and reverse primers (400 nM each), and 0.5 U Taq 
DNA Polymerase (D1806, Sigma-Aldrich) in PCR reaction buffer containing 2.5 mM 
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MgCl2. As an exception, the PCR reaction buffer used in the first PCR round of HERV-W 
ENV locus 5p12 only contained 1.5 mM MgCl2). Components of nested PCR were the 
same as listed above, except for the template which consisted of 1 µl of the first PCR 
product. Sequences of all primers used and cycling conditions for all assays are 
described in Table s1 and Table s2. All set of primers were in-house designed, except 
for those primers used in the pyrosequencing assays for POU5F1, LEFTY1 and 
SERPINA3 (Kim et al., 2011). PCR amplifications were performed in duplicate and PCR 
products from duplicate reactions were mixed before analyzed. The presence of 
amplified products was confirmed on a 2% agarose gel. Bisulfite-converted PCR 
products were sequenced using PSQ 96MA System (Pyrosequencing). Sequencing 
primer, the nucleotide dispensation order and the number of CpGs sites analysed in all 
pyrosequencing assays are described in Table s1 and Table s2. Some negative controls 
were included in the sequence to assess the absence of undesired PCR products 
(Figure s1). Technical replicates using different amount of DNA input were performed 
to exclude variability and validate every pyrosequencing assay. Percentage of 
methylation for each CpG site was calculated using the Pyro Q-CpG software (version 
1.0.9) (Biotage) applying the default settings. Only high-quality quantitative results, 
determined by the quality control thresholds of the software, were considered. 
Examples of the pyrograms obtained from assays described in Table s1 and Table s2 
can be observed in Figure s1 and Figure s2, respectively. 
Oligodendrocyte precursor cells culture and 5-aza-2′-deoxycytidine treatment 
Oligodendrocyte precursor cells (OPCs) characterized by expression of NG2, were 
differentiated from hESCs ES[4] as described in Manuscript IV (All et al., 2015). OPCs 
were treated with 100nM, 250nM, 500nM and 1µM 5-aza-2′-deoxycytidine (5-aza-dC) 
or untreated (mock) for 96 hours (drug-supplemented culture medium was renovated 
daily). After 96 hours, cells were harvested and gDNA was isolated as above. 
Lymphocytes culture, cell viability assay and 5-aza-2′-deoxycytidine treatment 
PBMCs were isolated from buffy coats (obtained by the Aragón Blood and Tissue 
Bank). PBMC were plated at a density of 1 x 106 cells/mL and cultured in RPMI-1640 
medium, supplemented with 1X glutamax, 10% heat-inactivated FBS and 10 ng/ml LPS 
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(Sigma). After 24 hours in culture, non-adherent cells (lymphocytes, both B and T cells) 
were centrifuged and plated aside the adherent cells (monocytes), in the same 
conditions used so far. The following day, lymphocytes were treated with 100nM, 
1µM, 3µM and 10 µM 5-aza-dC or untreated (mock) for 96 hours (drug-supplemented 
culture medium was renovated daily). After 96 hours, cells were harvested and gDNA 
was isolated.  
Human embryonic stem cell line ES[4] cell culture, cell viability assay and 5-aza-2′-
deoxycytidine treatment 
The human embryonic stem cell line ES[4] was provided by the Stem Cell Bank of 
Barcelona (BLCB) and propagated on Matrigel matrix (BD) in mTeSR1 medium 
(STEMCELL Technologies) as described by BLCB. ES[4] cells were passaged when they 
were approximately 80-85% confluent using ReLeSR™ (STEMCELL Technologies) 
according to manufacturer's’ protocol at a 1:8-1:10 split ratio, ensuring this way that 
cells were passaged every 3-4 days. To test for dose-dependent toxicity of 5-aza-2′-
deoxycytidine, ES[4] cells were plated, allowed to grow for 48 hours, and treated with 
0.1 nM, 1 nM, 10 nM, 100nM, 1µM and 5µM 5-aza-2′-deoxycytidine (5-aza-dC) or 
untreated (as control) for 96 hours (fresh culture medium and drug was added every 
24 hours). During treatment, cell viability was observed under the microscope and 
defined based on cell adherence and morphology. After treatment, cells were 
harvested and gDNA was isolated 
Statistical analysis 
Statistical analysis was performed as described before (M&M, Manuscript II). 
Results 
Methylation level of HERV-W-ENV-specific loci in PBMCs 
To analyse the potential changes methylation status related to MS, we decided to 
assess methylation levels of HERV-W ENV in PBMCs of MS patients. We took 
advantage of a previous work in which we defined HERV-W ENV copies overexpressed 
in PBMCs of a set of MS patients (Manuscript II). We now designed copy-specific assays 
for some of the most representative HERV-W ENV copies. After validation, these assays  
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Figure 1. Schematic representation of methylation assays. Methylation assays for loci HERV-W ENV 
indicated on the left (19q13.2, 15q21.3 and Xq22.3). Arrows represent the pair of primers used in PCR to 
selectively amplify each HERV-W element. Biotinylated and sequence primers are indicated in Table s1. 
The round symbols (  ) indicate individual CpG sites within the amplicons analyzed. It is not drawn to 
scale. LTR: long terminal repeats.   
 
 
 
 
 
Figure 2. DNA methylation levels of HERV-W loci in PBMCs. Pyrosequencing-based methylation analysis 
was performed on genomic DNA from PBMCs of MS patients (n=5) and control individuals (n=6). Results 
are represented as de median of the methylation levels across all CpG sites (Figure 1) analysed. The 
table shows numerical values taken from the graph.  
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were applied in a set of PBMCs from MS patients (n=5) and controls (N=6). 
MSRV/HERV-W ENV expression had previously been observed to be upregulated in 
those MS patients (data not shown). Assays were based on the resistance of 
methylated cytosine to conversion into uracil by bisulfite treatment (Frommer et al., 
1992).  Bisulfite-converted DNA was used for the amplification of the region of interest 
followed by pyrosequencing. Different set of primers were designed around certain 
CpG sites and used to selectively amplify HERV-W ENV loci 19q13.2, 15q21.3 and 
Xq22.3 (Figure 1). The resulting PCR products were analysed by pyrosequencing and, 
the methylation status of individual CpG sites within each amplicon was determined. 
Examples of the pyrograms obtained from the analyses are shown in Figure s1. 
Amplicon of HERV-W ENV 19q13.2 was 95.38% and 97.75% methylated in MS patients 
and controls, respectively (t-student; p= 0.639) (Figure 2). Amplicon of HERV-W ENV 
15q21.3 was 100% methylated in both MS patients and controls (U. de Mann Whitney; 
p= 0.787). And amplicon of HERV-W ENV Xq22.3 was 92.3% and 93.33% methylated in 
MS patients and controls, respectively (U. de Mann Whitney; p= 0.273). Therefore, we 
did not detect DNA methylation changes related to MS in the loci studied. 
 
Effect of 5-azadC on DNA methylation in oligodendrocyte precursor cells and 
lymphocytes 
As we failed to detect alterations in genomic HERV-W methylation, we wanted to 
address whether there is a correlation between changes in HERV-W methylation levels 
and the expression levels. As immune responses typical of MS attack oligodendrocytes, 
we analysed 5-azadC-mediated demethylation in oligodendrocyte precursor cells 
(OPCs). 5-azadC treatment inhibits methylation of the newly formed DNA strand 
formed upon DNA synthesis, and therefore depends on cell proliferation. First, we 
examined the effect of 5-azadC on cell viability. OPCs were treated with increasing 
concentrations of 5-azadC (100 nM to 1µM) for 96 hours. During treatment, cell 
viability was observed under the microscope and defined based on cell adherence and 
morphology. We found that cell viability was not affected by any of the treatments 
used (data not shown). Therefore, the conditions used in following assays was the 
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maximum tested exposure to the drug, which consisted of an exposure of 1µM 5-
azadC for 96 hours.  
To test the effect of 5-azadC on DNA demethylation, methylation levels of an amplicon 
within HERV-W 19q13.2 was assessed. This HERV-W copy was chosen since it was 
abundantly transcribed in MS patients (Manuscript II) and we had already optimized a 
pyrosequencing assay for this locus (Figure 1). LRRC27 was included as a control gene 
since it is expressed in brain tissues and its expression is regulated by DNA methylation 
(Huynh et al., 2014). First, a pyrosequencing assay was optimized so that methylation 
levels of several CpGs within the LRRC27 locus could be analysed (Figure 3). Examples 
of the pyrogram obtained from the assay is shown in Figure s2. The resulting assay was 
applied to 5-azadC treated-OPCs. We found that the average methylation level of the 
amplicon of HERV-W 19q13.2 and the LRRC27 gene did not vary between untreated 
and treated OPCs (Figure 4A). While LRRC27 methylation amounted to 47% and 49%, 
respectively, the levels of methylation level in the amplicon of HERV-W 19q13.2 
measured at 94 % and 90%, respectively (Figure 4A). Therefore, while we applied a 
prolonged treatment with a relatively high concentration of 5-azadC, no changes in the 
methylation of the amplicon of HERV-W 19q13.2 were observed and we failed to prove 
that demethylation has occurred. 
In the hope of improving demethylation, 5-azadC treatment was applied to cells with a 
higher proliferative capacity. Lymphocytes were treated with increasing 
concentrations of 5-azadC (100nM to 10 µM) for 96 hours. During treatment, the 
number of viable cells was determined using the trypan blue dye exclusion test of cell 
viability, and cell proliferation was maintained by daily adding fresh LPS. We found that 
cell viability was neither affected by any of the 5-azadC treatments used, nor induced 
by LPS (data not shown). Lymphocytes were exposed to 10µM 5-azadC for 96 hours, 
and DNA demethylation was assayed in the amplicon of LRRC27. We found that, just 
like OPCs, the average LRRC27 methylation level did not vary between untreated and 
5-azadC treated lymphocytes, the levels measured at 15 % and 18%, respectively 
(Figure 4B). Therefore, the 5-azadC treatment also failed to induce DNA demethylation 
in lymphocytes.  
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Figure 3. Schematic representation of the methylation assay designed for gene LRRC27. Arrows 
represent the pair of primers used in PCR to selectively amplify LRRC27. Biotinylated and sequence 
primers are indicated in Table s2. The round symbols (  ) indicate individual CpG sites within the 
amplicons analyzed.  
 
 
 
Figure 4. Dose-dependent effect of 5’aza2D on methylation levels in oligodendrocyte precursor cells 
(OPCs) and lymphocytes. A) OPCs were exposed to 1 µM 5-aza-2-deoxycytidine (5-AzadC) for 96 hours 
or left untreated (mock). B) Lymphocytes were exposed to 10 µM 5-aza-2-deoxycytidine (5-AzadC) for 
96 hours or left untreated (mock). In both assays, methylation levels of indicated targets were 
determined by pyrosequencing. Results are represented as the average of the percentage of 
methylation of CpG sites across loci. For the assay A, none standard deviation could be calculated since 
there was just one biological replicate (N=1). On the contrary, for assay B, standard deviation was 
calculated (N=2). The tables below show numerical values taken from the graphs. 
Effect of 5-azadC on DNA methylation in human embryonic stem cells  
In a last attempt of induce a 5-azadC-mediated DNA demethylation, we applied the 
drug to human embryonic stem cells (hESCs), which are highly proliferative cells likely 
to be susceptible to 5-azadC action. We first examined the effect of 5-azadC on cell 
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viability. ES[4] cells were treated with increasing concentrations of 5-azadC (0.1 nM to 
5µM) for 96 hours. After treatment, cell viability was observed under the microscope 
and defined based on cell adherence and morphology. We found that cell attachment 
was markedly reduced after 48 hours of treatment with doses of 100 nM 5-azadC and 
higher (data not shown). In contrast, doses lower than 10 nM 5-azadC were observed 
not to have any effect on cell adherence and morphology after 96 hours of treatment 
(data not shown). These results revealed that the most suitable conditions for ES[4] 
cells treatment were an exposure of 10 nM and 100 nM 5-azadC for 96 and 48 hours, 
respectively.  
To test the effect of 5-azadC on DNA demethylation, methylation levels of the 
amplicon of HERV-W 19q13.2 and some control genes were assessed. First, 
pyrosequencing assays for genes expressed in hESCS and whose expression is 
regulated by DNA methyaltion (Kim et al., 2011) were carried out. Pyrosequencing 
assays for POU5F1, LEFTY1 and SERPINA3 (Kim et al., 2011) were optimized and 
validated, allowing analysis of a single CpG site in the amplicons for POU5F1, LEFTY1 
and two CpG sites in the amplicon for SERPINA3 (Figure 5). Examples of the pyrograms 
obtained from these assays are shown in Figure s2. Next, ES[4] cells were treated with 
10 nM and 100 nM 5-azadC for 96 and 48 hours, respectively or left untreated (mock). 
We found that POU5F1, LEFTY1 and SERPINA3 methylation levels in untreated ES[4] 
cells were 54%, 87%, and 89%, respectively (Figure 6). After treatment with 10nM 5-
azadC for 96 hours, POU5F1 and LEFTY1 methylation levels were 42%, 79%, and 89%, 
respectively (Figure 6). And therefore, POU5F1 and LEFTY1 methylation levels 
decreased 22% and 9% respectively, and no variation was detected for SERPINA3 
(Figure 6). After treatment with 100nM 5-azadC for 48 hours, the levels of methylation 
of POU5F1, LEFTY1 and SERPINA3 were 37%, 67% and 76%, respectively (Figure 6). 
Therefore, methylation levels decreased by 31%, 23% and 15%, respectively. 
Therefore, we observed a 5-azadC dose-dependent DNA demethylation across loci in 
hESCs. When we analysed the methylation levels of the amplicon of HERV-W 19q13.2 
(Figure 1), we found that methylation levels in untreated ES[4] cells were 94% (Figure 
6). However, we found that methylation levels did not change upon treatment with 10 
nM and 100 nM 5-azadC for 96 and 48 hours, and the levels measured at 96 % and 
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94%, respectively (Figure 6). Unfortunately, the resistance of the amplicon of HERV-W 
19q13.2 to 5-azadC-induced demethylation precluded the study of the association 
between HERV-W methylation and expression levels. 
 
 
Figure 5. Schematic representation of the methylation assay designed for genes POU5F1, LEFTY1 and 
SERPINA3. Arrows represent the pair of primers used in PCR to selectively amplify each gene. 
Biotinylated and sequence primers are indicated in Table s2. The round symbols (  ) indicate individual 
CpG sites within the amplicons analyzed. It is not drawn to scale. 
 
 
Figure 6. Dose-dependent effect of 5’aza2D on methylation levels in ES[4] cells. ES[4] cells were 
exposed to 10 nM and 100 nM 5-aza-2-deoxycytidine (5-AzadC) for 96 and 48 hours respectively or left 
untreated (mock). Methylation levels of indicated targets were determined by pyrosequencing Results 
are represented as the average of the percentage of methylation of CpG sites across loci. Biological 
replicates are indicated (N). The corresponding standard deviation was calculated except for those 
assays performed only once (N=1). The table below shows numerical values taken from the graph.  
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Discussion 
While some reports have shown that changes in DNA hypomethylation correlate with 
HERVs activation in cancer cells or in CD4+ T cells from lupus patients (Goering et al., 
2011; Wu et al., 2015), HERV-W methylation status remains unknown in the context of 
MS. In a previous study (Manuscript II), we detected that HERV-W expression was 
slightly increased in PBMCs of MS patients. In the present study, we directly addressed 
the hypothesis that increased HERV-W expression in MS patients may be promoted by 
HERV-W hypomethylation. We successfully developed locus-specific methylation 
assays for 3 HERV-W loci: 19q13.2, 15q21.3 and Xq22.3. However, our results showed 
that the methylation status of three HERV-W loci did not differ in MS patients and 
controls, and that HERV-W loci were hypermethylated in all cases (Figure 2). The most 
straightforward conclusion of this data is that methylation levels do not correlate with 
changes in HERV-W expression in MS patients. However, a potential correlation could 
be masked by imperfect study design. As HERV-W expression was only slightly 
increased in MS patients (Manuscript II), a potential small difference in HERV-W 
methylation levels between MS patients and controls may have fallen below the 
detection limit of our assays. This may be the case if differences are restricted to a 
subset of cells. The observed lack of correlation between HERV-W expression and 
methylation might also be explained by the design of our methylation assays, which 
targets HERV-W ENV regions. We intended to analyse HERV-W ENV regions since we 
had observed a HERV-W ENV expression increase in MS patients (Manuscript II). 
However, the expression of HERVs is thought to be regulated by promoter and 
enhancer regions within the long terminal repeats (LTRs) located at both ends of HERV 
sequence (Kovalskaya et al., 2006; Nelson et al., 2003). For the HERV-W locus ERVWE1 
(which encodes Syncytin-1), evidence indicate that the promoter region is located 
within the 5’ LTR (Cheng et al., 2004), and that hypermethylation of the 5'LTR 
correlates with decreased Syncytin-1 mRNA and protein levels in preeclamptic 
placentas (Zhuang et al., 2014). Therefore, it is possible that the methylation state of 
the LTR region of HERV-W is more relevant. While we tried to design and validate 
copy-specific methylation assays in the LTR, we failed in obtaining such PCR products 
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(data not shown). But it might be possible that the methylation state of the ENV region 
of HERV-W could be irrelevant for transcription.   
As we did not observe differences in DNA methylation within HERV-W loci in MS 
patients, we wanted to study whether DNA methylation regulates gene expression 
levels. To do so, we artificially induced DNA demethylation in different cell types in 
culture and analyses the effect on HERV-W expression. We treated OPCs, lymphocytes 
and hESCs with the demethylating agent 5-azadC. No differences in the DNA 
methylation level were detected neither in OPCs nor lymphocytes after 5-AzadC 
treatment (Figure 4). It had to be considered that 5-AzadC does not act demethylating 
existing DNA but demethylating new DNA. Therefore, effectiveness of 5-AzadC 
treatment depended on DNA synthesis and, it can be possible that longer treatments 
or higher 5-AzadC doses are requires to observe changes in DNA methylation. 5-AzadC 
treatment in hESCs yielded DNA demethylation of some control genes but not HERV-W 
elements (Figure 6). Both, inefficiency of 5-AzadC treatment and the resistance of 
HERV-W elements to 5-azadC-induced demethylation, prevented us from analysing 
whether DNA hypomethylation correlates with HERV-W activation. Taken together, 
our findings indicate that further studies are required to understand the role that DNA 
methylation modifications may play in MS. 
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Supplementary materials 
 
 
Figure s1. Representative pyrograms of HERV-Wenv locus-specific methylation assays. Pyrosequencing 
analyses for the indicated loci are represented in pyrograms. Vertical axis: signal intensity; horizontal 
axis: order of residues analyzed. The % methylation of each CpG sites analyzed are indicated in colored 
boxes. The quality of the result at each position is estimated by the software, and represented through a 
color-based score: blue (“passed”), yellow (“to check”) and red (“failed”). The yellow/brown bar shows a 
C analyzed to confirm complete conversion of non-methylated cytosines. 
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Table s1. HERV-Wenv locus-specific PCR amplification and DNA methylation assays. The first column shows the HERV-Wenv locus target and the second column 
indicates the oligo sequences used for individual HERV-Wenv locus-specific PCR amplification and pyrosequencing analysis. (For= forward; Rev= reverse; ext: first 
nested PCR round; int: second nested PCR round; seq: sequence primer). The third and fourth columns indicate the cycling conditions for the first and the second 
PCR round respectively. The last column shows the nucleotide dispensation order for the pyrosequencing analysis. CpGs sites are highlighted in yellow. 
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Figure s2. Representative pyrograms of gene-specific methylation assays. Pyrosequencing analyses for 
the indicated loci are represented in pyrograms. Vertical axis: signal intensity; horizontal axis: order of 
residues analyzed. The % methylation of each CpG sites analyzed are indicated in colored boxes. The 
quality of the result at each position is estimated by the software, and represented through a color-
based score: blue (“passed”), yellow (“to check”) and red (“failed”).  
Sofía Macías Redondo 
124 
 
 
Table s2. Gene-specific PCR amplification and DNA methylation assays. The first column shows the gene and the second column indicates the oligo sequences used 
for PCR amplification and pyrosequencing analysis. (For= forward; Rev= reverse; Btn: biotin; seq: sequence primer). The third and fourth columns indicate the cycling 
conditions for PCR and the last column shows the nucleotide dispensation order for the pyrosequencing analysis. CpGs sites are highlighted in yellow. 
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Manuscript IV. Immune responses in human oligodendrocyte precursor 
cells cultured in vitro 
 
Abstract 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
(CNS), characterized by the loss of myelin and the damage of oligodendrocytes. 
Evidence suggests that upregulated human endogenous retrovirus family W (HERV-W) 
expression in autopsied brain tissues and peripheral blood mononuclear cells (PBMCs) 
is associated to MS. The first line of defence against viral infection depends on the 
activation of intracellular receptors called toll-like receptors (TLR). For instance, HERV-
W proteins provoke a TLR4-mediated immune response in PBMCs and monocytes. 
However, the possible relationship between upregulated HERV-W RNA expression and 
TLR signalling has not yet been addressed in cell types from the CNS. Here we aimed to 
study the possible TLR3-mediated innate immune system stimulation by RNA 
transcribed from a HERV-W in human oligodendrocytes. We implemented two 
published protocols to differentiate human embryonic stem cells (hESCs) into O4+ 
oligodendrocyte cells. In my hands, none yielded O4+ oligodendrocytes starting from 
ES4 cells. A partial HERV-W ENV copy (locus 5p12) named HERV-W ENV 5p12 was 
cloned, linked to a ubiquitous promoter, and inserted into a lentiviral vector. After 
transduction into human neural progenitor cells (NPCs), we observed an increased 
HERV-W ENV expression compared to non-transduced NPCs. Such increase was 
associated with an increase of both TLR3 and type I interferon β (IFNβ) expression. We 
conclude that HERV-W overexpression triggers a type I interferon response in NPCs, 
possibly via TLR3-activation.  
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Introduction 
Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous 
system (CNS) characterized by the loss and damage to oligodendrocytes, the highly 
specialized cell type of the CNS that produce the myelin (Brück et al., 2002; Lucchinetti 
et al., 2000; Trapp et al., 1998). As a result, myelin sheaths are affected resulting in 
neuronal dysfunction (Nylander and Hafler, 2012). Although mechanisms that trigger 
the autoimmune response remain unclear, genetic, environmental, and viral causes 
contribute to the development of the disease (Koriem, 2016). Inflammation of the CNS 
is the result of both a peripherical and local immune response. The massive infiltration 
of peripherical mediators of the immune system in the brain causes an inflammatory 
response that causes oligodendrocyte and axonal damage (Brück, 2005). Also, 
microglia, the resident immune cells of the CNS not only can interact with cells of the 
adaptive immune system (such as T cells and B cells), but can also directly cause 
neuroinflammatory tissue damage (Hemmer et al., 2015; Macchi et al., 2015).  
As the human brain is inaccessible for experimental approaches for obvious reasons, in 
vitro models are used to study the pathology in human oligodendrocyte associated 
with MS. In recent years, a number of protocols for generating in vitro human 
pluripotent stem cells-derived oligodendrocytes have been stablished (All et al., 2015; 
Douvaras and Fossati, 2015; Ehrlich et al., 2017; García-León et al., 2018; Stacpoole et 
al., 2013). In such protocols pluripotent cells are converted first into neural progenitor 
cells (NPCs), then into oligodendrocyte precursor cells (OPCs) and finally into O4+ 
oligodendrocytes. This works for both human embryonic stem cells (hESCs), and 
induced pluripotent stem cells (iPSCs) derived from MS patients (Douvaras et al., 
2014), the latter representing an important approach for the study of MS 
pathophysiology.  
Human endogenous retroviruses family W (HERV-W) have been related to MS 
pathogenesis since different studies have reported that HERV-W expression is elevated 
in cerebrospinal fluid (CSF), autopsied brain tissues and peripheral blood mononuclear 
cells (PBMCs) from MS patients versus controls (Dolei et al., 2002; Garson et al., 1998; 
Mameli et al., 2007). In response to viral infection, antiviral innate immunity is mostly 
mediated by toll-like receptors (TLRs). TLRs belong to a family of innate immune 
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system receptors whose stimulation causes a response of the innate immune system. 
In particular, TLRs activation leads to the transcriptional activation of genes encoding 
proinflammatory cytokines, chemokines and type I interferons (IFN-α/β). The latter 
subsequently trigger innate immune responses and modulate adaptive immunity 
(Hernández-Pedro et al., 2013; Xagorari and Chlichlia, 2008). TLR receptor are usually 
expressed on innate immune response cells such as microglia, but also on other cells of 
the CNS, including oligodendrocytes, astrocytes and neurons (Carpentier et al., 2008; 
Kielian, 2006; Trudler et al., 2010). TLRs are fundamental for the induction of antiviral 
innate immune responses (Lester and Li, 2014; Xagorari and Chlichlia, 2008). For 
instance, HERV-W proteins have the potential to trigger a TLR4-mediated immune 
response in PBMCs and monocytes (Rolland et al., 2006). Also, recent data showed 
that overexpression of viral double-stranded (ds) RNA in cancer cells activated a type I 
interferon-mediated immune response through TLR3 signalling (Chiappinelli et al., 
2015). However, the possible relationship between upregulated HERV-W RNA 
expression in brain of MS patients and TLR recognition has not yet been addressed. 
In the present study, we first aimed to establish hESC-derived O4+ oligodendrocytes 
and oligodendrocyte precursor cells (OPCs), as a simplified model for disease-related 
processes. We took advantage of two already stablished differentiation protocols (All 
et al., 2015; García-León et al., 2018). We aimed to monitor immune responses 
provoked by HERV-W overexpression. To this end, a cloned partial HERV-W copy (locus 
5p12) was overexpressed in NPCs. After induction of HERV-W expression, the 
expression level of genes relevant to innate immunity was assessed.  
Materials and methods 
Human embryonic stem cell line ES[4] cell culture 
The human embryonic stem cell line ES[4] was provided by the Stem Cell Bank of 
Barcelona (BLCB) and propagated on Matrigel matrix (BD) in mTeSR1 medium 
(STEMCELL Technologies) as described by BLCB. ES[4] cells were passaged when they 
were approximately 80-85% confluent using ReLeSR™ (STEMCELL Technologies) 
according to manufacturer's’ protocol at a 1:8-1:10 split ratio, ensuring this way that 
cells were passaged every 3-4 days. For hESCs ES[4] morphology see Figure s.1. 
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Oligodendrocyte differentiation (All et al., 2015) 
Oligodendrocyte precursor cells were differentiated from hESCs ES[4] as described (All 
et al., 2015). In brief, ES[4] cells were lifted using ACCUTASE™ (STEMCELL 
Technologies) and seeded in suspension so that embryoid bodies (EBs) were 
generated. On the second day, medium was changed from mTeSR1 medium to N2B27 
medium supplemented with 150 ng/ml LDN-193189 (axonmedchem) and 20 ng/ml 
basic fibroblast growth factor (FGF2) (Peprotech). N2B27 medium contained 
Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12) (Thermo 
Fisher Scientific) supplemented with 1 X non-essential amino acids (SIGMA), 1 X 
Glutamax (Thermo Fisher Scientific), 1 X N2 supplement (Thermo Fisher Scientific), 1 X 
B27 supplement (Thermo Fisher Scientific), 50 µM 2-Mercaptoethanol, 7,5% Bovine 
Serum Albumin (BSA) and 1 X Penicillin-Streptomycin. EBs were daily fed for 15 days 
with N2B27 medium, then they were plated onto Matrigel-coated 60mm culture plates 
in N2B27 medium supplemented with 20 ng/ml FGF2 for 5 days, leading to 
differentiation into neural progenitors (NPCs). NPs were expanded in this media for 7 
days and glial progenitors (GPCs) were subsequently induced by adding 10 ng/ml 
epidermal growth factor (EGF) (STEMCELL Technologies) for 7 days. After 7 days in GP 
media, cells were split with collagenase IV (Thermo fisher) and transferred into new 
Matrigel-coated culture plates. Oligodendrocyte precursor cells (OPs) were induced by 
supplementing N2B27 medium with 20 ng/ml EGF and 20 ng/ml platelet-derived 
growth factor AA (PDGF-AA) (STEMCELL Technologies) for 25 days. 
Oligodendrocyte differentiation (García-León et al., 2018) 
Oligodendrocytes were differentiated from hESCs ES[4] using SOX10 overexpression as 
described (García-León et al., 2018). Briefly, on day 0, NPCs were induced by switching 
medium from mTeSR™1 medium to NPC differentiation medium supplemented with 
25 ug/ml insulin (I9278, Sigma), 10 mM SB431542 (301836-41-9, axonmedchem), 1 
mM LDN193189 and 100 nM retinoic acid (RA) (R2625, Sigma) until day 8. NPC 
differentiation medium consisted of Dulbecco's Modified Eagle Medium/Nutrient 
Mixture F-12 (DMEM/F-12) (Thermo Fisher Scientific), 1 X non-essential amino acids 
(SIGMA), 1 X Glutamax (Thermo Fisher Scientific), 1 X N2 supplement (Thermo Fisher 
Scientific), 1 X B27 supplement (Thermo Fisher Scientific), 50 µM 2-Mercaptoethanol 
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and 1 X Penicillin-Streptomycin. On day 8, SB431542 and LDN193189 were removed 
and 1 mM smoothened agonist (SAG) (73412, STEMCELL Technologies) added until day 
12, when NPCs were dissociated, plated, and transduced with lentiviral particles 
containing FUW-SOX10 vector. FUW-Sox10 was a gift from Catherine M. Verfaillie 
(García-León et al., 2018). The next day, medium was changed to OL differentiation 
medium consisting of NPC differentiation medium supplemented with 25 ug/ml insulin 
(Sigma), 10 ng/ml of PDGF-AA (Peprotech), 10 ng/ml insulin-like growth factor 1 (IGF1) 
(STEMCELL Technologies), 5 ng/ml hepatocyte growth factor (HGF) (STEMCELL 
Technologies), 10 ng/ml neurotrophin 3 (NT3) (Peprotech), 100 ng/ml biotin (Sigma), 1 
µM adenosine cyclic monophosphate (cAMP) (Sigma), 60 ng/ml thriiodothytonine (T3) 
(Sigma) and 1 µg/ml doxycycline (Sigma). Cells were maintained for 7–10 days. 
RNA isolation and cDNA synthesis  
RNA isolation and cDNA synthesis were performed as described before (M&M, 
Manuscript II). 
Semiquantitative analysis by PCR 
PCR reaction was carried out in a 50-µl volume using 2 µl of cDNA, 200 µM dNTPs, 
forward and reverse primers (400 nM each), 0.5 U Taq DNA Polymerase (D1806, 
Sigma) and its appropriated buffer. For primer sequences see Table s1. PCR was 
performed in a Veriti Thermal Cycler (Applied Biosystems) and the cycling conditions 
consisted of 98 °C for 2 minutes and then 35 cycles of 94 °C for 1 minute, 60 °C for 
1minute and 72 °C for 1 minute, with a final extension of 72 °C for 5 minutes. The 
presence of amplified products was confirmed on 1.5 % agarose gels, visualized using 
Gel RedTM (41003, Biotium) and photographed on a Gel Doc transilluminator (BioRad). 
Flow cytometry: extracellular staining protocol 
A single-cell suspension was prepared lifting cells with ACCUTASE™ (STEMCELL 
Technologies). All antibodies were suspended in Blocking buffer (5% fetal bovine 
serum (FBS) in PBS). Cells were pelleted at 200 g for 3 minutes and incubated with 
primary antibody for 1 hour at 4 °C after resuspension. Cells were subsequently 
washed with Blocking buffer and incubated with secondary antibody for 30 minutes at 
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4 °C. When using a conjugated primary antibody, cells were incubated for 30 minutes 
at 4 °C. After labelling, cells were washed, resuspended in 200 µl PBS and stained with 
SYTOX™ Dead Cell Stain Sampler Kit (S34862, Thermo Fisher Scientific) prior to data 
collection. Antibodies and dilutions used: CD 29 Mouse Anti-Human (CD2901, Thermo 
Fisher Scientific; 1:10), Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary 
Antibody, Alexa Fluor 488 (A11029, Invitrogen; 1:50), Oligodendrocyte Marker O4 
Alexa Fluor 488-conjugated antibody (FAB1326G, R&D Systems; 1.25µg). 
Quantification was carried out using a FACSAria™ instrument (BD BioSciences) 
equipped with a 488-nm laser. Data were analysed using the WEASEL Flow Cytometry 
Software. Gates were established based on the corresponding unstained and isotype 
controls. To analyse GFP expression, gates were set based on non-transduced cells. 
Plasmid constructs  
To induce HERV-W overexpression, HERV-W copy located on chromosome 5p12 
(HERV-W 5p12) was amplified and fused to the phosphoglycerate kinase (PGK) 
promoter (HERV-W 5p12-PGK). Both sequences, HERV-W 5p12 and HERV-W 5p12-PGK 
were then fused to the plasmid pSIN-EF2-Lin28-Pur which contains the EF-1α promoter 
(Figure s.2). Plasmids were constructed through the following steps. All enzymes 
mentioned were from Thermo Scientific unless specified otherwise. For primer 
sequences see Table s.2. 
A genomic HERV-W 5p12 copy was amplified by PCR as follows. The PCR reaction was 
carried out in a 50-µl volume using 100 ng of gDNA, 200 µM dNTPs, forward and 
reverse primers (400 nM each), 0.5 U Taq DNA Polymerase (D1806, Sigma) and its 
appropriate buffer. gDNA was boiled at 100 °C for 3 minutes before addition to the 
reaction. Cycling conditions consisted of 35 cycles of 94 °C for 1 minute, 60°C for 
1minute and 72°C for 1 minute, with a final extension of 72 °C for 5 minutes. The 
presence of amplified products was confirmed on 1% agarose gels, visualized using Gel 
RedTM (41003, Biotium) and products were vizualized on a Gel Doc transilluminator 
(BioRad). PCR product was cleaned up using the Geneclean Turbo kit (MP Biomedicals), 
precipitated with sodium acetate-ethanol and cloned into the pGEM®-T Easy Vector 
System I (Promega) according to manufacturer's instructions. The vector was 
RESULTS/ MANUSCRIPT IV 
 
133 
 
transformed into E. coli XL1 cells and cultured in Luria–Bertani (LB)-agar plates 
supplemented with 50 µg/mL ampicillin at 37 °C. Colonies were analysed by plasmid 
miniprep, screened for the presence of insert by digestion with EcoRI and further 
sequencing (Secugen S.L). Among all clones analysed, one with a 5’-T7 promoter- 
5’insert-3’insert-SP6 promoter-3’ orientation was selected and purified using a 
midiprep kit (K210004, Invitrogen). Purified plasmid was digested with SpeI and EcoRI. 
Digested product was cleaned up using phenol-chloroform, precipitated with sodium 
acetate-ethanol and re-suspended in TE buffer. The resulting product was gel-purified  
(Geneclean Turbo kit, MP Biomedicals).  
The PGK promoter was amplified by PCR as above, using a PGK-containg plasmid as a 
template and specific primers (Table s2). Resulting PCR product was purified using the 
Diffinity RapidTip®2 (Sigma), digested two with BamHI and XbaI and cloned after 
purification into appropriately digested pSIN-EF2-Lin28-Pur plasmid (16580, Addgene).  
pSIN-EF2-Lin28-Pur plasmid (16580, Addgene) was digested with EcoRI, and either 
BamHI or SpeI. Digestion products were treated with Shrimp Alkaline Phosphatase 
(Fermentas) at 37 °C for 30 minutes and subsequently, gel-purified as above.  
Both PGK promoter fragment (BamHI- XbaI) and HERV-W 5p12 (EcoRI- SpeI) fragment 
were ligated into pSIN-EF2-Pur After transformation, colonies were screened for the 
presence of insert by digestion and verified further sequencing (Secugen S.L). The 
resulting clones were named pSIN-EF2-HERV-W 5p12 and pSIN-EF2-HERV-W 5p12-PGK.  
High-quality plasmid DNAs was isolated using a midiprep kit (K210004, Invitrogen).  
Plasmid DNA transfection of 293T cells 
Human embryonic kidney 293 T cells were cultured in 293T cells were culture in 
Dulbecco’s modified Eagle’s medium. 293T cells were transfected on PolyDLysin-
coated dishes using LipofectamineTM reagent (Invitrogen) with either pSIN-EF2, pSIN-
EF2-HERV-W 5p12 or pSIN-EF2-PGK-HERV-W 5p12 vector. After 48 hours, cells were 
homogenized with TRIzol® reagent (Invitrogen) for future RNA isolation. 
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Production of lentiviral particles and cell transduction  
FUW-SOX10, pSIN-EF2-HERV-W 5p12, pSIN-EF2-PGK-HERV-W 5p12 and pLOX-CWgfp (a 
green fluorescent protein (GFP)-containing vector; addgene #12241) vectors were 
independently co-transfected with the packaging (psPAX2, addgene #12260) and the 
envelope (pMDs.G, addgene #12259) plasmids into the 293T cell line using FUGENE 6 
Transfection reagent (Promega). The supernatant containing lentiviruses was collected 
after 48 hours, filtered through 0.45µm filter and stored in aliquots at -80°C for further 
use. For the O4+ oligodendrocyte cells differentiation (García-León et al., 2018), NPCs 
at day 12 were lifted using ACCUTASE™ (STEMCELL Technologies) and plated at 50.000 
cells/cm2 on 0.1 mg/ml poly-Lornithine/10 µg/ml laminin (P3655, L2020 Sigma) coated 
dishes before transduction. The original protocol could not be replicate due to cell 
adhesion problems. For the induction of HERV-W expression, NPCs at day 12 (García-
León et al., 2018) were separately transduced with pSIN-EF2-HERV-W 5p12, pSIN-EF2-
PGK-HERV-W 5p12 and pLOX-CWgfp lentiviral vectors for two consecutive days. Each 
day, cells were cultured with 1 ml of culture medium plus 1 ml of lentiviral 
supplemented with polybrene. Transduction efficiency was assessed by flow 
cytometry, and estimated as the percentage of cells expressing GPP, that is, the 
percentage of cells transduced with pLOX-CWgfp. After transduction, lentiviral 
supernatant was removed, cells were washed three times with PBS (14190144, 
Thermo Fisher Scientific), and maintained in NPC differentiation medium with 100 nM 
RA and 1 mM SAG until collecting data. 
Quantitative real-time PCR 
cDNA was analyzed by Real-Time PCR on a ViiA™ 7 Real-Time PCR System (Applied 
Biosystems) using the SYBR Green Master Mix (SYBR Premix Ex Taq II (Tli RNase H Plus), 
RR820A, Takara) according to manufacturer’s protocol. Amplification efficiency of all 
set of primers between 90% and 110% was assessed in standard curves (Appendix I) 
and, sequences of all primers used (used at 200 nM) are listed in Figure s3. All 
reactions were carried out in triplicate and only measurements with a standard 
deviation < 0.2 were considered. Target gene expression levels were recalculated as 2-
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ΔΔCt with respect to the mean Ct value of the samples in the control group, using 
GAPDH as a reference gene (Livak and Schmittgen, 2001).  
Results 
Generation and characterization of in vitro human oligodendrocytes  
With the aim of generating in vitro O4+ oligodendrocyte cells, we followed a publish 
differentiation protocol (Figure 1) (All et al., 2015). The first step consisted on the 
formation of embryoid bodies (EBs). For this, human embryonic stem cells (hECs) were 
seeded in suspension and within 24 hours EBs were formed. Such EBs increased in size 
and complexity over the course of differentiation, until showing a spheroid shape with 
a darker centre (Figure 2A). EBs were subsequently plated and, within 24 hours, cells 
with a neuroectodermal morphology were observed with projections extending 
outwards from the centre of the EBs (Figure 2B), leading to differentiation into neural 
progenitor cells (NPCs) (Figure 2C). NPCs were expanded for a week (Figure 2D) and 
glial progenitor cells (GPCs) were subsequently induced (Figure 2E), and finally 
converted into oligodendrocyte progenitor cells (OPCs). The obtained cells had the 
characteristic rounded shape with multiple filopodial-like extensions (Figure 2F) (All et 
al., 2015). In short, we found that the cells underwent morphologic changes consistent 
with the transition from the undifferentiated pluripotent stage into oligodendrocyte 
precursor cells. 
 
Figure 1. Timeline of oligodendrocyte differentiation based on All et al., 2015. Time is given in days, 
adherent of suspension culture is indicated as well as coating used, growth factors added to the medium 
(daily) are also pointed out. Starting with embryoid bodies (EB) formation at day 0, followed by the 
neural precursor cells (NPC) expansion. Then, glial precursor cell (GPC) are induced, and subsequent 
differentiated into oligodendrocyte precursor cells (OPC). LDN, LDN193189; FGF 2, fibroblast growth 
factor 2; EGF, Epidermal growth factor; PDGF, platelet-derived growth factor; T3, thriiodothytonine.  
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Figure 2. Bright field microscopy images of the different stages of oligodendrocyte differentiation. 
Representative pictures of the following intermediates are depicted:  Embryoid bodies (EBs) (A). Neural 
precursors cells (NPCs) (B, C, D). Glial precursors cells (GPCs) (E), oligodendrocyte progenitors (OPCs) (F). 
Images A-C were taken using magnification 5X, while images D-F were taken using magnification 10X. 
The proper progression from a pluripotent state into OPCs was also determined by 
gene expression and flow cytometry analyses (Figure 3 and 4). We found that 
pluripotency marker REX1 expression was increased in both ES[4] cells and at the EBs 
stage, but was undetectable in NPCs, GPCs and OPCs (Figure 3). On the contrary, NPCs 
and GPCs exhibited upregulated markers of early neural and glial differentiation 
respectively. For instance, SOX10 was expressed in NPCs while OLIG2 expression was 
increased in GPCs (Figure 3). Final OPCs identity was confirmed by the pronounced  
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Figure 3. mRNA expression of stage-specific genes during oligodendrocyte differentiation of hESC. 
Semi-quantitative RT-PCR analysis indicates gene expression of the markers indicated specific for 
pluripotency (REX1), neural precursors (SOX1), glial precursors (OLIG2) and oligodendrocyte precursors 
(NG2) at various steps during the differentiation process outlined in Figure 2. Stages analyzed: 
undifferentiated human embryonic stem cells (hESC); embryoid bodies (EB); neural precursors cells 
(NPC); glial precursors cells (GPC) and oligodendrocyte progenitors (OPC). 
 
Figure 4. Flow cytometry analysis of oligodendrocyte precursors marker O4 in OPCs. Flow cytometry 
dot plots showed the amount of oligodendrocyte precursor cells expressing surface antigen marker 
beta1 integrin (CD29) (D) and oligodendrocyte precursors marker O4 (C). Gating and data analysis were 
adjusted according to an unstained control (A) and an isotype control (B). 
Sofía Macías Redondo 
138 
 
NG2 expression, a marker indicative of oligodendrocyte precursor cells (Figure 3). 
However, flow cytometry analysis revealed that OPCs failed to be oligodendrocyte 
precursors marker O4 positive cells (Figure 4C). Therefore, morphological 
characterization, marker gene expression analysis and flow cytometry analysis 
confirmed that we obtained OPCs but not mature oligodendrocyte.  
While this work was in progress, an improved method to generate more mature O4-
positive cells was published (García-León et al., 2018). We aimed to replicate this 
protocol, which ensured the generation of a O4+ population within a month, thanks to 
the lentivirus-mediated overexpression of the transcription factor SOX10 (Figure 5). 
Firstly, NPCs were induced. NPCs identity was confirmed by the expecting morphology, 
a homogenous population of closely packed NPC which exhibited a neuroepithelium 
morphology (Figure 6A). Also, neuronal progenitor markers, such as PAX6 and OLIG2, 
expression was increased in NPCs, while pluripotency marker OCT4 expression was 
decreased in NPC stage compared to ES[4] (Figure 6B). 
 
Figure 5. Timeline of oligodendrocyte differentiation based on García-León et al., 2018. Time is given in 
days, starting with neural precursor cells (NPC) differentiation at day 0. At day 12, cells were transfected 
with lentiviral particles with SOX 10 gene cloned. Following the successful transfection, cells were 
differentiated into oligodendrocyte (OL). RA, retinoic acid; LDN, LDN193189; SB, SB431542, SAG, 
Smoothened Agonist; PDGF, platelet-derived growth factor; IGF, insulin-like growth factor 1; HGF, 
hepatocyte growth factor; NT3, neurotrophin-3; cAMP, adenosine cyclic monophosphate; T3, 
thriiodothytonine. 
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Figure 6. Bright field microscopy image of neural precursor cells obtained using the protocol described 
by García-León et al., 2018, and characterized by semi-quantitative RT-PCR. A) Human neural precursor 
cells (NPC) after 8 days of differentiation were closely packed, had a distinctive morphology, and the 
culture appeared to be homogeneous. Image was taken using magnification 5X. B) Analysis of mRNA 
expression shows different expression at different time points of markers specific for pluripotency 
(OCT4) and neural precursors (PAX6, OLIG2) markers through the steps of differentiation: human 
embryonic stem cells (hESC) and neural precursors cells (NPC) at day 5 and 11 of differentiation. 
However, transduction of NPCs with lentiviral particles containing the FUW-SOX10 
vector could not be performed due to ES[4] cell line-specific adhesion problem. ES[4] 
cell line inability to adhere to matrigel coating after being lifted precluded the 
successful replication of the differentiation protocol. Hence, O4+ oligodendrocyte cells 
could not be generated. And at this point, we decided to continue pursuing the aim of 
this study with cells in the previous differentiation stag: NPCs. 
Induction of HERV-W ENV RNA expression triggers a type I interferon response via 
TLR3 signalling  
We next intended to study whether HERV-W overexpression in NPCs could trigger an 
inflammatory immune response. First, to induce the overexpression of HERV-W ENV 
5p12, a genome DNA partial sequence of HERV-W ENV 5p12 was cloned into the pSIN-
EF2 vector and linked to EF1a promoter or PGK promoter (Figure s2). To prove 
promoters’ activity, 293T cells were independently transfected with either pSIN-EF2 
(pSIN), pSIN-EF2-HERV-W 5p12 (W5s) or pSIN-EF2-PGK-HERV-W 5p12 (W5s/as) vectors 
(Figure 7A). After transfection, HERV-W ENV expression levels were assessed using a 
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specific qPCR for MSRV ENV (Mameli et al., 2009). We found a 1258-fold induction of 
HERV-W ENV expression in cells transfected with the W5s vector, and a 602-fold 
induction in cells transfected with the W5s/as vector, compared to HERV-W ENV 
expression in 293T cells transfected with the pSIN vector (Figure 7B). Promoter’s 
activity from both plasmid constructions was therefore validated to induce HERV-W 
ENV overexpression. 
 
Figure 7. Transfection of 293T cells. A) Graphical representation of the general structure of the vectors 
used in this experiment: pSIN-EF2 vector (pSIN); pSIN-EF2-HERV-W 5p12 vector (W5s) and pSIN-EF2-
HERV-W 5p12-KGPp vector (W5s/as). Green arrows show promoters, while black arrows indicate 
direction of transcription. B) Quantification of HERV-W ENV expression in transfected 293T cells. Vectors 
were individually transfected in 293T cells in duplicate. After 48 hours, cells were harvested and 
analyzed for HERV-W ENV expression. Results are represented as mean fold changes compared to the 
mean expression in 293T cells transfected with pSIN vector. Biological replicates are indicated (N). The 
table shows the numerical values of the graph. 
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Subsequently, lentiviral particles containing W5s, W5s/as and pLOX-CWgfp (GFP) 
vectors were generated. NPCs were first independently transduced with lentiviral 
particles containing W5s and GPF vectors, and HERV-W ENV expression levels were 
subsequently assessed using the same assay described above (Mameli et al., 2009). 
Although only 25.6% of the NPCs were efficiently transduced (Figure 8A), 3 and 4 days 
after transduction, W5s-transduced NPCs showed a 628.2-fold and an 843.4-fold 
increased HERV-W ENV expression, respectively, compared to GFP-transduced NPCs 
(Figure 8B).  
 
Figure 8. Transduction of neural progenitor cells (NPCs). hESCs-derived NPCs were obtained using a 
published protocol (García-León et al., 2018). In a single experiment, NPCs were then independently 
transduced with W5s, W5s/as and GFP vector (Figure 7A). A) Flow cytometry dot plot shows the 
percentage of NPCs expressing GFP (ii). Gating and data analysis were adjusted according to non-
transduced cells (i). B) NPCs were harvested 3 (3d) or 4 days (4d) after transfection and expression levels 
of indicated targets were analysed by qPCR. Results are represented as fold changes compared to the 
GFP-transfected NPCs. The table shows the numerical values of the graph. 
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Once the efficient lentivirus-mediated HERV-W ENV overexpression in NPCs was 
confirmed, the possible immune system activation was analysed by assessing TLR3, 
IRF7 and IFN-β expression levels in the W5s-transduced NPCs. 3 days after 
transduction, TLR3, IRF7 and IFN-β expression levels were increased 1.9, 2.1 and 2.6 
times, respectively, compared to GFP-transduced NPCs (Figure 8B). While 4 days after 
transduction, expression levels increased up to 2.4, 2.4 and 4 times, respectively 
(Figure 8B).  
Transfection and expression assays were repeated, this time also transducing NPCs 
with lentiviral particles containing W5s/as. Transduction efficiency was much lower 
this time at 2.77% (Figure 9A). However, 4 and 7 days after transduction, W5s-
transduced NPCs showed a 52.5-fold and a 57.5-fold increased MSRV-like HERV-W 
expression, respectively, when compared to GFP-transduced NPCs (Figure 9B). And 4 
and 7 days after transduction, W5s/as-transduced NPCs showed a 34.8-fold and a 31.2-
fold increased MSRV-like HERV-W expression, respectively, when compared to GFP-
transduced NPCs (Figure 9B). We observed that HERV-W ENV induction was directly 
proportional to transduction efficiency (%) (Figure 10). 4 days after transduction, TLR3, 
IRF7 and IFN-β expression was increased 0.9, 1.1 and 0.8 times, respectively, in W5s-
transduced NPCs, while 7 days after transduction, TLR3, IRF7 and IFN-β expression 
increased up to 2.6, 3.4 and 7.4 times, respectively (Figure 9B). In parallel, 4 days after 
transduction, TLR3, IRF7 and IFN-β expression was increased 0.9, 1.4 and 0.5 times, 
respectively, in W5s/as-transduced NPCs, while 7 days after transduction, TLR3, IRF7 
and IFN-β expression increased up to 0.9, 1.1 and 3 times, respectively (Figure 9B). 
HERV-W overexpression in NPCs was therefore enough stimulus to trigger a type I 
interferon immune response possibly via activation of TLR3 and IRF7. 
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Figure 9. Transduction of neural progenitor cells (NPCs). hESCs-derived NPCs were obtained using a 
published protocol (García-León et al., 2018). In a single experiment, NPCs were then independently 
transduced with W5s, W5s/as and GPF vectors (Figure 7A). A) Flow cytometry dot plot shows the 
percentage of NPCs expressing GFP (ii). Gating and data analysis were adjusted according to non-
transduced cells (i). B) NPCs were harvested and expression levels of indicated targets were analysed 4 
(4d) and 7 days (7d) after transfection. Results are represented as fold changes compared to the GFP-
transfected NPCs. The table shows the numerical values of the graph. 
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Figure 10. Relationship between the efficacy of transduction of NPCs with pSIN-EF2-HERV-W 5p12 
vector (W5s), and the induction of HERV-W ENV expression 4 days after transduction. The graph 
shows a direct relation between the number of efficiently transduced NPCs and the fold-change 
induction of HERV-W ENV expression. Efficacy of transduction was defined as the percentage of GFP+ 
NPCs achieved after transduction (Figure 8A and 9A). Relative HERV-W ENV expression is expressed as a 
fold change compared to the expression measured in NPCs transduced with pLOX-CWgfp (GFP) vector 
(Figure 8B and 9B). Numbers within the graph indicate de x-value and y-value for each point. 
Discussion  
Although the increased presence and expression of HERV-W elements has been 
repeatedly associated with MS, little is known about HERV-W contribution to MS 
pathogenesis. In the present study, we show that HERV-W overexpression activates 
IRF7 and induces IFNβ upon TLR3 stimulation in NPCs. It is important to highlight the 
absence of ORFs over 30 aminoacids long in the RNA produced, indicating that it is the 
RNA itself and not the proteins it encodes that cause immune 
activation. Overexpression of HERV-W-derived RNAs, therefore, can activate the innate 
immune system and trigger a local inflammatory response. We therefore hypothesise 
that abnormal HERV-W expression in MS patients may derive in a similar HERV-W-
mediated inflammatory response, which subsequently may contribute to MS 
pathogenesis. Pending further confirmations showing immune activation in more 
mature cells and absence of protein products in the RNAs produced, our results 
support the idea that immune reactions within the CNS, apart from the peripherical 
immune reactions, may contribute to MS pathogenesis.  
Although the most widely accepted hypothesis suggests that MS onset is characterised 
by the activation of the peripheral immune system (Garg and Smith, 2015; Sospedra 
and Martin, 2005), local immune response undeniably contributes to MS pathogenesis 
as well (Hemmer et al., 2015; Macchi et al., 2015). Interestingly, different patterns of 
demyelination have been found within cerebral lesions of autopsied MS patients 
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(Lucchinetti et al., 2000). While some studies have mainly observed high amounts of T 
cells within cerebral MS lesions (Chitnis, 2007; Kivisäkk et al., 2004), other cerebral 
lesions have been characterised by oligodendrocyte apoptosis and microglial activation 
with little presence of lymphocytes (Barnett and Prineas, 2004). These latest findings 
suggest that oligodendrocyte damage and the subsequent local immune response 
activation may happen before the massive lymphocyte infiltration. In fact, in an animal 
model, the induced apoptosis of oligodendrocytes resulted in demyelination and 
microglia activation in the absence of peripherical lymphocytes (Caprariello et al., 
2012).  
Considering all the above, we hypothesise that one possible mechanism underlying 
oligodendrocyte damage in the absence of peripherical inflammation could be a HERV-
W-mediated local inflammation. Immunohistochemical analysis of autopsied brains of 
MS patients has revealed enhanced expression of TLR3 and TLR4 in inflamed lesions 
(Bsibsi et al., 2002). In an mouse model, the induced TLR3 stimulation in glial cells 
resulted in microglia activation and pre-oligodendrocyte cell death (Steelman and Li, 
2011). Likewise, also in a mouse model, induced TLR3 stimulation in neurons resulted 
in inhibition of axonal growth (Cameron et al., 2007). All these findings showed that 
TLR3 activation has the potential to cause CNS degeneration. Since TLR3 is expressed 
in many of the human CNS cell types such as oligodendrocytes, astrocytes and 
microglia (Bsibsi et al., 2002), HERV-W-mediated TLR3 stimulation may also trigger a 
detrimental local inflammatory response within the CNS of MS patients.  
In vitro differentiation from hESCs and/or iPSCs into relevant cell types can be helpful 
to generate the cell types affected by diseases. We initially intended to generate in 
vitro hESCs-derived oligodendrocytes since they are one of the main CNS cell types 
affected in MS. However, two published protocols for differentiation turned out 
difficult to reproduce, and we finally analysed the effect of HERV-W overexpression in 
a precursor cell type for neural differentiation. The challenges we found for generating 
oligodendrocytes using the first protocol (All et al., 2015) were due to the length of 
culture time required (up to 2 months), and the low amount of OPCs obtained. The 
second protocol we followed (García-León et al., 2018), was promisingly shorter and 
more efficient. However, cell attachment problems prevented us from generating 
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oligodendrocytes. We therefore experienced the arduousness of generating 
differentiated oligodendrocytes in vitro. Although published protocols claim good 
efficiency of oligodendrocyte production, the reality is that protocols are difficult to 
replicate and may produce variable results dependent on the stem cell lines used. 
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Supplementary materials 
 
Figure s.1. Bright field microscopy images of [ES]4 cell line cultured on matrigel matrix in mTeSR1 
medium. Images illustrate the typical morphology of hESCs. ES[4] cells are rounded, have a high nucleo-
cytoplasmic ratio and prominent nucleoli. These cells are tightly packed with each other and form 
individual colonies. Images were taken using three magnifications: 5X, 10X and 20X.  
 
 
Figure s2. Plasmids construction. To induce unidirectional HERV-W expression, HERV-W copy located on 
chromosome 5p12 (HERV-W 5p12) was cloned and fused to pSIN-EF2 plasmid, which contains the 
constitutive EF-1α promoter. Bidirectional HERV-W expression was achieved by also fusing the 
constitutive phosphoglycerate kinase (PGK) promoter to pSIN-EF2 plasmid, so that PGK and EF-1α 
promoters control antisense and sense HERV-W 5p12 expression respectively. Green arrows: promoters. 
Black arrows: direction of transcription. 
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Gene Sequence (5’-3’) 
REX1 For: ACATGACAGGCAAGAAGCTTCCGC 
Rev: GAGCCCGGATCCTACTTTCCCTCTTGTTCATTCTT 
OCT4 For: CGACCATCTGCCGCTTTGAG 
Rev: CCCCCTGTCCCCCATTCCTA 
PAX6 For: AATAACCTGCCTATGCAACCC 
Rev: AACTTGAACTGGAACTGACACAC 
SOX1 For: CAATGCGGGGAGGAGAAGTC 
Rev: RCTCTGGACCAAACTGTGGCG 
OLIG2 For: CCCTGAGGCTTTTCGGAGCG   
Rev: GCGGCTGTTGATCTTGAGACGC  
NG2 For: CTTCACTCAGGCAGAGGTCTACGC 
Rev: GAGGACAGCTGGAGCTCTAGGGT 
GAPDH For: ATCAGCAATGCCTCCTGCAC 
Rev: TGGCATGGACTGTGGTCATG 
Table s1. List of set of primers used for the analysis of phenotypic markers expression by semi-
quantitative PCR. The first column shows the target, the second column indicates the oligo sequence 
(For= forward; Rev= reverse). 
 
Target Sequence (5’-3’) 
HERV-W 5p12 For: TGGAGCAGGAGTGCTAGGTAGA 
Rev: TGGTCGGGTGTGAGCTAAGT 
PGK promoter For: ATCTGCGGATCCTACCGGGTAGGGGAGGCGC 
Rev: ATCTGCTCTAGATTCGAAAGGCCCGGAGATGAG  
Table s2. List of set of primers used for the plasmids construction and subsequent analysis. The first 
column shows the target, the second column indicates the oligo sequence (For= forward; Rev= reverse). 
 
Gene Sequence (5’-3’) 1mM MgCl
2
 addition 
MSRV-like HERV-Wenv 
(Mameli et al., 2009) 
For: CTTCCAGAATTGAAGCTGTAAAGC 
Rev: GGGTTGTGCAGTTGAGATTTCC 
No 
GAPDH For: ATCAGCAATGCCTCCTGCAC 
Rev: TGGCATGGACTGTGGTCATG 
No 
IFN-β  For: AGTAGGCGACACTGTTCGTG 
Rev: GCCTCCCATTCAATTGCCAC 
Yes 
IRF7 For: CCCCCATCTTCGACTTCAGA  
Rev: CAGGACCAGGCTCTTCTCCTT 
No 
TLR3 For: GGTGTGTCTTCCCTGGATAG 
Rev: GCTCCAGCTCCATAAGGAAG 
Yes  
Table s3. List of set of primers used for the plasmids construction. The first column shows the target, 
the second column indicates the oligo sequence (For= forward; Rev= reverse). 
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HERVs and autoimmunity 
Innate immune detection of nucleic acids (DNA and RNA) is crucial for the host defence 
against viral infection (Stetson et al., 2008; Theofilopoulos et al., 2011). In mammals, 
foreign nucleic acids can be recognised by two kind of intracellular receptors: TLRs and 
cytoplasmic nucleic acid sensors. TLRs are transmembrane sensors expressed in a cell 
type specific way in immune cells and other cells types including oligodendrocytes and 
neurons (Carpentier et al., 2008; Kielian, 2006; Trudler et al., 2010).  Within the TLRs 
family, TLR3, 7, 8 and 9 are nucleic acid-sensing TLRs. TLR3 is activated by dsRNA, TLR7 
and 8 detect ssRNA, and TLR9 senses ssDNA that contains unmethylated CpG 
sequences. All these nucleic acid-sensing TLRs are localized within intracellular 
endosomal compartments, in which they detect the presence of nucleic acids in 
compartments where endogenous nucleic acids would not normally reside (Ewald and 
Barton, 2011; Pelka et al., 2016). In contrast, cytoplasmic nucleic acid sensors are more 
broadly expressed and trigger a cell-intrinsic antiviral response. These cytosolic sensors 
are composed of an ample variety of receptors including RIG-I, MDA5 and LGP2 
(Theofilopoulos et al., 2011). Activation of either of these two kinds of receptors leads 
to a type I INF response, a group of cytokines with antiviral activity (Stetson et al., 
2008; Theofilopoulos et al., 2011). Although these antiviral responses are usually 
beneficial, if excessive, they can result in pathogenic inflammatory and autoimmune 
diseases (Assmann et al., 2015; Barrat et al., 2005; Christensen et al., 2006; Fischer and 
Ehlers, 2008; Sakata et al., 2018; Theofilopoulos et al., 2011).  
One of the main concerns in nucleic acid recognition is the discrimination between 
viral and self-nucleic acids. Since HERVs are part of the genome, HERV-derived nucleic 
acids should theoretically be recognised as self-nucleic acids. However, a limited 
number of situations have been described in which HERV-derived nucleic acids activate 
the innate immune system (Chiappinelli et al., 2015; Hurst and Magiorkinis, 2015). 
Expression of HERV elements has been reported in several autoimmune diseases 
(Gröger and Cynis, 2018; Lättekivi et al., 2018; Morandi et al., 2017). Our data also 
indicate that HERV-W expression may be slightly induced in MS patients (Manuscript 
II). In parallel, we demonstrate that the number of transcribed HERV-W loci is larger in 
PBMCs of MS patients than in controls (Manuscript II). Altogether, our findings provide 
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evidence of the HERV-W RNA accumulation in MS. Combining HERV-induced activation 
of innate immunity and upregulated expression of HERV in autoimmune disease, a 
contribution of HERV to autoimmunity has been hypothesised (Hurst and Magiorkinis, 
2015; Stetson, 2012). 
Independent of the molecular origin of MSRV, the relatedness of MSRV to HERV-W, 
the copies of HERV-W involved and even the exact levels of accumulation, we aimed to 
directly test whether HERV-W-derived RNA may activate the innate immune system. 
Overexpressing HERV-W RNA to high levels in NPCs, we show that HERV-W RNA 
triggers a type I IFN response in NPCs, potentially via TLR3 signalling (Manuscript IV). 
We therefore suggest that an IFN-mediated antiviral response mediated by HERV-W 
transcripts could contribute to MS. This may apply especially to individuals genetically 
and environmentally predisposed to develop autoimmunity.  
In a mouse model for Aicardi-Goutières syndrome (AGS), a HERV-driven INF response 
was independent of lymphocytes (Gall et al., 2012). Trex1 is a ssDNA-specific 
exonuclease whose loss resulted in the accumulation of cytosolic DNA, including 
HERVs-derived DNA (Stetson et al., 2008). In Trex1-deficient mice, this cytosolic DNA 
accumulation Ied to a lethal and type I INF-dependent autoimmune response (Stetson 
et al., 2008). Interestingly, the INF response that drives disease in Trex1-deficient mice 
was found to be independent of lymphocytes (Gall et al., 2012), revealing a non-
hematopoietic origin of the antiviral response. We provide evidence that 
overexpressed HERV-W RNA triggers a type I IFN response in NPCs (manuscript IV). As 
opposed to a DNA-dependent INF response in the mouse autoimmunity model (Gall et 
al., 2012), an RNA-dependent INF response may contribute to MS. While the event 
triggering the response in MS may be a local response in the CNS, HERV-W expression 
could as well activate cell-intrinsic antiviral sensors outside the CNS. Similar to the 
Trex1-deficient mouse model for AGS, the initial type I INF response may subsequently 
activate lymphocytes in the periphery, which finally would target the CNS. 
Of course additional research is required to clarify the potential contribution of HERV 
expression to autoimmune diseases in general and MS in particular. Our initial 
experiments forcing HERV-W overexpression in NPCs, provide a framework for future 
experiments. Immune reactions can be compared between astrocytes, neurons and 
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oligodendrocytes all derived from stem cells in vitro. In subsequent studies patient-
derived iPSC can be compared to control cells, and the effect of activated microglia on 
particular cell types is of interest. The use of cellular models may allow the dissection 
of immune responses elicited by HERV, and their contribution to MS.  
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Conclusions 
 
1. PCR-based assays have been developed that allow for the identification of novel 
HERV-W insertions in the human genome. 
2. Application of this technique to a limited set of samples has not produced evidence 
for neither MSRV nor MS-associated HERV-W elements within the human genome.  
3. MSRV/HERV-W copy number has been shown to be similar in PBMCs from MS 
patients and controls. 
4. MSRV/HERV-W expression has been found to be slightly increased in PBMCs from 
MS patients. 
5. It appears unlikely that aberrant expression of a unique HERV-W element causes 
overexpression of HERV-W in MS, since the most abundantly transcribed HERV-W loci 
are the same in PBMCs of MS patients and controls.  
6. The slight difference in MSRV/HERV-W expression between MS patients and 
controls may arise from the sum of HERV-W elements transcribed, which, although 
transcribed to a lesser extent, are expressed at higher levels in MS. These HERV-W 
elements may contribute to MS. 
7. The ENV region of HERV-W elements are heavily methylated in PBMCs from both MS 
patients and controls or in human PBMCs, independent of MS. The observed 
overexpression of HERV-W ENV in MS patients, is therefore unlikely to be regulated by 
DNA methylation. 
8. It is been observed that HERV-W overexpression triggers an INF-β response in 
hESCs-derived NPCs, which resembles a TLR3-mediated antiviral response. 
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Conclusiones 
 
1. Se ha desarrollado una metodología, basada en ensayos de PCR, que permite la 
identificación de nuevas inserciones de HERV-W en el genoma humano. 
2. El uso de esta técnica en un número limitado de muestras no ha permitido 
identificar MSRV o copies de HERV-W asociadas a MS en el genoma humano. 
3. Se ha detectado que el número de copias de MSRV/HERV-W en el genoma es similar 
en PBMCs de pacientes de MS y controles. 
4. Se ha detectado que los niveles de expresión de MSRV/HERV-W a nivel de RNA se 
encuentran ligeramente elevados en las PBMCs de pacientes de MS. 
5. No parece probable que la sobreexpresión de un único elemento de HERV-W cause 
la sobreexpresión de HERV-W detectada en pacientes de MS, ya que los loci de HERV-
W que se transcriben más abundantemente son los mimos en PBMCs de pacientes de 
MS y controles.  
6. El ligero incremento en expresión de MSRV/HERV-W en PBMCs de pacientes de MS 
podría provenir de la suma de loci de HERV-W que, aunque transcritos en menor 
medida, se expresan más en pacientes de MS. Estos elementos HERV-W podrían 
contribuir a MS. 
7. La región ENV de los elementos HERV-W se encuentra muy metilada en las PBMCs 
de pacientes de MS y de controles, y en PBMCs humanas no relacionadas con EM. Por 
lo tanto, la sobreexpresión de HERV-W ENV en pacientes de MS no parece estar 
regulada por la metilación del DNA. 
8. Se ha observado que la sobreexpresión de HERV-W desencadena la producción de 
INF-β en NPCs derivados de hESCs, la cual se asemeja a una respuesta antiviral 
mediada por TLR3. 
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qPCR primer efficiency standard curve analysis. A qPCR standard curve is graphically represented as a 
semi-log regression line plot of Ct value versus log of input gDNA or cDNA. The efficiency (E) is calculated 
with the formula E=10 (-1/slope)-1. Thus, a slope of -3.32 indicates a PCR reaction with 100% efficiency. A 
range of 80% < E < 110% was considered acceptable. 
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